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Summary  
The liver is essential for the metabolism of medicinal substances. Liver disease, 
especially liver cirrhosis, may lead to various pharmacokinetic and 
pharmacodynamic changes, predisposing patients with liver cirrhosis to adverse 
drug events (ADEs). In contrast to patients with renal failure, where dose 
adjustment can be performed by means of creatinine clearance, no such surrogate 
parameter exists for patients with liver disease. Specific dosage recommendations 
for patients with liver cirrhosis are often not available in the product information.  
We contributed to the development of a database that categorizes drugs according 
to their pharmacokinetic characteristics and allows for specific dosage 
recommendations for patients with liver disease.  
In the first study, we summarized this database for all anti-infective drugs on the 
Swiss market in 2012. Forty-seven % (N = 49) and 44% (N = 46) of the 104 anti-
infectives on the market were primarily eliminated by the liver and the kidney, 
respectively. For 9 drugs, the elimination pathway could not be elucidated. One 
fifth of all drugs was eliminated ≥50% by bile. CYP P450 enzymes were involved 
in the metabolism of 27% of the drugs. For 48% of the anti-infectives, studies on 
pharmacokinetic alterations in liver disease were found. The Swiss product 
information provides specific recommendations for patients with liver disease for 
only 50% of anti-infective drugs.  
The aim of the second study was the assessment of diagnoses, medication 
patterns, adverse drug reactions (ADRs), and potential drug-drug interactions 
(pDDIs) in cirrhotic patients at hospital admission. For this purpose, we performed 
a cross-sectional retrospective study including 400 patients with liver cirrhosis. At 
hospital admission, the 400 patients had 2415 diagnoses (median 6 per patient) 
and 1999 drugs (median 5 per patient), whereof 68% were predominantly 
eliminated by the liver. In total, 200 ADRs and 132 pDDIs were detected in 112 
(28%) and 86 (21.5%) patients, respectively. Fifteen ADRs were directly caused 
by 17 DDIs, whereof three resulted in hospital admission. Patients with ADRs were 
older, had more comorbidities, were treated with more drugs, and had a worse 
renal function and more pDDIs than patients without ADRs. 
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In the third study, the medication at hospital admission of the same population 
described in the second study was analyzed in greater detail with the goal to 
determine the prevalence of incorrectly dosed drugs (IDDs) and their association 
with ADRs. The adequacy of the drugs with respect to dosing or prescribing was 
investigated retrospectively by means of previous publications or the above-
mentioned database. Additionally, we calculated potential cost savings associated 
with IDDs and additional hospital stay due to IDD-induced ADRs. In contrast to the 
second study, we excluded vitamins and minerals for the analyses. Of the 
remaining 1653 drugs prescribed (median 4 per patient), 336 (20%) were IDDs in 
184 patients. Overall, 198 ADRs (83% preventable) occurred in 110 patients. 
Sixty-one (31% of all ADRs) were associated with IDDs in 40 patients, whereof 
77% were considered to be preventable. Especially non-steroidal anti-
inflammatory drugs and psycholeptics were a frequent cause of preventable 
ADRs. Overall, IDDs were more frequently associated with ADRs than correctly 
dosed drugs and patients with IDDs were more frequently admitted to the hospital 
due to ADRs. Hospitalizations due to IDD-induced ADRs resulted in 94 additional 
hospital days. Potential drug-cost savings as a result of mere dose adjustment in 
patients with liver cirrhosis was minor, but considerable when taking into account 
hospitalizations due to preventable ADRs caused by IDDs. 
Pharmacotherapy in patients with liver cirrhosis is complex and specific 
recommendations for dosage adjustment frequently not available. Prescribing 
physicians should be aware of problematic drugs and the principles of dosage 
adjustment in patients with liver cirrhosis. Prevention of IDDs and associated 
ADRs potentially leading to hospital admission can contribute to the reduction of 
healthcare costs.  
By developing a database allowing for specific dosage recommendations in 
patients with liver disease, we are contributing to a safer drug treatment in patients 
with liver cirrhosis.  
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Zusammenfassung 
Der Metabolismus von vielen Medikamenten hängt von der Leber ab. 
Leberinsuffizienz, insbesondere Leberzirrhose, kann zu unterschiedlichen 
pharmakokinetischen und –dynamischen Änderungen führen, was Patienten mit 
Leberzirrhose für unerwünschte Arzneimittelereignisse anfällig macht. Im 
Gegensatz zu Patienten mit Niereninsuffizienz, bei denen die Dosierung gemäss 
Kreatinin-Clearance angepasst werden kann, gibt es bei Leberkrankheit keinen 
entsprechenden Surrogatparameter. Zudem stellt die Fachinformation häufig keine 
konkreten Dosierungsempfehlungen für Patienten mit Leberkrankheit zur 
Verfügung. 
Wir trugen zur Entwicklung einer Datenbank bei, die Medikamente anhand ihrer 
pharmakokinetischer Parameter einteilt und die dadurch ermöglicht, spezifische 
Dosisempfehlungen für Patienten mit Lebererkrankungen zu machen. 
In der ersten Studie haben wir diese Datenbank für alle Antiinfektiva 
zusammengefasst, die anfangs 2012 in der Schweiz auf dem Markt waren. 
Siebenundvierzig % (N = 49) bzw. 44% (N = 46) von den 104 Antiinfektiva auf 
dem Markt wurden vor allem über die Leber bzw. über die Niere ausgeschieden. 
Für 9 Medikamente konnte der Eliminationsweg nicht geklärt werden. Ein Fünftel 
der Medikamente wurde zu ≥50% über die Galle ausgeschieden. CYP P450 
Enzyme trugen zum Metabolismus von 27% der Medikamente bei. Für 48% der 
Antiinfektiva haben wir Studien über pharmakokinetische Änderungen bei 
Leberkrankheiten gefunden. Die Schweizer Fachinformation stellt nur für 50% der 
Antiinfektiva konkrete Dosisempfehlungen bei Leberinsuffizienz zur Verfügung. 
Die zweite Studie hatte zum Ziel, Diagnosen, Medikation, unerwünschte 
Arzneimittelwirkungen (UAW) und potentielle Medikamenteninteraktionen (pMIA) 
von Zirrhose-Patienten bei Spitaleintritt genauer zu erfassen. Dazu haben wir eine 
retrospektive Querschnittsstudie mit 400 Patienten mit Leberzirrhose durchgeführt. 
Bei Spitaleintritt hatten die 400 Patienten 2415 Diagnosen (Median 6 pro Patient) 
und 1999 Medikamente (Median 5 pro Patient), wovon 68% vor allem hepatisch 
eliminiert wurden. Insgesamt wurden 200 UAW bzw. 132 pMIA in 112 (28%) bzw. 
86 (21.5%) Patienten festgestellt. Siebzehn pMIA führten zu 15 UAW, wovon drei 
zu einer Hospitalisation führten. Verglichen mit Patienten ohne UAW waren 
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Patienten mit UAW älter, hatten mehr Komorbiditäten, erhielten mehr 
Medikamente und hatten eine schlechtere Nierenfunktion als auch mehr pMIA.  
In der dritten Studie wurde die Medikation derselben Population wie in der zweiten 
Studie detaillierter analysiert mit dem Ziel, die Prävalenz von inkorrekt dosierten 
Medikamenten (IDM) und deren Assoziation mit UAW zu bestimmen. Dabei wurde 
mithilfe von früheren Publikationen oder der oben erwähnten Datenbank 
retrospektiv untersucht, ob die Medikamente angemessen verschrieben und/oder 
dosiert wurden. Zusätzlich haben wir mögliche Kostenersparnisse berechnet, die 
mit IDM oder zusätzlichem Spitalaufenthalt aufgrund von IDM-assoziierten UAW in 
Zusammenhang stehen. Verglichen mit der zweiten Studie haben wir hier 
Vitamine und Mineralstoffe für die Analyse ausgeschlossen. Von den 
verbleibenden 1653 verschriebenen Medikamenten (Median 4 pro Patient), waren 
336 (20%) IDM bei 184 Patienten. Insgesamt kamen 198 UAW (davon 83% 
vermeidbar) bei 110 Patienten vor. Einundsechzig (31% von allen UAW) waren mit 
IDM bei 40 Patienten assoziiert, wovon wiederum 77% als vermeidbar angesehen 
wurden. Vor allem nicht-steroidale Antirheumatika und Psycholeptika waren häufig 
verantwortlich für vermeidbare UAW. Insgesamt waren IDM häufiger mit UAW 
assoziiert als korrekt dosierte Medikamente und Patienten mit IDM wurden 
häufiger hospitalisiert aufgrund einer UAW. Hospitalisationen aufgrund von UAW, 
die durch IDM ausgelöst wurden, führten zu 94 zusätzlichen Spitaltagen. Mögliche 
Kostenersparnisse lediglich aufgrund von Dosisanpassungen waren minimal, 
wurden aber beträchtlich, wenn man die zusätzlichen Hospitalisationen aufgrund 
vermeidbarer UAW, die durch IDM ausgelöst wurden, ebenfalls in Betracht zieht. 
Die medikamentöse Therapie bei Patienten mit Leberzirrhose ist komplex und 
konkrete Empfehlungen für eine Dosisanpassung sind häufig nicht erhältlich. 
Verschreibende Ärzte sollten sich problematischer Medikamente und den 
Grundlagen der Dosisanpassung bei Leberzirrhose bewusst sein. Die Vermeidung 
von IDM und damit verbundenen UAW, die zu einer Spitaleinweisung führen 
können, kann zur Senkung von Gesundheitskosten beitragen. 
Indem wir eine Datenbank entwickeln, die es ermöglicht, spezifische 
Dosisempfehlungen für Patienten mit Lebererkrankungen zu machen, tragen wir 
zu einer sichereren Therapie bei Patienten mit Leberinsuffizienz bei. 
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1 Aims of the thesis 
 
The main goal of this PhD thesis is to contribute to a better understanding of the 
characteristics of patients with liver cirrhosis and to improve drug safety in this 
patient population. 
 
First, we contributed to the development of a database containing pharmacokinetic 
and toxicologic data of drugs on the Swiss market. We classified drugs according 
to their elimination pathway and reviewed the literature and product information for 
pharmacokinetic changes and dosage recommendations in patients with liver 
disease. Based on pharmacokinetic as well as pharmacodynamic data, the 
database provides specific dosage recommendations for patients with impaired 
hepatic function whenever possible. In collaboration with Documed AG, the 
development of a clinical decision support (CDS) tool is planned.  
With our first study, where we present a part of the database using the example of 
anti-infective drugs, we aimed at simplifying drug prescription of anti-infectives in 
patients with liver disease by giving specific recommendations.  
 
The aim of the second study was to identify characteristics and drug-related 
problems in patients with liver cirrhosis. For this purpose, we included a population 
of 400 patients with liver cirrhosis. We characterized the patients in respect of their 
demographic data, comorbidities, prevalent drugs at hospital admission, adverse 
drug reactions (ADRs), and potential drug-drug interactions (pDDIs). We tried to 
work out the prevalence of ADRs and pDDIs as well as associated and/or critical 
drugs in hepatically impaired patients.  
By comparing cirrhotic patients with ADRs to those without ADRs, we could 
identify potential risk factors for ADRs. 
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The goal of the third study was to investigate the medication (prevalent at hospital 
admission) of the 400 patients with liver cirrhosis in greater detail. To this end, we 
judged the adequacy of the administered drugs and their doses according to the 
recommendations of previous publications or the above-mentioned database. On 
the one hand, we investigated if there was an association between incorrectly 
dosed drugs (IDDs) and the rate of ADRs. ADRs associated with IDDs were 
described in detail. On the other hand, the relationship between a drug’s 
elimination pathway and the occurrence of ADRs was assessed. Furthermore, we 
calculated potential cost savings associated with IDDs and additional hospital stay 
due to IDD-induced ADRs. 
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2.1 The liver 
2.1.1 Liver anatomy and function  
The liver is a gland of approximately 1.5kg situated in the right upper quadrant of 
the abdomen. It is the central organ for synthesis, storage, and metabolism of 
important endogenous and exogenous substances. It is divided into four lobes of 
different size. The histologic units of the liver are the small (1-2mm in diameter) 
hexagonal liver lobules, whereof about 500’000 exist in the liver [1, 2]. The most 
important cells of these lobules are the hepatocytes or parenchymal cells, which 
are organized as one-cell thick plates. Nonparenchymal cells consist of endothelial 
cells, pit cells (the natural killer cells of the liver), Kupffer cells with phagocytic 
activity, and the contractile hepatic stellate cells, which contain large amounts of 
retinoids (95% of body store) [1]. 
Hepatic blood supply occurs by the portal vein (75-80%) and the hepatic artery 
(20-25%). Both vessels enter the liver at the porta hepatis at the lower side of the 
liver, whereas the bile ducts leave the liver at this site. The portal vein drains 
venous blood from almost the whole gastrointestinal tract [3] and spleen into the 
liver and serves as a carrier of nutrient-derived or other ingested substances (e.g. 
drugs). Blood enters the hepatic lobule at the portal triads at the corners of the 
hexagon, and then passes the hepatic capillaries, which are called sinusoids, 
unidirectionally towards the middle of the lobule, where it empties into the central 
vein (Fig. 1) [1, 2].  
The sinusoidal wall is made up of endothelial cells and hepatic stellate cells. 
Instead of being continuous, the sinusoidal wall has pores, so-called fenestrae 
(1000 Ǻ in diameter). It is separated from the hepatocytes by a small space, the 
space of Disse [1, 2]. Except for substances with a diameter >1000 Ǻ, certain 
proteins, soluble compounds, or waste products that are filtered or taken up by the 
endothelial cells, many blood components can penetrate the sinusoidal wall and 
interact with the hepatocytes’ microvilli, which project into the space of Disse. 
Uptake into hepatocytes is mediated by various, partially specific (e.g. for bile or 
amino acids) transport proteins, which may be regulated by different endogenous 
and exogenous factors such as electrogenic state of the hepatocyte or fasting. 
Bilirubin is transported by an anion carrier, which is also involved in the transport 
of hydrophobic anionic drugs, which may lead to hyperbilirubinemia if the 
transporter is saturated [1].  
2 Introduction 
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Fig. 1 Schematic illustration of a hepatic lobule. While the portal vein (blue) and the hepatic artery 
(red) enter the lobule at the portal triad, the biliary tract (green) leaves the lobule there (modified 
from [2]).  
 
A major purpose of the hepatocytes is the metabolism of endogenous and 
exogenous substances by activation, inactivation, or detoxification, as well as their 
elimination (see also section 1.1.2 The role of the liver in drug metabolism). The 
hepatocytes are categorized into three zones according to their distance from the 
afferent blood vessels. Zone 1 cells are located near the portal triad, whereas 
zone 3 cells are near the central vein, and zone 2 cells are in between. According 
to their zonation, hepatocytes differ with respect to key enzymes, cell receptors, 
subcellular structures, and cell matrix interactions. For example, more cytochrome 
P450 (CYP) enzymes are located in zone 3 hepatocytes compared to zone 1 
hepatocytes, whereas the opposite is true for the enzyme sulfotransferase (SULT). 
Since perfusion along the sinusoid is unidirectional and blood composition 
changes along the sinusoids, hepatocytes are confronted with heterogeneous 
microenvironments. Next to basic genetic expressions, various signals from these 
microenvironments lead to the development of the above mentioned zonation [1]. 
The hepatocytes play a major role in bile formation. They actively secret bile acids, 
electrolytes, and organic solutes such as bilirubin. Bile flows in canaliculi along the 
liver cell plate and forms a countercurrent to the blood flow through the sinusoids 
Arterial 
blood 
Portal triad Portal 
blood 
Bile 
Central vein 
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(Fig. 1). Bile serves as an elimination pathway for hydrophobic substances on the 
one hand, and as a fat emulsifier in the gastrointestinal tract to increase absorption 
of fat-soluble substances on the other hand [1]. Thereby, bile acids are recycled: 
they are excreted into the duodenum and reabsorbed in the ileum (so-called 
enterohepatic circulation) [2]. 
 
2.1.2 The role of the liver in drug metabolism 
Metabolic enzymes exist in many tissues of the body, however, the liver 
possesses the highest amount and diversity of enzymes [4]. For example, 90-95% 
of CYP enzymes are located in the liver and only 1-2% in the gastrointestinal 
epithelium. Next to the liver, uridine diphosphate glucuronosyltransferase (UGT) is 
also expressed in the gut, the kidney, the lung, the prostate, the skin, and the brain 
[5]. 
Regarding the metabolism of xenobiotics, one differentiates between phase I and 
II metabolism. During phase I, the substances are chemically altered in order to 
make them more polar. The principal enzymes belong to the CYP family and 
typically perform N- or O-dealkylation, N- or S-oxidation, aliphatic or aromatic 
hydroxylation, or deamination [6]. Further enzymes involved in phase I reactions 
are alcohol and aldehyde dehydrogenases, xanthine oxidases, amine oxidases, 
esterases, or epoxide hydrolases [5]. During phase II metabolism the following 
conjugation reactions take place: glucuronidation, sulfation, methylation, 
acetylation, glutathione (GSH) and amino acid conjugation. Involved enzymes are 
UGT, SULT, N-acetyltransferases, GSH S-transferases, methyl transferases, and 
catechol O-methyl transferases [6]. These reactions usually contribute to the 
inactivation of substances and also increase their hydrophilicity, facilitating 
excretion by the kidney and bile [5]. Exceptionally, metabolism may lead to more 
active substances compared to the parent compounds or even to toxic products. 
Examples are morphine-6-glucuronide, which shows a two to four times higher 
analgesic potency than its parent drug morphine [7], and N-acetyl-p-
benzoquinoneimine (NAPQI), a highly reactive metabolite of acetaminophen 
resulting from N-hydroxylation mainly by CYP2E1 and 1A2 [8, 9]. NAPQI is usually 
detoxified by GSH conjugation, but can lead to hepatotoxicity if high amounts of 
acetaminophen are ingested [8] or in GSH-depleted patients [10]. 
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2.1.3 Liver cirrhosis: epidemiology and pathology 
Due to the focus on patients with liver cirrhosis in this PhD thesis and the 
pronounced impact of cirrhosis on liver architecture and function, this section will 
focus on liver cirrhosis.  
 
In western Europe, the yearly mortality rate due to liver cirrhosis between 1997 
and 2001 was between 9.7 (Netherlands) and 43.5 (Austria) per 100,000 males 
and between 5.6 (Sweden) and 16.7 (Austria) per 100,000 females [11]. In 
countries with a higher frequency of hepatitis B virus (HBV) and hepatitis C virus 
(HCV) infections, e.g. in Asia or Africa, these numbers are even higher [12].  
As a response to chronic liver damage, excess extracellular matrix is produced 
(fibrogenesis) in order to replace the injuries by regenerative scar tissue. Activated 
myofibroblasts derived from hepatic stellate cells and fibroblasts are involved in 
this process [1, 12]. Liver fibrosis develops, which may progress to liver cirrhosis 
[12, 13]. Histologically, liver cirrhosis presents as regenerative nodules surrounded 
by fibrous bands [12], leading to an increased intrahepatic blood flow resistance. 
Consequently, portal hypertension may develop and lead to intra- and extrahepatic 
portosystemic shunts circumventing the liver [4, 12].  
Next to a decreased number of functional hepatocytes in patients with liver 
cirrhosis [14], altered hepatic architecture impairs normal function of remaining 
hepatocytes [1, 12]. For example, a process called sinusoidal capillarization (Fig. 
2) occurs, where sinusoidal endothelium is replaced by a collagen basement 
membrane, most of the endothelial fenestrae lost, and the space of Disse filled 
with scar tissue [1, 12]. Furthermore, the hepatocytes lose their microvilli [1]. As a 
result, exchange between blood in the sinusoids and the hepatocytes is impaired 
[1, 4].  
Liver cirrhosis represents the terminal stage of many liver diseases of different 
etiologies. The primary cause for liver cirrhosis in industrial countries is alcohol 
abuse, followed by HBV and HCV infections [13]. Other possible causes are toxic 
substances, chronic autoimmune hepatitis, chronic biliary obstruction, non-
alcoholic steatohepatitis, hepatic porphyrias, vascular disorders (e.g. Budd Chiari 
syndrome), or metabolic diseases such as Morbus Wilson or hemochromatosis [2, 
12, 13]. 
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Fig. 2 While blood and solutes can readily interact with the hepatocytes microvilli in a normal 
sinusoid, this interaction is impaired in capillarized sinusoids due to closed fenestrae, a 
collagenous basement membrane and lack of microvilli (modified from [1]). 
 
Patients with compensated liver cirrhosis may be asymptomatic or present with 
unspecific symptoms such as fatigue or gastrointestinal disturbances (anorexia, 
nausea, diarrhea, obstipation) [12, 13]. More specific symptoms are ascites, 
jaundice, pruritus, dermatologic changes (spider angioma, palmar erythema), or 
bleeding tendency [2, 13]. However, it is still common that patients come to clinical 
attention for the first time due to decompensation of liver cirrhosis with serious 
complications such as ascites, esophageal variceal bleeding, spontaneous 
bacterial peritonitis, or hepatic encephalopathy [12, 13]. 
The combination of clinical and laboratory signs (e.g. increased liver enzymes or 
bilirubin, or decreased albumin or prothrombin time) and symptoms, a known 
exposure to a causal agent, and imaging strategies (ultrasonography, 
computerized tomography, magnetic resonance imaging) frequently allow to 
suppose the presence of liver cirrhosis. To confirm the diagnosis, however, a liver 
biopsy is necessary [12]. 
The therapy of cirrhosis depends on the causal agent. While patients with 
alcoholic cirrhosis profit from alcohol abstinence, patients with viral hepatitis 
should be treated with antiviral agents to prevent disease progression and/or 
hepatocellular carcinoma [12]. Although liver cirrhosis is generally thought to be 
irreversible, regression of cirrhosis has been reported in patients treated 
successfully for HCV [15] and HBV [16]. 
Liver cirrhosis may lead to various complications (Fig. 3). Patients with liver 
cirrhosis have hemodynamic alterations. Due to portal hypertension followed by 
Endothelial 
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splanchnic vasodilation and arterial hypovolemia, the body counteracts by 
activation of vasoconstricting systems (sympathetic nervous system and renin-
angiotensin-aldosterone system [RAAS]). This leads to sodium and water retention 
in the kidney, which can compensate for arterial underfilling in the beginning. 
Additionally, edema and ascites (fluid accumulation in the peritoneal cavity) may 
develop, causing further sodium and water retention. If disease progresses and 
vasoconstrictors prevail in the kidney, renal perfusion decreases, eventually 
resulting in hepato-renal syndrome with renal failure [17].  
Spontaneous bacterial peritonitis is a complication where ascitic fluid is 
spontaneously infected by bacteria, supposedly originating from the 
gastrointestinal tract. Thereby, decreased phagocytic function of the 
reticuloendothelial system and decreased anti-microbial activity of the ascitic fluid 
are risk factors for the development of spontaneous bacterial peritonitis [17]. 
Hepatic encephalopathy is a term used for neuropsychiatric changes in patients 
with liver disease. Due to a circumvention of the liver by portosystemic shunts on 
the one hand and a decreased hepatic clearance (CLhep) on the other hand, a 
greater amount of potentially toxic substances which are normally detoxified by the 
liver become systemically available. It is unknown whether such substances (e.g. 
ammonia) directly lead to neurotoxicity in the brain or induce secondary alterations 
in brain neurochemistry [18].  
Due to the obstructed portal blood flow in patients with liver cirrhosis, blood flow 
across portosystemic communications increases (e.g. at the cardia of the 
stomach). As a result, vasodilation occurs in these blood vessels and they become 
varicose veins. Eventually, rupture of these gastroesophageal varices may cause 
hemorrhage with a mortality of up to 20-30% [3].  
Hemorrhage may be more problematic in cirrhotic patients than in healthy 
subjects, because synthesis of all coagulation factors except for factor VIII occurs 
in the liver and may be affected by liver diseases. Another important product 
affected by impaired hepatic synthesis is the plasma protein albumin [19]. 
Hypoalbuminemia is a contributing factor to ascites due to a reduced oncotic 
pressure in plasma [2]. 
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Fig. 3 Liver cirrhosis and the pathophysiology of its complications, complications in orange boxes. 
Modified from [17, 18]. RAAS = renin-angiotensin-aldosterone system. 
 
The most common prognostic models used in patients with liver cirrhosis are the 
Child Pugh score and the Model for End-Stage Liver Disease (MELD). While the 
MELD [20, 21] includes serum bilirubin, serum creatinine, the international 
normalized ratio (INR), and the etiology of liver disease for the evaluation of 
patients with liver cirrhosis, the Child Pugh score [22] includes serum bilirubin, 
serum albumin, the INR, and the presence of encephalopathy and ascites (Tab. 
1). The Child Pugh classification has some limitations [20]. First, some parameters 
can be interpreted subjectively (e.g. ascites) depending on the observer and the 
diagnostic method used. Secondly, the measurement of laboratory values (e.g. 
albumin) may vary between different laboratories. Thirdly, the discriminatory power 
is limited, e.g. a patient with bilirubin of 3.5mg/dl and one with 20mg/dl both have 3 
points for bilirubin (so-called ceiling effect). Furthermore, physical findings used for 
the classification such as ascites can be influenced by medication. Many of these 
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problems are circumvented by the MELD, e.g. it bases on objective parameters 
[20]. However, laboratory values used for the MELD may also vary depending on 
the methods used (e.g. creatinine) [23]. A systematic review comparing the two 
prognostic models used in patients with liver cirrhosis has found no superiority of 
the MELD compared to the Child Pugh model [24].   
As liver cirrhosis at the University Hospital Basel is graded by the Child Pugh 
score, this model was used in our studies.  
 
Tab. 1 Child Pugh Score [22] 
Parameters Points* 
 1 2 3 
Ascites absent slight moderate 
Bilirubin <2mg/dL 2-3mg/dL >3mg/dL 
Albumin >3.5g/dL 2.8-3.5g/dL <2.8g/dL 
Prothrombin time prolongation 
or 
INR 
1-4s 
 
<1.7 
4-6s 
 
1.7-2.3 
>6s 
 
>2.3 
Encephalopathy (grade) none 1 and 2 3 and 4 
* By adding up the points a score between 5 and 15 results: patients with a score of 5-6, 7-9, and 
10-15 have mild (Child Pugh A), moderate (Child Pugh B), and severe (Child Pugh C) liver 
cirrhosis, respectively. 
 
 
2.2 Impact of liver disease on drug distribution and 
efficacy 
2.2.1 Pharmacokinetic alterations in patients with liver disease 
In patients with liver cirrhosis, the absorption process may be altered due to 
potential gastrointestinal dysfunction (e.g. hypertensive gastropathy [25]), whereas 
the amount absorbed does not seem to be influenced [26].  
For hydrophilic drugs, the volume of distribution (Vd) increases in patients with 
ascites. To achieve effective blood concentrations rapidly, a higher loading dose 
may be indicated in such cases [4, 27]. According to Eq. 1, applicable for drugs 
with linear pharmacokinetics [28], an increased Vd leads to a prolonged elimination 
half-life (t1/2), if systemic clearance (CLsys) is unchanged.  
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1/2 CL
Vd
*7.0t =  (Equation 1) 
 
As described earlier, synthetic function of the liver decreases in patients with liver 
cirrhosis potentially resulting in decreased production of plasma proteins such as 
albumin or α1-acid glycoprotein [4]. Consequently, free fraction and possibly also 
free concentration of highly protein-bound drugs may be increased in patients with 
liver cirrhosis [27], leading to a more pronounced pharmacodynamic effect. 
Additionally, certain endogenous substances binding to plasma proteins such as 
bilirubin may accumulate in liver disease, potentially competing with drugs for 
binding sites [4].  
Systemic bioavailability may be increased in patients with liver cirrhosis due to 
portosystemic shunting and reduced hepatic blood flow on the one hand and 
reduced metabolism on the other hand [4]. Phase I metabolizing enzymes, whose 
function depends on molecular oxygen, seem to be more sensitive to liver disease 
than phase II enzymes [4, 27, 29, 30]. In advanced disease stages, 
glucuronidation seems also to be impaired, but further studies are necessary to 
clarify the impact of liver disease on glucuronidation [4]. But even within the CYP 
enzyme family, the observed alteration in functionality was inhomogeneous. For 
example, CYP2C19 seems to be affected in an earlier disease stage than 
CYP2D6 [31].  
Additionally, the impact of liver disease on a drug’s metabolism also depends on 
the characteristics of the drug itself. For further information see section 2.3 
Classification of drugs according to their pharmacokinetic parameters. 
Biliary excretion of drugs may be impaired in patients with liver cirrhosis, even in 
patients without obvious mechanical biliary obstruction. Potential mechanisms 
include alterations of the membrane or the cytoskeleton of bile canaliculi, altered 
activity of transporters or paracellular pathways, or impaired intracellular calcium 
homeostasis. Intra- and extrahepatic cholestasis may lead to an accumulation of 
drugs that normally undergo mainly biliary excretion [4]. Enterohepatic cycling may 
be interrupted [32]. Furthermore, impaired function of hepatic CYP enzymes was 
reported in patients with cholestasis [4, 27].  
Finally, impaired kidney function is often observed in patients with liver cirrhosis 
(hepato-renal syndrome) [4, 27]. 
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2.2.2 Pharmacodynamic alterations in patients with liver disease 
Apart from pharmacokinetic changes, patients with liver disease also have 
pharmacodynamic alterations.  
For diuretics and β-adrenoreceptor antagonists for example, a decreased 
pharmacodynamic effect was observed, while sensitivity was increased for 
centrally depressing drugs and non-steroidal anti-inflammatory drugs (NSAIDs) [4, 
27].  
There is some evidence that β-adrenoreceptors are less sensitive in patients with 
liver cirrhosis [4, 33]. For diuretics, a higher concentration in the renal tubule is 
necessary for the excretion of a certain amount of sodium [4, 27]. This was shown 
for the loop-diuretics torasemide [34, 35], furosemide [35-37], bumetanide [38], 
and triamterene [39, 40]. For certain substances with hepatic elimination such as 
torasemide, compensatory increased renal elimination may counterbalance the 
decreased pharmacodynamic effect [34].  
Cirrhotic patients have increased central sensitivity to centrally depressing drugs 
such as opiates, benzodiazepines, or antipsychotics [4, 27]. These substances 
may precipitate hepatic encephalopathy in patients with liver cirrhosis. Hypotheses 
to explain the increased brain sensitivity include altered permeability of the blood-
brain barrier, an increased presence of γ-aminobutyric acid (GABA) receptors, or 
changes in GABA-ergic tone [4, 41].  
As described earlier, patients with liver cirrhosis may have impaired kidney 
function. Renal prostaglandins (mainly prostaglandin E2 [42]) acting as 
vasodilators contribute to the maintenance of renal perfusion and function in these 
patients. The administration of NSAIDs, which inhibit prostaglandin synthesis, may 
precipitate renal failure in patients with liver disease [27, 43].  
 
2.2.3 Classification of drugs according to their pharmacokinetic 
characteristics and derived recommendations 
In contrast to patients with renal failure, where dosage of drugs can be adjusted 
according to the creatinine clearance, no such surrogate parameter exists in 
patients with liver disease [27]. By looking at the pharmacokinetic characteristics 
of a drug, the role of the liver in the elimination of the drug can be estimated.  
Fig. 4 shows our classification of drugs into five categories (CAT) with the 
corresponding recommendations. Additionally, the procedure to find ideal dose 
recommendations for patients with liver disease is depicted.  
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First, the extrarenal dose fraction (Q0) tells us if a drug is mainly eliminated 
unchanged by the kidney (Q0<0.5, CAT4) or if it undergoes mainly hepatic 
elimination (Q0≥0.5) and is excreted either by the kidney (as metabolites) or by the 
bile (unchanged and/or as metabolites). Secondly, drugs with mainly hepatic 
elimination can be further categorized, namely into drugs with low (E<0.3, CAT3), 
intermediate (E 0.3-0.6, CAT2), or high hepatic extraction (E>0.6, CAT1). Hepatic 
extraction E is an equivalent to the hepatic first pass effect. Therefore, the lower 
the value for E the higher the systemic bioavailability after oral administration, 
provided that gastrointestinal solubility and absorption is good [32]. Finally, CAT5 
refers to drugs with unknown Q0 and/or E. 
The CLhep of a drug can be calculated by Eq. 2: 
 
E*QClhep =   (Equation 2) 
 
where E is the hepatic extraction of the drug, and Q the hepatic blood flow 
(~54L/h). 
According to the “well-stirred” or “venous equilibrium” model, E can be calculated 
as shown in Eq. 3 due to its dependence on hepatic blood flow Q, intrinsic hepatic 
clearance CLint, and the unbound fraction fu of the drug [4, 27]. 
 
)CL*f(Q
CL*fE
intu
intu
+
=  (Equation 3) 
 
By replacing E in Eq. 2 by Eq. 3 the following equation for CLhep results.  
 
)CL*f(Q
)CL*f(*QCL
intu
intu
hep +
=  (Equation 4) 
 
For drugs with high hepatic extraction (E>0.6), CLint*fu>>Q. Thus, Eq. 4 can be 
shortened to 
 
QCLhep ≈   (Equation 5) 
 
This indicates that CLhep of drugs with high hepatic extraction, also called “flow-
limited” drugs, depends more on hepatic blood flow than on the unbound fraction 
and CLint. A reduced hepatic blood flow and portosystemic shunts in patients with 
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liver cirrhosis may have a major impact on oral bioavailability [4, 27]. An example 
of such a drug is clomethiazole, which has an oral bioavailability of 10% in normal 
subjects. In patients with liver cirrhosis, the reported oral bioavailability was 100% 
[44]. For oral administration of drugs with high hepatic extraction, a reduction of 
the initial and the maintenance dose by ≥ 50% is indicated in patients with liver 
cirrhosis. With parenteral administration, the hepatic first pass metabolism is 
avoided and only the maintenance dose has to be reduced.  
For drugs with low hepatic extraction (E<0.3), Q>>(CLint x fu). Thus, Eq. 4 can be 
shortened to  
 
)Cl*f(Cl intuhep ≈  (Equation 6) 
 
This indicates that CLhep of drugs with low hepatic extraction depends more on the 
unbound fraction and the CLint of the drug than on the hepatic blood flow. For 
these drugs, also called “enzyme-capacity limited” drugs, the reduced CLint in 
patients with liver disease may result in a prolonged t1/2. As a general rule, it is not 
necessary to reduce the initial dose of low hepatic extraction drugs in patients with 
liver cirrhosis, but maintenance dose should be reduced by up to 50%. An 
example for a low hepatic extraction drug is cefixime. An unaltered maximal 
plasma concentration (Cmax) with a 2-fold prolonged t1/2 was reported in patients 
with moderate to severe liver cirrhosis [45, 46]. Furthermore, unbound fraction fu 
may be increased in patients with liver cirrhosis and hypoalbuminemia. Hence for 
drugs with a high protein binding and a shown relationship between plasma 
concentration and response, it is crucial to measure the free plasma concentration 
to avoid enhanced pharmacodynamic effects. However considering Eq. 6, an 
opposed effect is also possible for low hepatic extraction drugs with a high protein 
binding and a linear pharmacokinetic behavior. According to this equation, an 
increased unbound fraction may result in an unaltered or even increased CLhep 
[27].  
Drugs with an intermediate hepatic extraction (E 0.3 – 0.6) have characteristics of 
both drugs with high and low hepatic extraction. Their pharmacokinetic behavior in 
patients with liver cirrhosis depends on all three variables hepatic blood flow, CLint, 
and unbound fraction [27]. E.g. for rabeprazole, an increase of Cmax by 50%, of the 
area under the concentration-time curve (AUC) and t1/2 by 100%, and a reduction 
of the CLsys to 38% was observed in patients with compensated liver cirrhosis [47]. 
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Hence, for intermediate hepatic extraction drugs, an initial dose in the lower range 
of normal and a reduced maintenance dose by approximately 50% should be 
administered orally. With parenteral administration, again only the maintenance 
dose has to be reduced. 
For all hepatic extraction categories (CAT1, CAT2, CAT3), adjustment of 
maintenance dose by means of clinical effect and dose-dependent ADRs is 
possible.  
Additionally, we should be aware of a potential accumulation of drugs with mainly 
biliary elimination in patients with cholestasis.  
Finally, if a drug with a low Vd is administered to patients with ascites, the initial 
dose should generally be chosen according to body weight and the maintenance 
dose in the lower range of normal.  
Next to pharmacokinetic data of the parent drug in patients with liver cirrhosis, we 
must not forget to think about possible pharmacokinetic alterations of active or 
toxic metabolites.  
 
For an optimal dose recommendation for patients with liver cirrhosis, apart from 
pharmacokinetic considerations, also pharmacodynamic data have to be taken 
into account. 
 
We can conclude that pharmacotherapy is complex in patients with liver cirrhosis. 
The more so because interindividual variability of alterations is high in patients with 
liver disease [4, 27, 32].  
  
 
Fig. 4 Classification of drugs according to pharmacokinetic data and corresponding recommendations for patients with liver disease. * E is either obtained from the 
literature or calculated by E = Q0*CLsys/Q; ADRs = adverse drug reactions; CLsys = systemic clearance; E = hepatic extraction; Foral = systemic bioavailability after 
oral administration (good gastrointestinal solubility and absorption assumed); ID = initial dose; MD = maintenance dose; Q = hepatic blood flow (~54L/h); Q0 = 
extrarenal dose fraction 
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2.3 Drug safety 
2.3.1 Background 
„Dosis sola facit venenum“, as Paracelsus wrote in 1538 [48], refers to the fact that 
every substance, administered to an organism in high enough amounts, causes 
damage. This phrase is frequently cited in association with toxic substances, but is 
also true for medicinal substances. Next to their desired and beneficial effects, 
drugs may be harmful.  
As outlined in the previous section, liver cirrhosis is associated with various 
pharmacokinetic and –dynamic changes, predisposing patients to untoward drug 
reactions. This section gives a short overview of the different terms used to 
describe drug-related problems.  
To clarify the meaning of the various drug-related problems explained below, an 
example will be given from our own results in patients with liver cirrhosis. 
 
Tab. 2 Definitions of most important drug-associated problems  
Drug-related problem “All circumstances involving a patient’s drug treatment that actually, or potentially, 
interfere with the achievement of an optimal outcome” [49]. 
Adverse drug event “Any injury related to the use of a drug, regardless of whether a therapeutically 
appropriate dosage is used. The causality of this relationship may not be proven” 
[50]. 
Adverse drug 
reaction 
“A response to a drug which is noxious and unintended and which occurs at doses 
normally used in human for prophylaxis, diagnosis, or therapy of disease or for the 
modification of physiologic function” [51]. 
Medication error “A medication error is a failure in the treatment process that leads to, or has the 
potential to lead to, harm to the patient” [52]. 
Drug drug interaction “The combining of two or more drugs such that the potency or efficiency of one drug 
is significantly modified by the presence of another” [53]. 
Lack of efficacy “Unexpected failure of a drug to produce the intended effect as determined by 
previous scientific investigation” [51]. 
Nonadherence If patients do not take their medication as prescribed by their health care providers 
[54]. 
Overdosage Intake of an excessive amount of drug potentially leading to increased 
pharmacologic and/or toxic effects. Overdosages may be accidental, intentional, or 
iatrogenic [55].  
Addiction If patients develop a strong tendency to increase the drug dose or the duration of 
therapy, whereas the drug is often not or no longer indicated. Addiction is 
characterized by dependence, tolerance development, and withdrawal reaction [55].   
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Fig. 5 Correlation between various drug-related problems (modified from [56]). DDIs not associated 
with ADEs or ADRs are called potential DDIs.  
ADEs = adverse drug events; ADRs = adverse drug reactions; DDIs = drug-drug interactions; MEs 
= medication errors 
 
2.3.2 Definitions 
Tab. 2 provides definitions for the most important terms. Fig. 5 shows the 
correlation of the terms, excluding lack of efficacy and addiction.  
 
2.3.3 Adverse drug events 
Any untoward effect related to the use of a drug is classified as adverse drug 
event (ADE). A causal relationship is not mandatory and the dosage can be 
appropriate or not (Tab. 2) [50]. Thus, next to ADRs occurring with appropriate 
dosage and given causality [56], also harm caused by overdosage or lack of 
efficacy are considered ADE.  
ADEs lead to increased morbidity, mortality, duration of hospital stay, and 
healthcare costs [56-58]. According to a review [56], 6.1% (range 0.17-65%) of all 
in-patients suffer from ADEs or ADRs. Only 5-15% of ADEs are detected by 
healthcare professionals [59, 60].  
Risk factors for ADEs are polymorbidity, polypharmacy, old age, female sex, but 
also altered drug elimination due to renal or hepatic impairment [61-63].  
An example for an ADE in patients with liver cirrhosis is the administration of 
diazepam 20mg/day to a patient with severe liver cirrhosis, after which the patient 
ADEs DDIs MEs ADRs 
Over-
dosages 
Non-
adherence 
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became confused and fell [64]. Since diazepam is contraindicated in patients with 
severe liver cirrhosis according to the Physicians’ Desk Reference (PDR) [65], the 
reason for the mentioned ADE is a ME.  
 
2.3.4 Adverse drug reactions 
For the definition of ADRs, see Tab. 2.  
In the US, severe ADRs are the reason or a contributing factor for 6-7% of hospital 
admissions [66], leading to a prolonged hospital stay and to costs similar to the 
drug treatment itself [67]. ADRs are under the top ten death causes in the United 
States [63]. 
Risk factors for ADRs are equal to the ones for ADEs [62, 63]. 
ADRs can be classified as type A or type B. Type A ADRs can be expected 
considering a drug’s pharmacologic profile. Thus, they are dose-dependent and 
predictable. Frequently, type A ADRs are detected in premarketing trials. Type B 
ADRs are also called idiosyncratic. They happen unexpectedly and cannot be 
predicted by the pharmacologic profile of a drug. Since type B ADRs are less 
frequent than type A ADRs and they possibly occur only in certain susceptible 
patient populations, they are often only detected after market entry of the drug 
[63].  
Since the recognition of ADRs is not easy [63], many ADRs stay undetected 
leading to increased healthcare costs due to additional investigations and 
treatment.  
An example for an ADR in patients with liver cirrhosis is the development of 
hyponatremia after the administration of torasemide 10mg/day to a patient with 
severe liver cirrhosis [68]. The administered dose is adequate and a possible 
causal relationship was determined.  
 
2.3.5 Drug-drug interactions 
Drug-drug interactions (DDIs) are present if the efficacy or tolerability of a drug is 
influenced by the presence of one or more other drugs [69]. Three different 
mechanisms of DDI exist, namely pharmacokinetic, pharmacodynamic, or 
pharmaceutic DDI [70].  
According to a review, less than 5% of all potential DDI result in an ADE. In in-
patients, 17% (range 4.8-31%) of all ADE are due to a DDI [56].  
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It is obvious that an increasing amount of administered drugs results in an 
increased likelihood for DDIs [70]. 
An example for a DDI in patients with liver cirrhosis is the development of epistaxis 
after the administration of ibuprofen and dalteparin. NSAIDs combined with low 
molecular weight heparins lead to an increased bleeding risk [71]. Additionally, 
patients with liver cirrhosis may already have coagulopathy (see above).  
 
2.3.6 Medication errors 
For a safe drug therapy, five “rights” are essential: The right drug must be given to 
the right patient at the right dose by the right route at the right time. If there is an 
error in the medication process, a ME is present. The error can happen at various 
steps of the medication process, that is during drug prescription, distribution, or 
administration [49]. According to a review, approximately 6% (range 0.04-56%) of 
administrations were erroneous in hospitalized patients. Errors at the drug 
prescription and administration level were most prevalent [56].  
Most MEs (>95%) do not result in an ADE [56, 72, 73]. In patients with liver 
cirrhosis, MEs may be quite frequent, since a significant amount (20%) of drugs is 
administered incorrectly regarding dosing or prescribing. Of all patients receiving 
one or more IDD(s), only 22% had an ADE [64].  
 
2.3.7 Preventability of adverse drug events 
It was estimated that in the US more than 1.5 Mio preventable ADEs occur every 
year [74]. As the ADR was reported to be the most frequent type of ADE [69, 75] 
and most ADRs are type A reactions (80%, range 51-100% [56]), many ADEs 
could potentially be prevented.  
Other aspects for the assessment of preventability are the time-course of the 
event and the susceptibility of the patient [76]. In dependence of when the ADE 
occurs after drug administration, different measures can be taken to prevent the 
ADE. For example, an ADE occurring only after long-term therapy (e.g. 
tolerance/dependence to benzodiazepines [77]) could be prevented by reducing 
the duration of therapy. Knowledge about a patient’s susceptibility for a certain 
ADE can help to increase drug safety. However, we must consider that not every 
susceptibility factor necessarily results in an ADE. Possibly, only the risk is 
increased, while the ADE itself rarely develops. For more detailed considerations 
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regarding preventability of ADEs, the study of Aronson et al. [76] provides a good 
overview.   
A general problem concerning preventability may be that at the moment, ADRs or 
ADEs are usually diagnosed retrospectively and by exclusion of other causes. 
Better would be a prospective consideration and recognition of ADRs or ADEs 
[63]. 
The following factors can contribute to the prevention of ADEs.  
First, education of healthcare professionals regarding prescribing patterns [61], 
common ADRs and pharmacovigilance is important [62].  
Secondly, drug therapy should regularly be reconsidered, especially if 
polypharmacy is present [62], to prevent DDIs or duplicate prescriptions. For drugs 
with a small therapeutic window, therapeutic drug monitoring should be considered 
[69]. In the surveillance of pharmacotherapy, community or clinical pharmacists 
can play a major role. 
Thirdly, characteristics of the individual patient should be taken into account. Risk 
factors for ADEs should be recognized and preventive measures considered [61]. 
In this respect, pharmacogenomics identifying genetic risk factors for ADRs may 
become more and more relevant with the aim to lead to safe and effective therapy 
for each individual patient [66]. In elderly patients or patients with hepatic or renal 
impairment, a dosage reduction followed by slow up-titration may be indicated [56, 
62]. 
The patient himself should be informed about the significance of taking his 
medication as well as about important ADRs [61, 62]. Additionally, caregivers such 
as nurses should also be informed about preventive measures [61].  
Finally, various health information technologies for the improvement of drug safety 
are being developed. On the one hand, the medical history of patients is recorded 
electronically, e.g. in integrated electronic medical records including demographic 
data, medical problems, medications, laboratory and radiologic results [74]. On the 
other hand, computerized physician order entry (CPOE) improves the legibility and 
appropriateness of orders [78]. Clinical decision support (CDS) tools, which can be 
integrated into CPOE, provide information regarding allergies, DDIs, correct 
prescribing or dosing, e.g. in patients with renal failure. Additional technologies 
used are bar code medication verification, intravenous infusion safety systems, 
and electronic medication administration records. For further information see the 
2 Introduction 
- 25 - 
 
publication of Forni et al. [78] or Cheng et al. [74]. It could be shown, that these 
technologies are effective in preventing MEs and/or ADEs [78].  
Regarding patients with liver cirrhosis, to the best of our knowledge, up to now 
neither CDS-tools for dose adjustment in patients with liver disease nor general 
studies investigating drug-related problems in patients with liver cirrhosis exist.  
 
2.3.8 Pharmacovigilance 
During clinical trials, i.e. before a drug is marketed, often only dose-dependent and 
frequent ADRs are observed. Furthermore, it is noteworthy that some populations 
are usually under-represented during clinical trials, such as women, the elderly, 
children, or patients with various comorbidities. Pharmacovigilance starts at the 
registration of a drug and is defined as the process of identifying, monitoring, and 
effectively reducing ADRs [63]. It deals for example with the detection of ADRs 
that were not observed before market entry. This may be due to a low frequency of 
these ADRs or because they occur only in special populations, e.g. in children, in 
patients with renal failure, or in pregnant women [62, 79].  
In Switzerland, it is mandatory to document and report serious and/or unexpected 
ADRs. Such reports of ADRs, so called individual case safety reports (ICSRs), are 
sent to one of six regional pharmacovigilance centers, which forward the ICSRs to 
the Swiss Agency for Therapeutic Products, Swissmedic. In case of serious ADRs 
associated with a specific drug or an abnormal frequency of reported ADRs, 
Swissmedic can take action, resulting e.g. in altered product information or drug 
withdrawal from the market [80]. Between 1972 and 1994 in the United Kingdom, 
approximately 4% of all new approvals were removed from the market due to 
ADRs [81]. 
The problem of under-reporting is well-known. A review found that a median of 6% 
(interquartile range 2-18%) of ADRs are reported to spontaneous reporting 
systems [82]. Wooten et al. [62] reported the following possible reasons for under-
reporting: “takes too much time”, “the form is too difficult to fill out”, “no one’s going 
to review this anyway”. However, the documentation and reporting of serious and 
unexpected ADRs is essential to gain more information about a drug’s safety 
profile. Therefore, all health care professionals should be educated and motivated 
to document and report ADRs [62, 80]. 
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3.1.1 Abstract 
Introduction: Efficacy of anti-infective therapy is vital, especially in weakened 
patients. Pharmacokinetic and/or pharmacodynamic changes are prevalent in 
case of impaired liver function. Up to now, no surrogate parameter allows to 
estimate the impact of liver disease on the pharmacokinetics of a drug.  
Methods: For each anti-infective drug on the Swiss market in 2012, we searched 
the literature for dose-dependent ADRs, hepatic ADRs, pharmacokinetics, and 
information about dose adjustment in patients with liver disease. We categorized 
the drugs according to their Q0 and hepatic extraction E into five categories. 
Results: Of the 104 anti-infectives on the Swiss market in 2012, 32, 13, and 4 
drugs underwent low, intermediate, and high hepatic extraction, respectively. 
Forty-six drugs were mainly renally eliminated and of 9 drugs, the elimination 
pathway was unknown. CYP P450 enzymes were involved in the metabolism of 
27% of all drugs. Biliary elimination affected one fifth of all drugs. The literature 
search revealed reports on hepatic ADRs for almost all of the drugs (N = 101). 
Pharmacokinetic alterations in liver disease were reported for 48% of the drugs. 
Discussion: With anti-infective therapy in liver disease, an ideal dose should be 
effective and non-toxic at the same time. Since liver disease does not lead to 
uniform pharmacokinetic alterations, dosage recommendation is difficult. 
Categorizing the drugs according to their pharmacokinetic properties and 
reviewing the literature helps to increase the awareness of the problem and allows 
for specific recommendations for many drugs. 
 
3.1.2 Introduction 
Anti-infective drugs and their early administration play a crucial role in the 
management of infections. In patients with impaired hepatic function, an effective 
anti-infective therapy is vital. Hepatic disease may debilitate these patients, 
predisposing them to increased morbidity due to infections. Moreover, the disease 
may be caused by a virus.  
While dose adjustment in renal failure is possible by means of creatinine 
clearance, no surrogate parameter allows estimating the severity and the 
pharmacokinetic impact of liver disease. Various authors have reviewed the 
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pharmacokinetic and/or pharmacodynamic changes in liver insufficiency [4, 14, 26, 
27, 83-86]. 
An approach to estimate the necessity of dose adjustment in liver disease bases 
on the pharmacokinetic characterization of drugs [27]. Eq. 4 describes the CLhep of 
a drug: 
 
( )
( ) QCL*f
Q*CL*fCL
intu
intu
hep +
=   (Equation 4, see Section 1.2.3 in Introduction) 
 
Q is the hepatic blood flow, fu the free fraction of the drug, and CLint the intrinsic 
clearance of the drug. 
For drugs with high hepatic extraction (E>0.6), where (CLintxfu)>>Q, we can 
simplify Eq. 4 to CLhep ≈ Q. CLhep of such drugs depends more on the hepatic 
blood flow Q than on the free fraction fu and the CLint of the drug. These drugs 
have a low bioavailability (<40%). If they are administered orally, a decreased 
blood flow across the liver, e.g. due to portosystemic shunts in liver cirrhosis, 
results in profoundly increased bioavailability. 
For drugs with low hepatic extraction (E<0.3), where Q>>(CLint x fu), Eq. 4 can be 
expressed as CLhep ≈ (fu x CLint). CLhep depends rather on fu and CLint than Q. 
Provided that solubility in the gastrointestinal tract and absorption is good, these 
drugs have a high bioavailability (>70%) and liver disease causes a problem due 
to reduced CLint resulting in a prolonged elimination phase. 
Drugs with intermediate hepatic extraction (E 0.3 – 0.6) have a bioavailability of 
40 - 70%, and their characteristics lie between the other two groups. For further 
information on this classification see the publication of Delcò et al. [27] 
With this work, we aimed at (i) categorizing anti-infective drugs according to their 
pharmacokinetic data to estimate the necessity of dosage adjustment in patients 
with liver disease, (ii) reviewing the literature for information about 
pharmacokinetic alterations and dose adjustment in case of impaired hepatic 
function, and (iii) providing dosage recommendations for patients with hepatic 
disease. 
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3.1.3 Methods 
For each anti-infective drug for systemic use (Anatomical Therapeutic Chemical 
Classification System [ATC] class J) on the Swiss market in the beginning of 2012, 
we searched for dose-dependent ADRs, hepatic ADRs, pharmacokinetics in 
general as well as pharmacokinetic alterations in patients with liver disease, and 
information about dose adjustment in patients with liver disease. For basic data, 
we consulted the Swiss product information [87], Micromedex® 1.0 [71] and 2.0 
System [88], the PDR [65], as well as other standard literature [89-93]. 
Furthermore, we performed a literature search (MEDLINE, EMBASE) for studies 
concerning the topics mentioned above using the key terms pharmacokinetics, 
drug toxicity, and liver diseases combined with the generic name of each drug. 
To group the drugs, we modified the classification previously used by Tchambaz et 
al. [94] and Schlatter et al. [95]. We added one CAT for mainly renally eliminated 
drugs (CAT4) and used CAT5 for drugs with unknown elimination pathway. We 
grouped the drugs by means of their Q0 and E (Fig. 4). We obtained E from the 
literature or calculated it as follows: 
 
Q
CL*QE sys0=  (Equation 7) 
 
E is the hepatic extraction, Q0 the extrarenal dose fraction, CLsys the systemic 
clearance (L/h), and Q the hepatic blood flow (54L/h) [94].  
We generated a database summarizing pharmacokinetic data, hepatic and dose-
dependent ADRs, literature, and product information. Based on this data, we made 
specific dosage recommendations for patients with liver insufficiency where 
possible. As a general rule for the different drug CAT, the dosage can be adjusted 
as shown in Fig. 4. The route of administration of a drug has to be taken into 
account. In contrast to oral dosing, a reduction of the initial dose of a parenterally 
administered drug is generally not indicated due to the avoidance of the first liver 
pass effect with this route of administration. We also considered pathophysiologic 
alterations in patients with liver disease such as decreased albumin synthesis 
potentially resulting in a decreased protein binding of highly protein-bound drugs. 
Additionally, pharmacodynamic alterations were taken into account. All this 
information taken together allowed us to make specific dose recommendations for 
many drugs. 
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To visualize the pharmacokinetic alterations of a drug in patients with liver 
disease, we generated standard plasma-concentration-time curves for the drug 
categories with mainly hepatic elimination (CAT1, CAT2, CAT3).  
 
3.1.4 Results 
In the beginning of 2012, 104 anti-infective drugs for systemic use (amphotericin 
and amphotericin liposomal were counted as two drugs) were registered in 
Switzerland. The major part consisted of antibacterial (N = 50) and antiviral drugs 
(N = 38), followed by antimycotic (N = 10) and antimycobacterial (N = 5) drugs as 
well as one immunoglobulin (N = 1). Tab. 3 gives an overview of all the drugs and 
the corresponding elimination CAT. Fig. 6 shows the distribution of the anti-
infectives into the five CAT. A similar amount of drugs underwent mainly hepatic 
(CAT1, CAT2, CAT3; N = 48; 46.2%) or renal (CAT4; N = 46; 44.2%) elimination. 
For ten drugs (9.6%), the elimination pathway was unknown.  
 
 
Fig. 6 Number of anti-infective drugs per drug category. Category 1 = high hepatic extraction; 
category 2 = intermediate hepatic extraction; category 3 = low hepatic extraction; category 4 = 
mainly renal elimination; category 5 = unknown elimination pathway 
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The simulated changes in plasma-concentration-time curves in patients with liver 
cirrhosis for each drug CAT are shown in Fig. 7. As would be expected, most 
pronounced changes occur in drugs with a high hepatic extraction (CAT1, Fig. 7A). 
For CAT4 drugs with mainly renal elimination (plasma-concentration-time curve 
not shown), liver disease does usually not have a significant impact on the 
pharmacokinetics provided that renal function is normal. 
 
Tab. 3 Anti-infective drugs on the Swiss market at the beginning of 2012 (N = 104) with the 
corresponding elimination categories. 
Elimination category Drugs  
1  
(high hepatic extraction),  
N = 4 
Spiramycin, azithromycine, boceprevir, maraviroc 
2  
(intermediate hepatic 
extraction), N = 13 
Tigecycline, phenoxymethylpenicillin, erythromycin, clarithromycin, 
itraconazole, posaconazole, isoniazid, ribavirin, indinavir, 
fosamprenavir, telaprevir, zidovudine, didanosine 
3  
(low hepatic extraction),  
N = 31 
Doxycycline, minocycline, ceftriaxone, cefixime, ertapenem, 
sulfamethoxazole, clindamycin, moxifloxacin, fusidic acid, 
metronidazole, ornidazole, nitrofurantoin, linezolid, daptomycin, 
amphotericin B, amphotericin B (liposomal), voriconazole, 
caspofungin, anidulafungin, rifampicin, rifabutin, pyrazinamide, 
brivudine, ritonavir, lopinavir, tipranavir, darunavir, stavudine, 
abacavir, nevirapine, efavirenz 
4  
(mainly renal elimination), 
N = 46 
Limecycline, amoxicillin, benzylpenicillin, flucloxacillin, piperacillin, 
cefazolin, cefuroxime, cefamandole, cefaclor, cefprozil, ceftazidime, 
cefpodoxime, ceftibuten, cefepime, aztreonam, meropenem, 
doripenem, imipenem, trimethoprim, tobramycin, gentamicin, 
amikacin, ofloxacin, ciprofloxacin, levofloxacin, vancomycin, 
teicoplanin, colistin, fosfomycin, fluconazole, flucytosine, 
ethambutol, aciclovir, ganciclovir, famciclovir, valaciclovir, cidofovir, 
valganciclovir, foscarnet, lamivudine, tenofovir disoproxil, adefovir 
dipivoxil, emtricitabine, entecavir, zanamivir, oseltamivir 
5  
(unknown elimination 
pathway), N = 10 
Norfloxacine, ketoconazole, saquinavir, nelfinavir, atazanavir, 
telbivudine, etravirine, enfuvirtide, raltegravir, palivizumab 
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Fig. 7 Expected pharmacokinetic alterations of the plasma-concentration-time curves of the 
different drug categories in patients with liver cirrhosis. A category 1 (high hepatic extraction); B 
category 2 (intermediate hepatic extraction); C category 3 (low hepatic extraction); D category 5 
(unknown elimination pathway) 
 
Tab. 4 summarizes the database for high hepatic extraction drugs. The database 
for the rest of anti-infective drugs on the Swiss market is listed in Appendix Tab. 
11 (anti-bacterials) or is available from the attached CD (whole database). 
Regarding the metabolism of all anti-infective drugs, most drugs (55; 52.9%) 
underwent minimal metabolism. Eighteen (17.3%) were metabolized by CYP P450 
enzymes, 8 (7.7%) by other enzymes, 3 (2.9%) by mere conjugation 
(glucuronidation, sulfation), and 2 (1.9%) by non-enzymatic pathways. Ten (9.6%) 
drugs underwent CYP P450 metabolism as well as conjugation (glucuronidation). 
For 8 (7.7%) drugs, we found not enough information about metabolic pathways. 
Six antiviral drugs, namely tipranavir, darunavir, saquinavir, atazanavir, lopinavir, 
and fosamprenavir, all protease inhibitors and strongly metabolized by CYP3A4, 
are usually combined with ritonavir, a strong inhibitor of CYP3A4, to increase their 
bioavailability. 
Biliary elimination of ≥50% affected 22 (21.2%) drugs, while 69 (66.3%) were not 
excreted by the bile. Of 13 (12.5%) drugs, the amount eliminated by bile could not 
be defined.  
For almost all drugs (N = 101), the literature reported hepatic ADRs. For 
vancomycin, cidofovir, and zanamivir no hepatic ADRs have been described so 
far. 
A           3 B  B 
C                 3 D  D 
  
Tab. 4 Extract of the database draft summarizing pharmacokinetic data, adverse drug reactions, pharmacokinetic studies, and recommendations in liver disease for 
anti-infective drugs. Listed are the high hepatic extraction drugs.  
Drug (route of 
application)  
Metabolism Kinetic 
parameters 
Hepatic ADRs Potentially dose-
dependent ADRs 
Studies, product information, and dose recommendations 
Spiramycin 
(oral) 
The exact 
metabolic pathway 
is unknown. 
Enterohepatic 
circulation may 
occur [87, 90, 96, 
97]. 
Q0: 0.85 
T1/2: 5h 
Vd: 5L/kg 
PB: 10% 
Foral: 36% 
CLsys: 84L/h 
E: >0.99 
BE: major 
Rare: elevated 
liver enzymes, 
hepatitis with and 
without 
cholestasis [87].  
gastrointestinal 
disturbances, intestinal 
overgrowth by non-
susceptible organisms, 
paresthesia, cholestatic 
hepatitis [87, 90] 
Studies: Hepatic dysfunction appears not to markedly affect the kinetics of 
spiramycin [90]. It is accepted that no dose reduction is necessary, but 
patients with liver cirrhosis should be monitored [98-100]. 
Product information: Caution in patients with liver insufficiency due to the risk 
of cholestatic jaundice [87]. 
Recommendation: According to pharmacokinetic data and literature, initial 
dose should be chosen in the lower range of normal and maintenance dose 
adjusted according to clinical effect and dose-dependent adverse drug 
reactions. Caution in patients with cholestasis. 
Azithromycine 
(oral)  
Metabolism mainly 
by N-
demethylation, but 
also O-
demethylation and 
hydroxylation 
(metabolites 
inactive) [87, 90]. 
Q0: 0.9 
T1/2: 50h 
Vd: 31L/kg 
PB: 50% 
Foral: 37% 
CLsys: 38L/h 
E: 0.63 
BE: major 
Occasionally: 
reversible 
asymptomatic 
elevations of liver 
enzymes (>3x 
ULN). Rare: 
hepatitis, 
cholestatic 
jaundice, liver 
necrosis, liver 
failure [87, 90]. 
gastrointestinal 
disturbances, intestinal 
overgrowth by non-
susceptible organisms, 
ototoxicity, neurotoxicity 
(headache, dizziness, 
convulsions, asthenia, 
paresthesia), 
palpitations, 
arrhythmias (QT-
prolongation, torsades 
de pointes), cholestatic 
hepatitis, neutropenia 
[65, 87, 90] 
Studies: Despite its hepatic metabolism, no dose modification seems 
necessary according to the results from a single dose study with 500mg 
azithromycin in 16 cirrhotic patients with mild or moderate hepatic impairment 
(Child-Pugh Class A and B) [101]. No clinical data are available for patients 
with severe hepatic impairment (Child-Pugh Class C) or in patients with 
cholestasis. Azithromycin is not recommended in these cases [102]. 
Product information: In cirrhotic patients with Child Pugh A and B no significant 
differences in pharmacokinetics were observed after a single dose compared 
to healthy subjects. Renal clearance seems to be increased instead. No data 
is available for multiple dosing. Caution in patients with liver insufficiency, due 
to its high hepatic elimination. No dose adjustment seems necessary in 
patients with mild and moderate liver dysfunction [87]. 
Recommendation: Choose doses in the lower range of normal. Caution in 
patients with cholestasis. 
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Tab. 4 (continued) 
Drug (route of 
application)  
Metabolism Kinetic 
parameters 
Hepatic ADRs Potentially dose-
dependent ADRs 
Studies, product information, and dose recommendations 
Boceprevir 
(oral) 
Main 
metabolism by 
aldo-keto 
reductase, 
minor 
metabolism by 
CYP3A4/3A5 
[65, 71, 87]. 
Q0: 0.97 
T1/2: 3.4h 
Vd: 11L/kg 
PB: 75% 
Foral: n.k. 
CLsys: 161L/h 
E: >0.99 
BE: major 
Occasionally: 
elevated bilirubin. 
Rare: 
cholecystitis [87]. 
myelosuppression 
(anemia, neutropenia, 
thrombocytopenia, 
leucopenia), chills, 
asthenia, decreased 
appetite, gastrointestinal 
disturbances, arthralgia, 
myalgia, neurotoxicity 
(insomnia, irritability, 
visual and hearing 
disturbances, depression, 
paresthesia), triglyceride 
elevations, palpitations, 
chest pain, exanthema 
[65, 87] 
Studies: In patients with moderate and severe liver disease compared to 
patients with normal liver function, the mean AUC of the active diastereomer of 
boceprevir was 32% and 45% higher, respectively. Mean Cmax was 28% and 
62% higher, respectively. Patients with mild liver disease had unaltered 
exposure to the active diastereomer of boceprevir [65]. 
Product information: Contraindicated in autoimmune hepatitis. No dosage 
adjustment necessary in patients with mild, moderate, or severe liver disease. 
No clinically significant pharmacokinetic alterations observed. The combination 
with peginterferon and ribavirin is contraindicated in patients with severe liver 
disease or decompensated liver cirrhosis [87]. No data on safety and efficacy 
in patients with decompensated liver cirrhosis or HBV co-infection [65]. 
Recommendation: In spite of pharmacokinetic data showing high hepatic 
extraction, boceprevir can be used as recommended in patients with mild and 
moderate liver disease due to no evidence for marked pharmacokinetic 
alterations in liver disease in clinical studies. In patients with severe liver 
disease, boceprevir in combination with peginterferon alfa and ribavirin is 
contraindicated. Caution in patients with cholestasis. 
Maraviroc 
(oral) 
Oxidation, N-
dealkylation by 
CYP P450 
3A4. Major 
inactive 
metabolite is a 
secondary 
amine [87]. 
Q0: 0.78 
T1/2: 15h 
Vd: 2.8L/kg 
PB: 76% 
Foral: 28% 
CLsys: 44L/h 
E: 0.64 
BE: n.k. 
Frequent: 
elevation of ALT, 
AST, bilirubin. 
Occasionally: 
cholestatic 
jaundice, liver 
cirrhosis, liver 
failure, portal 
vein thrombosis 
[71, 87]. 
dizziness, postural 
hypotension, increased 
pulse rate, asthenia [65, 
87, 103] 
Studies: Child Pugh A: Cmax and AUC increased by 11% and 25%, 
respectively. Child Pugh B: Cmax and AUC increased by 32% and 46%, 
respectively. Child Pugh C: No data [87]. 
Product information: Caution in patients with liver disease or HBV or HCV co-
infection, risk for hepatotoxicity may be increased. Monitor patients [87]. In 
Child Pugh A and B generally no dose adjustments are necessary [71]. 
Recommendations: According to product information, start with normal initial 
dose in patients with Child Pugh A and B cirrhosis (despite high hepatic 
extraction) and reduce maintenance dose ≥50%. In patients with Child Pugh C 
cirrhosis, consider reduction of initial dose and reduce maintenance dose 
≥50%. Monitor all patients for hepatotoxicity.  
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Tab. 4 (legend) 
ADRs = adverse drug reactions; ALT = alanine aminotransferase; AST = aspartate 
aminotransferase; AUC = area under the concentration-time curve; BE = biliary elimination; Cmax = 
maximal plasma concentration; CLsys = systemic clearance; CYP = cytochrome P450 enzymes; E = 
hepatic extraction; Foral = systemic bioavailability after oral administration; HBV = hepatitis B virus; 
HCV = hepatitis C virus; n.k. = not known; PB = protein binding; Q0 = extrarenal dose fraction; T1/2 
= elimination half-life; ULN = upper limit of normal; Vd = volume of distribution. 
 
Tab. 5 Information about dosage adjustment in patients with liver disease provided by the Swiss 
product information [87] 
 Number of drugs, N (%) 
Total 104 (100) 
Specific 
recommendationa 
52 (50.0) 
No specific 
recommendationb 
22 (21.2) 
No 
recommendation 
29 (27.9) 
a Including contraindications or specific dosage recommendations 
b
  Including recommendations to reduce dosage (without specification), to use the drug 
cautiously, or to avoid risk factors 
 
The literature search revealed data on pharmacokinetic alterations in case of liver 
disease for 50 (48.1%) drugs, whereas no or minimal pharmacokinetic alterations 
were observed for 27 (26%) drugs. We found no studies for 27 (26%) drugs.  
Tab. 5 summarizes the information about dose adjustment provided by the Swiss 
product information [87]. For 50% of the drugs, specific recommendations are 
available, while for the other drugs only unspecific (21% of all drugs) or no 
recommendations (28% of all drugs) are provided. Additional or different 
recommendations from the Swiss product information [87] were found for 18 
(17.3%) drugs in PDR [65], Micromedex® [71, 88], or in studies from the literature.  
For many drugs (N = 65; 59.6%), the dosage recommendations / pharmacokinetic 
observations in the literature coincided with our recommendations made on the 
basis of pharmacokinetic data. For all CAT1 drugs (spiramycin, azithromycine, 
boceprevir, maraviroc), for five CAT2 drugs (tigecycline, clarithromycin, ribavirin, 
telaprevir, didanosine), and for ten CAT3 drugs (cefixime, ertapenem, 
sulfamethoxazole, clindamycin, linezolid, daptomycin, rifabutin, ritonavir, 
atazanavir, stavudine) the literature and/or product information proposed a higher 
dosage than we would recommend according to pharmacokinetic data. For 
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zidovudine (CAT2), the literature and/or product information proposed a lower 
initial dose than we would recommend according to pharmacokinetic data. For 
aztreonam (CAT4), clinical studies suggest pharmacokinetic alterations in patients 
with alcoholic liver cirrhosis in spite of mainly renal elimination (Q0 = 0.2) and thus, 
dosage adjustment is considered necessary in such patients. For the remaining 18 
(17.3%) drugs, we found not enough literature and/or pharmacokinetic data to 
allow for a comparison. 
There are seven drugs for the treatment of HBV / HCV infection. Three 
(lamivudine, tenofovir, entecavir) undergo mainly renal elimination, two (telaprevir, 
ribavirin) undergo intermediate hepatic excretion, and one (boceprevir) high 
hepatic extraction. The elimination pathway of the remaining drug (telbivudine) is 
unknown. Biliary elimination is negligible for four drugs (lamivudine, tenofovir, 
entecavir, ribavirin), major for one drug (boceprevir), and unknown for two drugs 
(telbivudine, telaprevir). We found pharmacokinetic studies / observations in 
patients with liver disease as well as reports on hepatic ADRs for all of these 
drugs. Furthermore, the product information makes specific dosage 
recommendations for every drug used in the treatment of HBV or HCV. 
 
3.1.5 Discussion 
Literature reviews addressing dose adjustment of anti-infective drugs in patients 
with liver disease are rare. We have only found three studies [32, 104, 105]. In 
1988, Davey [104] summarized the significant studies and recommendations in 
patients with liver disease. He categorized the drugs by means of impaired hepatic 
elimination, potential toxicity, and changed pharmacodynamics in liver disease. 
Furthermore, he emphasized to consider the free fraction of a drug in patients with 
liver disease due to potentially reduced synthesis of albumin or α1-acid 
glycoprotein. The second study [105] concerns dosage adjustment of antimicrobial 
drugs in pediatric cancer patients with impaired hepatic or renal function. It lists 
many anti-infective drugs outlining their pharmacokinetic properties, hepatotoxicity, 
nephrotoxicity, and necessity of dosage adjustment in renal or hepatic failure. The 
work points out that for most substances eliminated primarily by the liver, no exact 
dosage recommendations are available. The authors recommend avoiding these 
drugs. If no alternative agent can be found, liver function and, if possible, drug 
levels in blood should be monitored [105]. Tschida et al. [32] used a classification 
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similar to the one we use and summarized all available studies investigating 
pharmacokinetic alterations of anti-infective drugs in patients with liver disease.  
More than half of the anti-infective drugs reviewed in our study undergo mainly 
hepatic metabolism, indicating the importance of considering dose reduction in 
patients with impaired hepatic function. Furthermore, one fifth of the drugs are 
mainly (≥ 50%) eliminated by the bile. Their administration requires caution in 
patients with biliary obstruction to avoid accumulation. 
Respective the drugs with mainly renal elimination, we should keep in mind that 
patients with liver cirrhosis may also have an impaired renal function [4, 27]. CAT4 
drugs with a narrow therapeutic index should be used with caution in patients with 
liver cirrhosis.  
Specific recommendations for patients with liver disease are difficult to make due 
to the diversity and individuality of pharmacokinetic changes in such patients. As a 
result, the Swiss product information [87] makes specific recommendations for 
only half of the anti-infective drugs. For the rest, unspecific or no 
recommendations are provided. 
In anti-infective therapy, efficacy is particularly important to avoid aggravation of 
the infection and to avoid developing resistance. This fact poses a problem to the 
dosage adjustment in patients with liver disease. The ideal dose should be 
efficacious and non-toxic at the same time. Such a dose is difficult to define due to 
the interindividual variability of liver alterations in hepatically impaired patients. In 
life-threatening infections, initial efficacy may outbalance non-toxicity. 
Consequently, we felt that for maraviroc and for boceprevir, despite high hepatic 
extraction, normal initial dose can be administered at least in patients with mild 
and moderate liver disease.  
Fosamprenavir, saquinavir, lopinavir, atazanavir, tipranavir, and darunavir are 
usually combined with ritonavir, which inhibits liver metabolism by CYP 3A4. Thus, 
reduced metabolism in liver disease is not relevant. Therefore, usually normal 
initial dose, at least in mild liver disease, may be used and maintenance dose 
should be adjusted by means of clinical effect and dose-dependent ADRs. For the 
combination of ritonavir with saquinavir as well as with atazanavir, we found not 
enough pharmacokinetic data to make dose recommendations.  
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3.1.6 Conclusion and Outlook 
Since efficacy of anti-infective therapy can save lives, pharmacokinetic 
implications to reduce dosage can be ignored for some drugs, and normal initial 
doses can be used to control the infection, especially for short-term treatments. 
However, for most anti-infective drugs, dose reduction according to 
pharmacokinetic data is indicated to avoid dose-dependent toxicity. The ideal dose 
should be chosen between good efficacy and low toxicity, but this is very difficult to 
define in patients with liver disease due to the variable pharmacokinetic / 
pharmacodynamic alterations.  
By categorizing the drugs according to their pharmacokinetic properties and 
reviewing the literature, we increase the awareness of the problem and give 
specific recommendations where possible. 
We plan to integrate our data on anti-infective drugs into a software system for 
electronic drug prescription, allowing the physician to access the information if 
required. 
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3.2.1 Abstract 
Background and aims: Patients with liver cirrhosis may be at risk for pDDIs and/or 
ADRs due to the severity of their disease and comorbidities associated with 
polypharmacy. 
Methods: We performed a cross-sectional retrospective study including 400 
cirrhotic patients and assessed diagnoses, medication patterns, pDDIs and ADRs 
at hospital admission. 
Results: The median (range) age of the patients was 60 (21-88) years; 68.5% 
were male. They had a total of 2415 diagnoses, resulting in 6 (1-10) diagnoses per 
patient. Frequent were diagnoses of the digestive system (28.4%), circulatory 
system (14.2%), blood and blood forming organs (8.7%), and psychiatric disorders 
(7.5%); 60.7% of the diagnoses were not liver-associated. The median number of 
drugs per patient was 5 (0-18), whereof 3 (0-16) were predominantly hepatically 
eliminated. Drugs were primarily indicated for gastrointestinal, cardiovascular, or 
nervous system disorders, reflecting the prevalent diagnoses. In 112 (28%) 
patients, 200 ADRs were detected, mainly associated with spironolactone, 
torasemide, furosemide and ibuprofen. In 86 (21.5%) patients, 132 pDDIs were 
detected. Seventeen of these pDDIs were the direct cause of 15 ADRs, whereof 3 
resulted in hospital admission. Patients with ADRs were older, had more 
comorbidities, were treated with more drugs, and had a worse renal function and 
more pDDIs than patients without ADRs. 
Conclusions: Pharmacotherapy is complex in cirrhotic patients. Hepatologists 
should know the principles of dose adjustment in cirrhosis and renal failure, but 
also the most important pDDIs of the drugs used to treat liver disease and 
comorbidities in this population. 
 
3.2.2 Introduction 
Liver cirrhosis remains a frequent cause of morbidity and mortality in most 
countries, including countries in Europe. Between 1997 and 2001, the yearly 
mortality rate due to liver cirrhosis was between 9.7 (Netherlands) and 43.5 
(Austria) per 100,000 males and between 5.6 (Sweden) and 16.7 (Austria) per 
100,000 females [11].  
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Since the liver plays a crucial role in the metabolism of endogenous and 
exogenous substances, impaired hepatic function may influence the 
pharmacokinetics of drugs used in cirrhotic patients. The absorption process may 
be altered [27, 106] and bioavailability may be increased due to portosystemic 
shunting [27, 107]. The free fraction and possibly also the free concentration of 
highly protein-bound drugs is increased in patients with hypoalbuminemia [27]. 
Finally, CLhep is usually decreased due to lower hepatic blood flow [27, 108] and 
decreased activity of phase I enzymes [27, 29, 30]. Pharmacodynamic changes 
are also prevalent in patients with liver cirrhosis. Increased sensitivity has been 
shown for central effects of morphine [109] and benzodiazepines [110] and for 
renal adverse effects of NSAIDs [43]. 
All of these factors can potentially influence the effectiveness of a drug and/or the 
likelihood that a drug is causing adverse reactions. ADRs may further increase 
morbidity and mortality in patients with liver disease. 
The current study had several aims concerning drug treatment of patients with 
liver cirrhosis. First, we wanted to find out which drugs are commonly prescribed in 
this group of patients. Secondly, we investigated the quantity and severity of 
pDDIs in these patients. Thirdly, we identified the ADRs. For this purpose, we 
characterized the medication pattern of 400 patients with liver cirrhosis and 
assessed the prevalence of pDDIs and ADRs at hospital admission. 
 
3.2.3 Methods 
3.2.3.1 Patients 
In the present cross-sectional, retrospective study, we included 400 patients with 
liver cirrhosis diagnosed by liver histology and/or typical clinical, sonographic, and 
computer tomographic signs. They were hospitalized at the University Hospital, 
Basel, Switzerland, between January 2002 and December 2007. The protocol of 
the study was accepted by the cantonal Ethics Committee. 
 
3.2.3.2 Data collection 
For each patient, demographic and clinical data, diagnoses, drugs administered, 
characteristics of the drugs administered (dosage and Q0), and pDDIs and ADRs 
[56] were collected at hospital admission. Creatinine clearance was calculated by 
the Cockcroft Gault equation [111]. Severity of liver cirrhosis was classified by the 
Child Pugh Score [112]. Drugs were grouped according to the ATC code. Drugs 
3 Results 
- 44 - 
 
with a Q0≥0.5 were defined as primarily hepatically eliminated. Potential DDIs were 
determined by screening the drug profiles using the online version of DRUG-REAX 
(Micromedex® 1.0 Healthcare Series, http://www.micromedex.com). Only pDDIs 
with moderate or major severity were considered. All ADRs were classified with a 
definite, probable, or possible causality-rating as described previously [113]. 
 
3.2.3.3 Statistical analysis 
The data were descriptively analyzed using Excel and/or SPSS (version 15.0). 
Comparisons between patients with ADRs and those without ADRs were 
performed using Student’s t-test or the chi-squared test without correction for 
repetitive testing. A significance level of 5% was chosen. 
 
3.2.4 Results 
3.2.4.1 Patient characteristics  
All patients studied were adults with males being more prevalent than females 
(Appendix Tab. 12). Most patients were in the Child Pugh classes B and C. The 
most frequent cause of liver cirrhosis was alcohol (69.8%), followed by viral 
hepatitis (13.5%) or a combination of both (9.7%). Almost 20% of the patients died 
during hospitalization, reflecting the severity of this disease. 
The patients had a total number of 2415 diagnoses at hospital admission, resulting 
in a median number of 6 (1-10) diagnoses per patient (Appendix Tab. 13). Most 
common were diseases of the digestive (28.4% of all diagnoses) or circulatory 
system (14.2%) as well as diseases of the blood and blood-forming organs (8.7%) 
and psychiatric disorders (7.5%). Approximately 40% of all diagnoses were 
associated with liver cirrhosis, e.g., spontaneous bacterial peritonitis, esophageal 
varices, and variceal bleeding. 
 
3.2.4.2 Medication at hospital admission  
The patients had a total of 1999 drugs at hospital admission (Tab. 6). The median 
number of drugs per patient was 5 (0-18); a median of 3 (0-16) were 
predominantly hepatically eliminated. Most prevalent were drugs affecting the 
alimentary tract and metabolism, mainly vitamins and proton pump inhibitors, as 
well as drugs for the cardiovascular system, primarily potassium-sparing diuretics, 
loop diuretics, and betablockers. Approximately 10% of all patients were treated 
with an angiotensin-converting enzyme (ACE) inhibitor. The most frequent drugs 
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for the nervous system were benzodiazepines and benzodiazepine-related drugs 
as well as opioids. Eleven percent of the patients were treated with 
phytomenadione, 7.5% with platelet-aggregation inhibitors, and 5% with oral 
anticoagulants. Astonishingly, 11% of the patients were treated with a 
cyclooxygenase (COX) inhibitor (NSAIDs, analgesic aspirin, or COX-2 inhibitor). 
About 68% of all administered drugs were eliminated primarily hepatically (Q0 
≥0.5).  
 
3.2.4.3 pDDIs and ADRs at hospital admission 
In 21.5% of all patients, a median of 1 (1-5) pDDI was detected (Tab. 7). Most 
prevalent possible adverse reactions due to pDDI were hyperkalemia (potassium-
sparing diuretics, ACE inhibitors, and potassium chloride), hypoglycemia 
(betablockers combined with insulin, sulfonylureas, and/or repaglinide), increased 
bleeding risk (anticoagulants such as dalteparin or phenprocoumon combined with 
NSAIDs), respiratory depression (benzodiazepines combined with opiates or 
phenobarbital), and cardiac problems (cardiac depression, QT prolongation). Of all 
pDDIs, 12.9% resulted in an ADR.  
ADRs were detected in 28% of the patients at entry (Tab. 8). Relative to the 
number of patients in each Child Pugh class, patients in class Child Pugh A were 
more frequently affected by ADRs (35.7% of patients) than those in class Child 
Pugh B (26.1%) or Child Pugh C (26.6%). Nonetheless, most ADRs (43.0%) 
occurred in patients with liver cirrhosis Child Pugh C. The drugs most frequently 
associated with an ADR were spironolactone, torasemide, furosemide, and 
ibuprofen. Most frequently, ADRs resulted in metabolic disorders (mainly 
hyperkalemia or hyponatremia associated with diuretics and/or ACE inhibitors), in 
gastrointestinal bleeding (associated with the use of NSAIDs or oral 
anticoagulants), and in urinary system disorders (mainly worsening renal function 
due to the use of diuretics and/or ACE inhibitors). Five percent of all ADRs 
affected the liver and/or the biliary system.  
Sixteen ADRs (8%) were the cause of hospital admission. These ADRs consisted 
of gastrointestinal bleeding associated with low dose aspirin, ibuprofen, or 
phenprocoumon; hyperkalemia associated with spironolactone or perindopril; and 
worsening renal function or ascites accumulation associated with ibuprofen. 
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Tab. 6 Drugs at hospital admission for patients with liver cirrhosis (n = 400 patients) 
 Number of drugs (% of 
patients receiving 
corresponding drug) 
Number of drugs with Q0 
≥0.5a (% of patients with 
corresponding drug) 
Number of drugs at hospital admission 1999 1360 
Drugs per patient at hospital admissionb 5 (0-18) 3 (0-16) 
Alimentary tract and metabolismc 650 255 
Vitaminsc 
Thiamine 
207 
89 (22.3%) 
6 
0 
Proton pump inhibitors 154 (38.5%) 154 (38.5%) 
Osmotically acting laxatives 83 (20.8%) 0 
Blood glucose lowering drugs 
(excl. insulins)c 
 
65 
 
38 
Magnesium 33 (8.3%) 0 
Insulins and analogues 27 (6.8%) 27 (6.8%) 
Calcium 27 (6.8%) 0 
Propulsives 12 (3.0%) 12 (3.0%) 
Potassium 11 (2.8%) 0 
Cardiovascular systemc 633 532 
Potassium sparing diureticsd 160 (40.0%) 160 (40.0%) 
Loop diuretics (high ceiling) 157 (39.3%) 127 (31.8%) 
Betablockers 
Propranolol 
146 (36.5%) 
78 (19.5%) 
134 (33.5%)  
78 (19.5%) 
ACE inhibitors 34 (8.5%) 8 (2.0%) 
Calcium antagonists 25 (6.3%) 25 (6.3%) 
Statins 23 (5.8%) 23 (5.8%) 
Angiotensin receptor blockers 19 (4.8%) 19 (4.8%) 
Thiazides 19 (4.8%) 0 
Organic nitrates 12 (3.0%) 12 (3.0%) 
Amiodarone 7 (1.8%) 7 (1.8%) 
Nervous systemc 270 257 
Benzodiazepines and related 
drugs 
Lorazepam 
Zolpidem 
Oxazepam 
Diazepam 
 
102 (25.5%) 
28 (7.0%) 
27 (6.8%) 
14 (3.5%) 
13 (3.3%) 
 
102 (25.5%) 
28 (7.0%) 
27 (6.8%) 
14 (3.5%) 
13 (3.3%) 
Opioids 
Methadone 
58 (14.5%) 
29 (7.3%) 
58 (14.5%) 
29 (7.3%) 
Antidepressants, excl. SSRIe 30 (7.5%) 30 (7.5%) 
SSRI 21 (5.3%) 21 (5.3%) 
Neuroleptics 17 (4.3%) 15 (3.8%) 
Antiepileptics 16 (4.0%) 10 (2.5%) 
Dopaminergic agents 8 (2.0%) 8 (2.0%) 
3 Results 
- 47 - 
 
Tab. 6 Drugs at hospital admission for patients with liver cirrhosis (n = 400 patients, continued) 
 Number of drugs (% of 
patients receiving 
corresponding drug) 
Number of drugs with Q0 
≥0.5a (% of patients with 
corresponding drug) 
Blood and blood-forming organsc 154 96 
Phytomenadione 44 (11.0%) 44 (11.0%) 
Platelet aggregation inhibitors 
(incl. aspirin low dose) 
 
30 (7.5%) 
 
30 (7.5%) 
Iron 26 (6.5%) 0 
Oral anticoagulants 21 (5.3%) 21 (5.3%) 
Heparins 15 (3.8%) 2 (0.5%) 
Folic acid 13 (3.3%) 0 
Musculo-skeletal systemc 93 89 
NSAIDs 28 (7.0%) 28 (7.0%) 
Paracetamol 23 (5.8%) 23 (5.8%) 
Allopurinolf  14 (3.5%) 14 (3.5%) 
Aspirin, analgesic 8 (2.0%) 8 (2.0%) 
COX-2 inhibitors 7 (1.8%) 7 (1.8%) 
Respiratory systemc 75  43  
Anti-infectives for systemic usec 63 30 
Antiviralsc 38 20 
Antibacterials 
Fluoroquinolones 
25 (6.3%) 
9 (2.3%) 
10 (2.5%)  
4 (1.0%) 
Systemic hormonal preparations, excl. 
sex hormones and insulinsc 
 
31 
 
31 
Corticosteroids 16 (4.0%) 16 (4.0%) 
Thyroid hormones 13 (3.3%) 13 (3.3%) 
Antineoplastic and immunomodulating 
agentsc  
 
15 
 
10  
Genito-urinary system and sex 
hormonesc 
 
10 
 
9  
Variousc 5 5 
a
 Only drugs with known Q0 included 
b
 Data are presented as median (range) 
c
 One individual patient may have >1 drug of the corresponding group, % not calculated 
d Spironolactone accounts for 97.5% of this group. It is mainly converted to active metabolites (the 
two major ones being canrenone and 7-alpha-thiomethylspironolactone), which are primarily renally 
eliminated 
e
 Including tri-, tetracyclic antidepressants, and venlafaxine 
f
 Allopurinol is rapidly converted by the liver to the slightly less active oxypurinol, which is renally 
eliminated. Dosage adjustment is necessary in both patients with liver and renal insufficiency 
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Tab. 7 Major and moderate pDDIs in patients with liver cirrhosis (n = 400 patients) 
DDI/potential outcome Number of 
pDDI 
Interacting drugs (number of cases) 
Total pDDIs 132 (100%)  
Major pDDIs 56 (42.1%)  
Moderate pDDIs 76 (57.9%)  
Number of different pDDIs 91  
Number of patients with ≥1 
pDDI 
86 (21.5% of 
all patients) 
 
pDDI per patienta, b 1 (1-5)  
DDIs resulting in an ADR 17 (12.9% of 
all pDDIs) 
 
Hyperkalemia 
 
 
 
+ risk for nephrotoxicity  
24 (18.2%) 
 
 
 
9 (6.8%) 
Major: Potassium-sparing diuretics + ACE 
inhibitors (9), potassium chloride + spironolactone 
(4), potassium chloride + lisinopril (1) 
 Moderate: Spironolactone + valsartan (1) 
Moderate: Potassium-sparing diuretics + NSAID 
(9) 
Hypoglycemia 23 (17.4%) Moderate: Betablocker + insulin (14), betablocker 
+ sulfonylureas (8), betablocker + repaglinide (1) 
Increased bleeding risk 17 (12.9%) Major: Dalteparin + acetylsalicylic acid (low dose) 
(1), dalteparin + clopidogrel (1), dalteparin + 
phenprocoumon (1), dalteparin + ibuprofen (1); 
acetylsalicylic acid (low dose) + phenprocoumon 
(2), acetylsalicylic acid (low dose) + venlafaxine (1) 
Moderate: Phenprocoumon + allopurinol (3), 
phenprocoumon + amiodarone (3), 
phenprocoumon + diclofenac (1); acetylsalicylic 
acid (low dose) + verapamil (2), acetylsalicylic acid 
(low dose) + ibuprofen (1) 
Respiratory depression  10 (7.6%) Major: Benzodiazepines + opiates (7), 
benzodiazepines + phenobarbital (2); fentanyl + 
hydrocodone (1) 
Cardiac depression 9 (6.8%) Major: Betablocker + calcium antagonist (4), 
betablocker + amiodarone (2) 
Moderate: Digoxin + betablocker (3) 
QT prolongation 7 (5.3%) Major: Amitriptyline + sulfamethoxazole, 
trimethoprim (2); ciprofloxacin + propafenone (1); 
fluoxetine + haloperidol (1), fluoxetine + 
methadone (1); risperidone + tramadol (1); 
trimipramine + venlafaxine (1) 
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Tab. 7 Major and moderate pDDIs in patients with liver cirrhosis (n = 400 patients, continued) 
DDI/potential outcome Number of 
pDDI 
Interacting drugs (number of cases) 
Digoxin toxicity 6 (4.5%) Major: Digoxin + hydrochlorothiazide (2), digoxin + 
spironolactone (2), digoxin + amiodarone (1)  
Moderate: Digoxin + furosemide (1) 
Altered methadone 
exposure 
6 (4.5%) Moderate: Methadone + HIV protease inhibitor (4), 
methadone + efavirenz (2) 
Serotonin syndrome 4 (3.0%) Major: Mirtazapine + fluoxetine (1), mirtazapine + 
tramadol (1), mirtazapine + venlafaxine (1); 
tramadol + venlafaxine (1) 
Reduced efficacy of 
levodopa 
4 (3.0%) Moderate: Levodopa + iron (2), levodopa + 
levomepromazine (1), levodopa + olanzapine (1) 
Other 22 (16.7)  
a
 Referring to the patients with one or more pDDI (n = 86) 
b
 Data are presented as median (range) 
 
Fifteen ADRs (7.5%) resulted from a DDI; among them five patients with bleeding 
disorders (gastrointestinal bleeding, epistaxis, anemia), four patients with 
hyperkalemia, three patients with cardiovascular disorders (hypotension, 
bradycardia, torsade de pointes) as well as one patient each with a psychiatric 
disorder, somnolence, and collapse. Three DDI-associated ADRs were the reason 
for hospital admission, namely gastrointestinal bleeding due to the combination of 
aspirin (100 mg/day) and phenprocoumon, symptomatic bradycardia due to the 
combination of amiodarone and propranolol, and hyperkalemia due to the 
combination of spironolactone and perindopril. 
The 36 NSAIDs prescribed (NSAIDs and analgesic aspirin) were associated with 
24 ADRs in 18 patients (50% of all patients with a NSAID) (Fig. 8). The most 
prevalent ADRs due to NSAIDs were gastrointestinal bleeding (14/24), bleeding-
associated anemia (3/24), exacerbation of ascites (2/24), and thrombocytopenia 
(2/24). The 53 ACE inhibitor or sartan prescriptions resulted in 20 ADRs in 10 
patients (19% of patients treated with an ACE inhibitor or sartan, Fig. 8). 
Symptoms observed were worsening renal function (6/20), syncope (4/20), 
hyperkalemia (3/20), hyponatremia (3/20), and hypotension (2/20). In contrast, of 
146 betablocker prescriptions, only 12 ADRs (hypotension, syncope, confusion) 
were identified in 9 patients (6% of all patients with a betablocker, Fig. 8). 
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Tab. 8 Prevalence of ADRs with a definite, probable, or possible causality rating in 400 patients 
with liver cirrhosis 
ADR Number of ADRs 
(total; according 
to Child Pugh A, 
B, C) 
Drugs associated with ADRa (cases according 
to Child Pugh A, B, C)b 
Total ADR 
Child Pugh A 
Child Pugh B 
Child Pugh C 
200 (100.0%) 
46 (23.0%) 
68 (34.0%) 
86 (43.0%) 
Spironolactone (9, 11, 30), torasemide (5, 7, 
20), furosemide (4, 1, 10), ibuprofen (1, 4, 6) 
Number of ADR per patientc,d 
Child Pugh A 
Child Pugh B 
Child Pugh C 
1 (1-5) 
1 (1-5) 
1 (1-5) 
1.5 (1-5) 
 
Patients with ≥1 ADR 
Child Pugh A 
Child Pugh B 
Child Pugh C 
112 (28% of all patients) 
25 (35.7% of Child Pugh A patients) 
41 (26.1% of Child Pugh B patients) 
46 (26.6% of Child Pugh C patients) 
ADR with definite/probable 
causality rating  
24 (12.0%)  
(8, 11, 5) 
Spironolactone (3, 1, 1), phenprocoumon (0, 
4, 0), ibuprofen (0, 1, 3), acetylsalicylic acid 
low dose (1, 3, 0) 
ADRs with possible causality 
rating 
176 (88.0%) 
(38, 57, 81) 
Spironolactone (6, 10, 29), torasemide (3, 7, 
19), furosemide (3, 1, 10), propranolol (2, 2, 
3) 
ADRs as a reason for 
hospital admission 
16 (8.0%) 
(6, 5, 5) 
Spironolactone (3, 0, 1), acetylsalicylic acid 
low dose (1, 2, 0), ibuprofen (0, 0, 3), 
torasemide (2, 0, 1), perindopril (2, 0, 0), 
phenprocoumon (0, 2, 0) 
ADRs due to ≥1 DDI 15 (7.5%) 
(6, 7, 2) 
Major: Spironolactone + ACE inhibitors (1, 0, 
1), opiates + benzodiazepines (1, 1, 0), 
acetylsalicylic acid low dose + dalteparin (0, 
1, 0), acetylsalicylic acid low dose + 
phenprocoumon (0, 1, 0), dalteparin + 
ibuprofen (1, 0, 0), diltiazem + betablockers 
(2, 0, 0), amiodarone + propranolol (0, 1, 0) 
ADR due to DDI causing 
hospital admission 
3 (2.0%) 
(1, 2, 0) 
Acetylsalicylic acid low dose + 
phenprocoumon (0, 1, 0), perindopril + 
spironolactone (1, 0, 0); amiodarone + 
propranolol (0, 1, 0) 
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Tab. 8 Prevalence of ADRs with a definite, probable, or possible causality rating in 400 patients 
with liver cirrhosis (continued) 
ADR Number of ADRs 
(total; according 
to Child Pugh A, 
B, C) 
Drugs associated with ADRa (cases according 
to Child Pugh A, B, C)b 
ADR according to system 
organ class 
Metabolic and 
nutritional disorders 
 
 
54 (27.0%) 
(13, 13, 28) 
 
 
Spironolactone (4, 6, 17), torasemide (1, 2, 
6), furosemide (3, 0, 3), hydrochlorothiazide 
(1, 2, 0), chlortalidone (3, 0, 0), amiloride (0, 
3, 0), ramipril (0, 0, 2), enalapril (0, 2, 0) 
Gastro-intestinal 
system disorders 
30 (15.0%) 
(6, 13, 11) 
Acetylsalicylic acid low dose (1, 4, 0) and 
analgetic (1, 1, 1), ibuprofen (0, 2, 3), 
mefenamic acid (1, 2, 1), iron (0, 2, 1), 
spironolactone (0, 0, 3), phenprocoumon (0, 
2, 0) 
Urinary system 
disorders 
25 (12.5%) 
(3, 9, 13) 
Torasemide (2, 3, 8), spironolactone (2, 2, 6), 
furosemide (0, 1, 4), enalapril (0, 1, 1), 
lisinopril (1, 0, 1) 
Cardiovascular 
disorders, general 
16 (8.0%) 
(6, 3, 7) 
Furosemide (1, 0, 2), amlodipine (2, 0, 1), 
diltiazem (2, 0, 0), ramipril (0, 1, 1), 
spironolactone (1, 0, 1), torasemide (0, 0, 2) 
Central and 
peripheral nervous 
system disorders 
15 (7.5%) 
(1, 6, 8) 
Zolpidem (1, 0, 2), oxazepam (0, 1, 1), 
propranolol (0, 0, 2), ropinirole (0, 2, 0), 
spironolactone (0, 1, 1), torasemide (0, 1, 1) 
Liver and biliary 
system disorders 
10 (5.0%)  
(1, 3, 6) 
Spironolactone (1, 1, 1), enalapril (0, 1, 1) 
Psychiatric disorders 10 (5.0%) 
(4, 4, 2) 
Midazolam (1, 0, 1), oxazepam (0, 2, 0), 
propranolol (1, 1, 0), zolpidem (1, 0, 1) 
Platelet, bleeding 
and clotting 
disorders 
10 (5.0%) 
(3, 5, 2) 
Spironolactone (1, 0, 1), torasemide (1, 0, 1) 
Red blood cell 
disorders 
8 (4.0%) 
(2, 2, 4) 
Ibuprofen (0, 1, 2), torasemide (1, 0, 2) 
Heart rate and 
rhythm disorders 
4 (2.0%) 
(1, 2, 1) 
e 
Other 18 (9.0%) 
(6, 8, 4) 
e 
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Tab. 8 Legend 
a
 Most frequent drugs associated with ADR mentioned 
b
 Sum of cases may exceed the number of ADRs (more than one drug can cause the same ADR) 
c Referring to the patients with one or more ADRs (n = 112) 
d Data are presented as median (range) 
e
 No drug responsible for more than one case 
 
 
Tab. 9 Cirrhotic patients with one or more ADRs in comparison with cirrhotic patients without an 
ADR 
a
 Data are presented as median (range) 
b
 Due to incomplete data (body weight, serum creatinine), n = 107 and 279 for patients with and 
without ADR, respectively 
c
 Due to incomplete data (body weight, height), n = 63 and 186 for patients with and without ADR, 
respectively 
Characteristics Patients with ADR (n = 
112) 
Patients without ADR (n 
= 288) 
p-
value 
Age (years)a 61 (35-88) 58 (21-87) 0.017 
Male 77 (68.8%) 197 (68.4%) 0.947 
Creatinine clearance (mL/min)a, b 64 (9-290) 92 (9–280) 0.001 
BMI (kg/m2)a, c 24.3 (16.0-42.0) 24.9 (13.5-47.2) 0.997 
Child Pugh classification 
Child Pugh A 
Child Pugh B 
Child Pugh C 
 
25 (22.3%) 
40 (35.7%) 
47 (42.0%) 
 
45 (15.6%) 
117 (40.6%) 
126 (43.8%) 
0.282 
Diagnoses per patienta 6 (3-10) 6 (1-10) 0.036 
Drugs per patient 6 (0-15) 4 (0-18) <0.001 
Drugs with Q0 ≥0.5 per patient 4 (0-12) 3 (0-16) <0.001 
Patients with ≥1 hepatically 
eliminated drug 
111 (99.1%) 235 (81.6%) <0.001 
Number of pDDIs per patient 0 (0-5) 0 (0-5) 0.012 
Patients with ≥1 pDDI 35 (31.3%) 51 (17.8%) 0.004 
Length of hospital stay (days)a 12 (1-77) 14 (2-116) 0.984 
Patients died during hospitalization 23 (20.5%) 44 (15.3%) 0.233 
Cause of cirrhosis 
Alcohol 
Viral Hepatitis 
Both 
 
87 (77.7%) 
9 (8.0%) 
7 (6.3%) 
 
192 (66.7%) 
45 (15.6%) 
32 (11.1%) 
0.056 
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Fig. 8 Number of prescriptions, adverse drug reactions (ADRs), and patients with ADRs for specific 
drug classes. NSAIDs Nonsteroidal anti-inflammatory drugs, ACEIs angiotensin-converting enzyme 
inhibitors, ARBs angiotensin receptor blockers 
 
3.2.4.4 Cirrhotic patients with one or more ADR compared with cirrhotic patients 
without an ADR 
When comparing patients with ADRs to those without ADRs (Tab. 9), patients with 
ADRs were significantly older than those without ADRs (61 vs. 58 years, p<0.05), 
had a lower creatinine clearance (64.3 vs. 91.6mL/min, p<0.001), had more total 
diagnoses (6.38 vs. 5.91, p<0.05), as well as more non-liver-associated diagnoses 
(4.20 vs. 3.77, p<0.05). They had more drugs prescribed (6 vs. 4, p<0.001), as 
well as more drugs with predominantly hepatic elimination (4 vs. 3, p<0.001). 
Patients with ≥1 hepatically eliminated drug were more prevalent in the ADR group 
(99.1 vs. 81.6%, p<0.001). The same was true for patients with ≥1 pDDI at hospital 
admission (31.3 vs. 17.8%). Furthermore, pDDIs were more prevalent in patients 
with ADRs than in the control group (0.50 vs. 0.26 per patient, p<0.05). 
 
3.2.5 Discussion 
Studies on patients with liver cirrhosis focusing on drug therapy and drug-related 
problems are scarce in the literature. Lucena et al. investigated prescribing 
patterns and drug use in patients with liver cirrhosis [114, 115]. To prevent or treat 
complications of cirrhosis, diuretics, anti-ulcer drugs, laxatives, and vitamin K were 
the drugs prescribed most often [114]. Frequent medications for nonhepatic 
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comorbidities consisted of insulin, oral antidiabetics, cardiovascular drugs (calcium 
antagonists, ACE inhibitors, angiotensin receptor blockers), as well as drugs for 
the nervous (anxiolytics, hypnotics) and respiratory system [115]. The medication 
pattern of the patients in our study was similar to the patients reported by Lucena 
et al. [114, 115], suggesting that these studies reliably reflect the medication 
pattern in cirrhotic patients. 
Every fifth patient in our study population had a pDDI, every fourth had an ADR, 
and 8% of the patients were hospitalized due to an ADR. This is in line with the 5-
10% prevalence for ADR-related hospitalizations found in the meta-analysis by 
Lazarou et al. [116], but slightly more than the 5.1-6.5% reported in a retrospective 
cohort study [117] and in a prospective observational study [118]. Compared to 
patients without ADRs, patients with ADRs had more diagnoses and more drugs 
prescribed, received more drugs eliminated hepatically, had more pDDIs, and had 
a more compromised renal function. 
Polypharmacy is a known risk factor for ADRs [56, 60, 119] and DDIs [120, 121]. 
Our data indicate that cirrhotic patients who have more comorbidities have more 
drugs prescribed and are therefore at a higher risk for ADRs. The relationship 
between number of diagnoses and number of drugs prescribed is well established 
[121]. The resulting polypharmacy is a risk factor for pDDIs [120, 121] and also for 
ADRs [56, 60, 119], which may be related to DDIs. 
Our data suggest also that treatment with drugs with predominantly hepatic 
elimination is a risk factor for ADRs. More than 50% of the drugs used in our study 
fall into this category. Patient exposure to such drugs may be increased mostly 
due to elevated oral bioavailability and/or decreased CLhep, possibly leading to an 
increased incidence of dose-dependent ADRs [27]. Astonishingly, systematic 
publications focusing on hepatically eliminated drugs as a risk factor for ADRs in 
patients with liver disease are lacking. The drugs with predominantly hepatic 
elimination associated with ADRs in our population were mostly cardiovascular 
drugs (torasemide, spironolactone, propranolol, amlodipine, diltiazem), NSAIDs 
(ibuprofen, acetylsalicylic acid, mefenamic acid), phenprocoumon, and 
benzodiazepines or related agents (midazolam, oxazepam, zolpidem). If possible, 
such drugs should be started at a low dose with careful up-titration until reaching a 
satisfactory drug response or toxicity. 
A further risk factor for ADRs is impaired renal function. Impaired glomerular 
filtration is a well-known risk factor for ADRs also in other populations such as the 
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elderly [56, 122]. In our study, patients with ADRs had a lower creatinine clearance 
as compared to patients without ADRs. Impaired glomerular filtration may be 
associated with decreased renal clearance and increased exposure to drugs with 
a predominantly renal excretion. Importantly, patients with liver cirrhosis and 
ascites can have a creatinine clearance <60mL/min in spite of a normal serum 
creatinine [123], mostly due to impaired hepatic formation of creatine and 
increased tubular secretion of creatinine [27, 124]. Since the Cockcroft formula 
may overestimate the creatinine clearance in cirrhotic patients, drugs with 
predominantly renal elimination and dose-dependent ADRs should be dosed very 
carefully in cirrhotic patients [27]. 
Another important risk factor for ADRs is the presence of pDDIs. In our study, 
7.5% of all ADRs were due to a DDI and 12.9% of the DDIs resulted in an ADR. In 
a recent review of hospitalized patients on different wards, 17% (range 5 - 31%) of 
all ADRs were reported to be due to DDIs [56]. In patients with hematopoietic stem 
cell transplantation (HSCT), 16% of the ADRs were caused by a DDI and 33% of 
all DDIs resulted in an ADR [113]. A comparison of the findings in patients with 
liver cirrhosis suggests that the DDIs in cirrhotics are less severe compared to 
DDIs in patients with HSCT. This is due to the fact that imidazole and triazole 
antimycotics used in patients with HSCT are CYP inhibitors interacting with 
immunosuppressants such as cyclosporin and tacrolimus, which are used 
routinely in HSCT patients. Nevertheless, pDDIs possibly resulting in severe ADRs 
are present also in cirrhotic patients; they are known and should be avoided. 
The drugs most frequently involved in ADRs and pDDIs in our patients were ACE 
inhibitors, diuretics, NSAIDs, and oral anticoagulants. ACE inhibitors predispose 
cirrhotic patients for electrolyte disturbances and renal ADRs. The risk for 
hyperkalemia in cirrhotic patients treated with ACE inhibitors is increased 5.2-fold 
compared to patients without liver disease [125]. Patients with liver cirrhosis and 
portal hypertension have an activation of the RAAS and of the sympathetic 
nervous system, leading to renal vasoconstriction, impaired renal perfusion and 
glomerular filtration [126], and increased sodium retention [127]. Since drugs 
interfering with the RAAS such as ACE inhibitors or sartans can further impair 
glomerular filtration due to reduced filtration pressure, they should be used very 
cautiously in cirrhotic patients. Nevertheless, ACE inhibitors and sartans are 
prescribed frequently in cirrhotic patients [115]. 
3 Results 
- 56 - 
 
NSAIDs and COX-2 inhibitors block renal production of prostaglandins, possibly 
leading to impaired renal perfusion and glomerular filtration, sodium retention and 
increase in ascites [27, 43]. Furthermore, NSAIDs may be associated with 
bleeding from esophageal varices and/or gastrointestinal ulcers due to their toxic 
effects on gastrointestinal epithelia and inhibition of thrombocyte function. In a 
case-control study including patients with esophageal varices with or without 
variceal bleeding, the use of NSAIDs in the week prior to the index day was 
significantly more common in bleeding patients (OR = 2.8) [128]. Taking into 
account the risks for gastrointestinal bleeding, deterioration of renal function and 
increase of ascites, it is astonishing that 7% of our patients used NSAIDs and 2% 
analgesic aspirin. A clearer communication of the risks associated with the use of 
these drugs and of the analgesic alternatives in this population is therefore 
necessary. 
Our study has several limitations. A first limitation is the retrospective character of 
the study. The elaborated data were therefore limited to the information provided 
in the medical records, and it was sometimes not possible to obtain more 
information on the patient‘s situation or drug history prior to hospitalization. A 
second limitation is the limited sample size, which resulted in relatively small 
numbers of ADRs and DDIs. Nevertheless, we are convinced that the study 
provides important safety data in patients with liver cirrhosis and helps in 
identifying medication risks. 
From the data of our study, we conclude that patients with liver cirrhosis have 
many comorbidities predisposing them to polypharmacy, which is associated with 
pDDIs and ADRs. Besides polypharmacy, important risk factors for ADRs in 
cirrhotic patients are lack of dose adjustment of drugs eliminated predominantly by 
the liver or by the kidney and certain pDDIs. Hepatologists should therefore not 
only know the principles of dose adjustment in patients with liver and/or renal 
failure, but also the most important DDIs of the drugs used to treat liver disease 
and comorbidities in this population. 
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3.3.1 Abstract  
Background & Aims: To assess drug-related problems in patients with liver 
cirrhosis by investigating the prevalence of IDDs and their association with ADRs 
and costs. 
Methods: Cross-sectional retrospective study assessing the dose adequacy of 
drug treatment of 400 cirrhotic patients at the day of hospital admission based on 
previous own studies and standard literature. We also determined the prevalence 
of total and preventable ADRs and potential drug-cost savings by dose adjustment 
and additional hospital stay due to preventable ADRs. 
Results: Of all 1653 drugs prescribed (median 4 per patient), 336 (20%) were 
IDDs in 184 patients. In total, 198 ADRs (83% preventable) occurred in 110 
patients. Sixty-one (31% of all ADRs) were associated with IDDs in 40 patients, 
whereof 77% were preventable. Especially NSAIDs and psycholeptics were a 
frequent cause of preventable ADRs associated with IDDs. IDDs were more 
frequently associated with ADRs than correctly dosed drugs (CDDs) and patients 
with IDDs were more frequently admitted to the hospital due to ADRs. 
Hospitalization of patients with IDDs causing preventable ADRs resulted in 94 
additional hospital days, costing 151,000 Euros. Potential drug-cost savings 
(averaging approximately 400 Euros per hospitalized patient) result mainly from 
hospitalizations due to preventable ADRs and to a lesser extent from consequent 
dose adjustment. 
Conclusion: IDDs in patients with liver cirrhosis are associated with an increased 
frequency of ADRs, hospital admissions, and costs. Education of prescribing 
physicians concerning problematic drugs in patients with liver cirrhosis should be 
improved. 
 
3.3.2 Introduction 
The elimination of the majority of drugs on the market depends on liver function. 
About two thirds of the drugs on the Swiss market have a Q0>0.5 and are thus 
cleared mainly by the liver. Most patients with liver cirrhosis have an impaired 
hepatic handling of such drugs, depending on the severity of cirrhosis [4, 27].  
In patients with liver cirrhosis, hepatic extraction can be impaired, leading to a 
substantial increase in bioavailability of drugs that have a high hepatic extraction in 
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healthy subjects. This is mainly due to an impaired exposure of the hepatocytes to 
blood because of extra- and intrahepatic shunts [14]. Furthermore, the access of 
drugs to hepatocytes may be diminished in cirrhotic livers due to capillarization of 
the sinusoidal endothelium [129].  
In addition to increased bioavailability, CLhep of most drugs mainly metabolized 
and/or excreted by the liver is reduced in patients with liver cirrhosis. For drugs 
with a high hepatic extraction, this is mainly due to impaired blood flow across the 
liver [4, 27, 108, 130]. For drugs with a low hepatic extraction, metabolism by 
phase I enzymes, in particular CYPs, is the critical factor [27]. Several 
investigations have shown that the enzyme content and/or the activity of the most 
important CYPs are reduced in cirrhotic livers [4, 27, 31]. CYPs appear to be more 
sensitive to liver cirrhosis than phase II enzymes such as UGT [4].  
Beside pharmacokinetic alterations, pharmacodynamic aspects must also be 
considered as a potential reason for ADRs in this patient population. For example, 
NSAIDs should be avoided due to the risk for impaired renal perfusion, eventually 
leading to renal failure [27]. Similarly, the susceptibility to central adverse effects of 
opiates such as morphine [109] and of benzodiazepines [110] is increased in 
patients with liver cirrhosis. 
We recently published a cross-sectional retrospective study presenting 
demographic data, medication patterns, pDDIs, and ADRs in 400 patients with 
liver cirrhosis admitted to the University Hospital of Basel [68]. We found that 28% 
of the patients had at least one ADR and 21.5% of the patients at least one pDDI 
at hospital admission. In the current study, we focused on the quality of dose 
adjustment in this population and we estimated the excess of ADRs, 
hospitalization days and costs in patients with IDDs at hospital admission. 
 
3.3.3 Patients and Methods 
The study is based on the same population described previously [68]. The study 
design, patients included, data collection, and previous descriptive analyses 
regarding patients, diagnoses, and medication are described in detail in this earlier 
study. 
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3.3.3.1 Drug categorization 
The drugs were classified by means of their Q0 and their hepatic extraction (E) into 
five CAT. Drugs with a Q0 ≥0.5 were considered to undergo mainly hepatic 
elimination. For drugs with Q0 ≥0.5, E was either obtained from the literature or 
calculated using Eq. 7: 
 
Q
CL*QE sys0=  (Equation 7) 
 
where CLsys is the systemic clearance (L/h), Q0 the extrarenal dose fraction of a 
specific drug, and Q the hepatic blood flow (~54L/h). 
The drugs were further categorized according to E into the three categories high 
hepatic extraction drugs (CAT1), intermediate hepatic extraction drugs (CAT2), 
and low hepatic extraction drugs (CAT3). Drugs with a Q0<0.5 are excreted mainly 
by the kidney (CAT4). CAT5 refers to drugs with an unknown Q0 and/or E. For 
further information regarding this classification, see Fig. 4 and the publications of 
Delco et al. [27], Tchambaz et al. [94], and Schlatter et al. [95]. 
 
3.3.3.2 Dose assessment and ADRs 
The patients’ dose at hospital admission was compared to published dosing 
recommendations in patients with liver cirrhosis (Fig. 4 and [27, 94, 95]) and 
judged using a prototypal internal drug database. This database has been 
constructed as described in our previous publications about medication in liver 
cirrhosis [27, 94, 95]. The recommendations concerning dosing in patients with 
liver cirrhosis within this database are based on published kinetic studies for 
individual drugs and on the recommendations provided in the PDR [65], 
Micromedex® [71] and/or the Swiss drug register (Arzneimittel-Kompendium) [87]. 
All patients included in the study were on long-term medication and used their 
maintenance dose at hospital entry; initial doses were therefore not considered. 
According to the general recommendations [27, 94, 95], maintenance dose for 
CAT1, CAT2, and CAT3 drugs should generally be reduced by 50-75%, 
approximately 50%, or 0-50%, respectively, in patients with liver cirrhosis (Fig. 4). 
Since up-titration according to clinical effect and tolerability is recommended for 
most drugs, doses that exceeded the general recommendations had to be judged 
individually using the recommendations of the internal database described above. 
This database provides dosing recommendations adjusted to the severity of liver 
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disease (according to the Child class). Accordingly, for each dose assessed, 
characteristics of the individual patient (in particular the severity of liver disease), 
as well as of the drug administered were taken into account. For drugs which can 
be monitored by specific tests (e.g. INR for phenprocoumon, blood glucose for 
insulin and oral antidiabetics, serum levels), these values were taken into account 
for defining the correct dose. 
All drugs contraindicated or prescribed in an incorrect dose according to this 
database (IDDs) were further analyzed. We assessed how many patients received 
IDDs and which CAT and ATC codes were involved. We identified the ADRs 
associated with IDDs and classified each ADR as type A (dose-dependent, and 
thus preventable) or type B (dose-independent, considered to be not preventable) 
ADR. We then assessed the prevalence of total as well as preventable ADRs per 
drug CAT. Furthermore, we investigated the impact of IDDs and/or ADRs on 
mortality. Finally, the discontinuation rate of drug treatments at hospital entry was 
assessed as well as the reasons for discontinuation, in particular IDDs and ADRs. 
 
3.3.3.3 Risk assessment for incorrectly administered drugs  
To investigate whether IDDs are associated with an increased risk for ADRs, we 
calculated the relative risk for developing ADRs according to the ATC code in 
patients with IDDs compared to patients without IDDs and expressed it as an odds 
ratio (OR). A significance level of 5% was chosen. 
 
3.3.3.4 Contraindicated drugs 
The PDR [65] was consulted to check if the prescribed drugs were formally 
contraindicated in patients with liver disease. Drugs not listed in the PDR were 
checked in Micromedex® [71] and drugs listed neither in the PDR nor in 
Micromedex® were judged by means of our internal database which bases on 
published studies. According to our database, NSAIDs are contraindicated in 
patients with liver cirrhosis due to an increased risk for ADRs, in particular 
gastrointestinal bleeding and/or renal failure [27, 43, 131]. This judgment is 
supported by the results of our previous study, showing a bad tolerability of these 
drugs by patients with liver cirrhosis [68]. We also investigated the question 
whether ADRs were more frequently associated with contraindicated than with not 
contraindicated drugs. 
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3.3.3.5 Excess hospitalization days and potential cost savings 
For IDDs that were continued during hospital stay, the cost difference between 
administered and recommended dose was calculated as Euros per cirrhotic 
patient and day. For preventable ADRs associated with IDDs, the excess 
hospitalization days and costs for the hospitalizations were also calculated. 
 
3.3.4 Results 
3.3.4.1 Drug categories at hospital admission 
At hospital admission, the 400 patients with liver cirrhosis had 1653 prescriptions 
(median 4 drugs per patient, range 0-15), vitamins and minerals excluded. 
Considering drug CAT, most abundant were drugs with a low (29.4%) or high 
(27.4%) hepatic extraction, followed by drugs with intermediate hepatic extraction 
(19.2%), and drugs with mainly renal (12.3%) or unknown elimination (11.7%) 
(Appendix Fig. 11). Details to the drugs with hepatic elimination, e.g. individual 
drug classes, were published in our previous work [68]. 
 
3.3.4.2 Dose assessment and ADRs 
Overall, 336 (20.3%) of all drugs (47.6% of CAT2; 20.1% of CAT4; 18.1% of 
CAT3; 10.6% of CAT1; 4.1% of CAT5; Appendix Fig. 11) were judged to be IDDs 
in 184 patients. Thirty-six of these drugs were contraindicated in patients with liver 
cirrhosis and 300 were dosed inadequately high. The majority of drugs (68.4% of 
all drugs; 89.4% of CAT1; 81.7% of CAT3; 80.0% of CAT4; 51.7% of CAT2; 2.5% 
of CAT5) were dosed correctly (CDDs) and 11.1% of all drugs (93.3% of CAT5; 
0.6% of CAT2; 0.2 of CAT3; 0% of CAT1 and 4) could not be judged regarding 
dosing (not assessable drugs, NADs). According to the ATC-code, drugs for the 
alimentary tract and metabolism (ATC A; n=137), for the nervous system (ATC N; 
n=80), for the cardiovascular system (ATC C; n=62), and for the musculo-skeletal 
system (ATC M; n=31) were most frequently IDDs (Fig. 9). Most often involved 
drug classes were drugs for acid related disorders (A02), oral blood glucose 
lowering drugs (A10B), non-steroidal anti-inflammatory and antirheumatic products 
(M01A), hypnotics and sedatives (N05C), and other analgesics and antipyretics 
(N02B). 
In total, 198 ADRs (164 preventable reactions, 82.8% of all ADRs) occurred in 110 
patients (27.5%) (median 1 [range 1-5] per affected patient). Of all ADRs, 61 
(30.8% of all ADRs; 47 [77%] of them preventable) were associated with IDDs in 
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40 (10%) patients. ADRs associated with IDDs are listed in Tab. 10. As shown in 
the Table, especially NSAIDs and psycholeptics were frequently involved in these 
ADRs. Low, intermediate, and high hepatic extraction drugs were associated with 
27, 22, and 8 IDD-associated ADRs, respectively. Seven of the ADRs were due to 
a drug-drug interaction. 
 
 
 
Fig. 9 Fraction of each drug class (ATC-code) with correctly (CDDs) and incorrectly (IDDs) dosed 
drugs. A = alimentary tract and metabolism; B = blood and blood forming organs; C = 
cardiovascular system; D = dermatologicals; G = genito-urinary system and sex hormones; H = 
systemic hormonal preparations (excl. sex hormones and insulin); J = antiinfectives for systemic 
use; L = antineoplastic and immunomodulating agents; M = musculo-skeletal system; N = nervous 
system; P = antiparasitic products, insecticides and repellents; R = respiratory system; S = sensory 
organs; V = various; NADs = not assessable drugs. 
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Tab. 10 Adverse drug reactions (ADRs) associated with incorrectly dosed drugs (IDDs) 
Drug class 
(ATC-code) 
Drugs (n ADR) Type A ADR (n) Other ADR (n) 
Anti-
inflammatory 
and 
antirheumatic 
products (M01) 
 
ibuprofen (11*), 
diclofenac (7*), 
mefenamic acid 
(6*), piroxicam (1*) 
gastrointestinal hemorrhage/ulcer 
(12*; 1 DDI), anemia (3*), 
worsening of ascites (2*), 
hyperkalemia (1*; 1 DDI), reduction 
of creatinine clearance (1*), 
psychomotor agitation (1*), 
epistaxis (1*; 1 DDI)  
thrombocytopenia 
(2*), leucopenia 
(1*) 
Psycholeptics 
(N05) 
zolpidem (6), 
diazepam (2*, 1), 
midazolam (2), 
pipamperon (1) 
somnolence (3), confusion (1*, 2), 
gait disorder (1), mental retardation 
(1; 1 DDI), fall (1*)  
somnambulism (1), 
elevated ALT (1) 
Diuretics (C03) spironolactone 
(6), torasemide 
(2) 
reduction of creatinine clearance^ 
(3), hyperkalemia (2; 1 DDI), 
hyponatremia (1)  
anemia (1), 
diarrhea (1) 
Drugs used in 
diabetes (A10) 
metformin (3), 
rosiglitazone (2) 
loss of appetite (1), diarrhea (1), 
heart failure (1)  
thrombocytopenia 
(1), 
hyperbilirubinemia 
(1) 
Calcium channel 
blockers (C08) 
amlodipine (4) edema (2), dyspnea (1)  hyperbilirubinemia 
(1) 
Agents acting on 
the RAAS (C09) 
ramipril (2), 
losartan (2) 
syncope (1), hyperkalemia (1), 
hypotension (1)  
eosinophilia (1) 
Drugs for acid 
related disorders 
(A02) 
lansoprazole (1)  elevated ALT (1) 
Antithrombotic 
agents (B01) 
phenprocoumon 
(1) 
INR increased (1)  
Antineoplastic 
agents (L01) 
doxorubicin (1) neutropenic fever (1; 1 DDI)  
Analgesics 
(N02) 
acetylsalicylic 
acid (1*) 
gastrointestinal ulcer (1*)  
Other nervous 
system drugs 
(N07) 
Methadone (1) torsade de pointes (1; 1 DDI)  
ADR = adverse drug reaction; ALT = alanine transaminase; AP = alkaline phosphatase; ATC = 
anatomical therapeutic chemical classification system; DDI = drug-drug interaction (n); RAAS = 
renin-angiotensin-aldosterone system 
^partly type A ADR 
*contraindicated drug/ADRs associated with contraindicated drug 
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As reported in our previous study [68], 16 ADRs were the reason for hospital 
admission. Noticeably, patients with IDDs were more frequently admitted to 
hospital due to an ADR than patients with CDDs/NADs (7.1% and 1.4% of all 
patients with and without IDDs, respectively). In six cases, the IDD was the direct 
cause for the ADR (coma due to midazolam [1], worsening of ascites due to 
ibuprofen [1], gastrointestinal ulcer/hemorrhage due to diclofenac [1], ibuprofen [2] 
or the combination piroxicam-acetylsalicylic acid [1]). As shown in Fig. 10, ADRs 
were overall more frequent for IDDs compared to CDDs (overall in 18.2% vs. 
13.1% of the prescribed drugs; preventable 14.0% vs. 10.6%). Surprisingly, this 
was not the case for all drug CAT. For instance, ADRs were less frequent in CAT1 
drugs that were dosed incorrectly (16.7% vs. 20.0%; Fig. 10). The same was true 
for primarily renally eliminated drugs (CAT4), where the frequency of ADRs was 
12.2% for IDDs and 25.2% for CDDs (Fig. 10). In the other drug categories (CAT2, 
3, 5), more ADRs occurred for IDDs compared to CDDs. The difference was most 
pronounced in CAT3 drugs (30.7% vs. 13.9%, Fig. 10) followed by CAT2 (14.6% 
vs. 10.4%; Fig. 10). For CAT5, we compared the drugs which are contraindicated 
or not recommended in liver cirrhosis with the other drugs in this group (CDDs and 
NADs). ADRs were more frequent for drugs that are contraindicated/not 
recommended in liver cirrhosis (12.5% vs. 4.9%; Fig. 10). 
The only ATC group associated with a statistically significant increased risk for 
ADRs in case of IDDs was the musculo-skeletal system group (ATC M; OR 11.1, 
95% CI 2.5-66.5; Appendix Fig. 12), which contains the NSAIDs. 
At hospital admission, IDDs associated with an ADR were more likely to be 
stopped (total 36/42 [85.7%]; CAT4 and 5 100%; CAT2 92.9%; CAT3 84.2%; 
CAT1 60.0%) than CDDs associated with an ADR (total 96/127 [75.6%]; CAT4 
88.5%; CAT2 78.6%; CAT1 77.6%; CAT3 62.2%; CAT5 100%). IDDs without 
ADRs were less often stopped at hospital admission (total 90/294 [30.6%]; CAT5 
57.1%; CAT2 34.3%; CAT4 28.9%; CAT3 26.1%; CAT1 23.3%). 
An increased mortality rate was observed in patients with ADRs (see below). 
Correct dosing, however, had only a minor influence on mortality. In patients with 
ADRs, mortality was similar in patients with IDDs as compared to patients with 
CDDs/NADs (20.0% versus 21.7%, respectively). In comparison, in patients 
without ADRs, mortality rates were 15.2% and 15.1% in patients with IDDs and 
CDDs/NADs, respectively. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 10 Number of prescriptions, total number ADRs and number of preventable (Type A) ADRs stratified per drug category. Within each drug category, 
prescriptions and ADRs are classified further per adequacy of dose adjustment (CDDs: correctly dosed drugs; IDDs: incorrectly dosed drugs; NAD: non-assessable 
drugs). The sum of the ADRs can exceed the total number of ADRs, since ADRs caused by more than one drug (e.g. one IDD and one CDD) were counted more 
than once. 
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3.3.4.3 Contraindicated drugs 
Of all drugs, 36 (2.2%) were contraindicated in patients with liver disease 
(ibuprofen (12), diclofenac (9), mefenamic acid (5), diazepam (3), atorvastatin (2), 
acemetacin (1), piroxicam (1), acetylsalicylic acid (1), methyldopa (1), pravastatin 
(1)). Drug CAT involved were CAT1 with high (acetylsalicylic acid, atorvastatin, 
pravastatin), CAT2 with intermediate (diclofenac), and CAT3 with low hepatic 
extraction (acemetacin, ibuprofen, piroxicam, diazepam, zopiclone, methyldopa), 
as well as CAT5 with unknown elimination (mefenamic acid). 
In total, these drugs caused 28 ADRs; these ADRs are marked with a star (*) in 
Tab. 10. The most frequent ADRs were gastrointestinal hemorrhage/ulcer 
associated with NSAIDs. Related to prescriptions, approximately 7 times more 
ADRs (7.7 times more preventable ADRs) occurred due to treatment with 
contraindicated drugs as compared to non-contraindicated drugs. 
 
3.3.4.4 Potential cost savings  
Direct potential drug cost savings from dose adjustment was minor with <1 Euro 
per cirrhotic patient and day or 30 Euro per hospitalized patient with liver cirrhosis. 
However, 6 patients were admitted to the hospital due to a preventable ADR 
directly caused by an IDD. Taken together, these patients stayed in hospital for 94 
days, resulting in total costs of 151’575 Euros or 379 Euros per hospitalized 
cirrhotic patient. For the remaining 41 preventable ADRs associated with IDDs, the 
excess hospital stay and costs could not be estimated, since the patients were 
hospitalized for other reasons. In total, for every hospitalized cirrhotic patient, at 
least 409 Euros are spent due to IDDs. 
 
3.3.5 Discussion 
In the current study, we assessed drug dosing in 400 cirrhotic patients at hospital 
entry using our own recommendations [27, 94, 95] in combination with 
Micromedex® [71] and the respective product information [65]. 
Approximately three quarters of all drugs (excl. vitamins and minerals) used in this 
population have a predominantly non-renal elimination, in most cases involving the 
liver. Approximately 20% of the prescriptions were considered to be inappropriate, 
in most cases too high or contraindicated. IDDs were more frequently associated 
with ADRs (18.2% of prescriptions) compared to CDDs (13.1% of prescriptions). 
Patients with IDDs were more frequently admitted to hospital due to an ADR (7.1% 
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vs. 1.4%) than patients with CDDs/NADs. Since most IDDs associated with ADRs 
were recognized and eliminated at hospital entry, duration of hospitalization and 
mortality rates were not different between patients with or without IDD. 
To the best of our knowledge, there is so far no study in the literature, in which 
dosage adjustment in patients with liver cirrhosis was investigated systematically. 
A major problem may be that, in contrast to impaired renal function, no concrete 
dose recommendations exist for patients with impaired liver function. Particularly 
for older drugs, recommendations in the product information are often lacking or 
not helpful (e.g. “drug should be used with caution”), shifting the problem to the 
prescribers. 
In comparison to our previous publication involving the same group of patients 
[68], the number of prescriptions and ADRs are lower in the current study. This is 
due to the exclusion of vitamins and minerals for the current investigation. Since 
precise pharmacokinetic data for vitamins and minerals are usually not available, 
most of these substances would belong to CAT5 with unknown elimination 
pathway, resulting in an inadequate overestimation of this drug CAT (in our 
previous study, 17% of all prescriptions were vitamins and minerals [68]). Taking 
into account the generally good tolerability of vitamins and minerals, we feel that 
their exclusion from our analysis is acceptable. 
In our study, 20.3% of all prescriptions were dosed incorrectly in relation to liver 
function, and IDDs were more frequently associated with ADRs than CDDs. This 
could be expected taking into account the fact that most ADRs are dose-
dependent. Surprisingly, IDD-associated ADRs were not more frequent for drugs 
with a high hepatic extraction (CAT1) or predominant renal elimination (CAT4) 
compared to CDD-associated ADRs. It appears, therefore, that physicians are 
aware of the high risk drugs in these patients and of the necessity for dose 
adjustment in patients with liver cirrhosis. A contributing factor may be that the 
maintenance dose of such drugs can be adjusted according to clinical effect and 
tolerability in each individual patient. For certain drugs, the actual maintenance 
dose may therefore be higher than suggested by the recommendations. This is for 
example the case for betablockers, which were the most frequent CAT1 drugs in 
our population (e.g. propranolol and metoprolol). Therefore, the dosage of CAT1 
betablockers was judged only rarely as an inappropriate (in 3 of 109 CAT1 
betablocker prescriptions). 
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The IDDs in CAT4 were mainly due to the prescription of metformin and the 
dosage of ramipril. Metformin should be avoided in patients with liver cirrhosis due 
to an increased risk for lactic acidosis and ramipril should be used at a low dose, 
since hemodynamic changes in patients with liver cirrhosis predispose them for 
renal hypoperfusion and/or hypofiltration possibly leading to renal failure [27]. 
In our study, 82.8% of all ADRs and 77% of IDD-associated ADRs were classified 
as potentially preventable. These numbers correspond well with the frequencies 
reported in a review published in 2007 [56], stating that 80% (51-100%) of ADEs in 
hospitalized patients are potentially preventable. Prevention of such events could 
be achieved by using the lowest effective dose and by the elimination of DDIs and 
other MEs [56]. 
NSAIDs were by far the most often prescribed contraindicated drugs in this 
population. Of the 36 contraindicated drugs, 28 were NSAIDs. NSAIDs caused a 
total 25 ADRs, 21 of them were considered to be preventable and 5 were a reason 
for hospitalization. Cirrhotic patients treated with a NSAID had a 50% probability to 
develop a severe ADR. In total, patients treated with a contraindicated drug 
(including NSAIDs) had 7-fold higher risk to suffer from an ADR than patients 
without contraindicated drugs. These figures highlight the importance of avoiding 
contraindicated drugs in this population, in particular NSAIDs. Interestingly, 
NSAIDs are not contraindicated in cirrhotic patients by the PDR and Micromedex®, 
but by the Swiss “Arzneimittel-Kompendium”. Taking into account the high 
frequency of mostly severe ADRs caused by NSAIDs (leading to hospitalization 
and potentially death), NSAIDs should be considered to be contraindicated in 
cirrhotic patients. 
Interestingly, IDD-associated ADRs were most frequently related to drugs causing 
pharmacodynamic alterations in patients with liver cirrhosis; drug classes most 
often involved were NSAIDs, sedatives/hypnotics, and oral antidiabetics. While 
CNS-depressing drugs bear an increased risk for hepatic encephalopathy [27], 
oral antidiabetics may induce hypoglycemia due to impaired drug metabolism and 
possibly also impaired gluconeogenesis in patients with decompensated liver 
cirrhosis [132].  
Overall, potential cost savings by avoiding incorrect drug dosing per cirrhotic 
patient and hospitalization were at least 409 Euro in our study. These savings 
result mainly from six patients admitted to the hospital due to an ADR, which was 
directly caused by an IDD. The costs for the corresponding hospital stays (151’575 
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Euros) could have been prevented by not using IDDs in cirrhotic patients. The 
costs of the remaining 41 ADRs associated with IDDs present at hospital entry 
could not be calculated, since the ADRs were not the cause for hospital 
admission.  
In contrast, drug-cost savings by dose reduction in patients with liver cirrhosis 
appear to be minimal according to our results. In a study assessing dosage 
adjustment in patients with renal impairment, dose reduction resulted in drug-cost 
savings of 2250 US$ for four months in 300 patients [133]. If calculated per day 
and patient, this number is similar to our results. We should keep in mind, 
however, that dose-dependent ADRs frequently lead to prolongation of hospital 
stay and extra costs due to additional investigations or treatment. According to a 
review [56], each ADR in hospitalized patients increases the hospital stay by 3.4 
(1.2-8.5) days. Accordingly, the additional costs per ADR ranged between 1400 
US$ and approximately 5000 US$ [56]. Since we do not have data on ADRs 
occurring during hospital stay in our patients, we cannot calculate associated 
costs.  
Our study has several limitations. The retrospective character only allowed us to 
include the data documented in the medical records, which might not always be 
complete. Furthermore, the population size is quite small, resulting sometimes in 
large confidence intervals and possibly in non-significant results. 
In conclusion, our study shows that approximately 20% of the prescriptions in 
patients with liver cirrhosis are inappropriate for dose and/or contraindication. 
Patients with inappropriate prescriptions, especially those treated with 
contraindicated drugs, are at a high risk for ADRs, leading to a higher 
hospitalization rate due to ADRs with high costs. Careful dosing taking into 
account the clinical effect and dose-related ADRs and avoiding contraindicated 
drugs is mandatory in this group of patients. 
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4.1 Discussion 
Drug therapy in patients with liver cirrhosis is complex. First, no surrogate 
parameter exists for dosage adjustment in patients with liver disease [27]. 
Secondly, various non-uniform pharmacokinetic and pharmacodynamic alterations 
may be present in this patient population, making it difficult to estimate what 
impact liver disease has on a specific drug. Individualized dose adjustment 
according to clinical effect and dose-dependent ADRs should be considered. Dose 
recommendations in the product information for patients with liver disease are 
often lacking or unspecific (e.g. “drug should be used with caution”), for instance 
due to lack of studies. It is therefore not surprising that up to now neither a CDS-
tool giving dose recommendations for patients with liver cirrhosis nor studies 
systematically investigating dosage adjustment in patients with liver cirrhosis exist.  
To the best of our knowledge, apart from few general studies focusing on drug 
therapy in patients with liver cirrhosis [114, 115], general studies focusing on drug-
related problems in patients with liver cirrhosis are lacking in the literature.  
 
By categorizing drugs according to their pharmacokinetic parameters, we 
estimated the extent by which a certain drug is eliminated by the liver. Depending 
on this categorization, dosage recommendations for patients with liver disease can 
be derived. Additionally, pharmacodynamic changes must also be taken into 
account. Based on these considerations, we made specific dosage 
recommendations for patients with liver disease whenever possible. We 
summarized these recommendations in a database, together with the 
pharmacokinetic and toxicologic profile of a drug, studies on pharmacokinetic 
alterations in patients with liver disease, and available recommendations for this 
patient population. This database is the first step for the development of a CDS-
tool. Indeed, a software implementation of the database is planned in collaboration 
with Documed AG. Currently, preliminary tests are performed. Next to the 
information in the database, plasma-concentration-time curves as presented in 
section 3.1.4 will be provided, giving an overview on the impact liver cirrhosis has 
on the pharmacokinetics of a drug.  
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In our first study, we resumed the above-mentioned database for the anti-infective 
drugs on the Swiss market at the beginning of 2012.  
Forty-seven % of the 104 anti-infectives on the Swiss market in 2012 are mainly 
eliminated by the liver. Additionally, studies reported pharmacokinetic alterations in 
liver disease for 48% of all anti-infectives, indicating the importance of considering 
dose reduction in patients with impaired hepatic function. Moreover, 27% of the 
anti-infectives were at least partly metabolized by CYP P450 enzymes, which are 
more affected by liver cirrhosis than phase II enzymes [4, 27, 29, 30]. 
Forty-four % of the drugs were mainly eliminated by the kidney. In this respect, it is 
important to remember that liver cirrhosis may be associated with renal impairment 
(hepato-renal syndrome) [4, 27]. Biliary elimination ≥50% affected one fifth of all 
drugs. In patients with intra- or extrahepatic cholestasis, these drugs should be 
used with caution to avoid accumulation.  
We could confirm that specific dosage recommendations for patients with liver 
cirrhosis are often not available in the product information. In the Swiss product 
information [87], specific recommendations for patients with liver disease are only 
available for 50% of all anti-infective drugs. In line with this finding, specific 
recommendations were also frequently unavailable for antineoplastic and 
psychotropic drugs [94, 95]. In clinical practice, this leads to difficulties in choosing 
an adequate, effective, and safe dose for hepatically impaired patients. Therefore, 
the elaboration of a CDS-tool is crucial. 
 
In our second and third study, we first characterized 400 patients with liver 
cirrhosis in respect of their demographic data, diagnoses, medication at hospital 
admission, and the prevalence of ADRs and pDDIs. We found that 28% and 
21.5% of cirrhotic patients were affected by ADRs and pDDIs, respectively. 
Cirrhotic patients with ADRs showed the typical risk factors for ADRs/ADEs [61-
63], they were older, had more comorbidities, more drugs prescribed, more pDDIs, 
and worse renal function than cirrhotic patients without ADRs. Most ADRs were 
considered dose-dependent and thus potentially preventable. Of all 1653 drugs 
prescribed excluding vitamins and minerals, 20% were IDDs in 184 patients. IDDs 
were more frequently associated with ADRs than CDDs and patients with IDDs 
were more frequently admitted to the hospital due to ADRs than patients with 
CDDs/NADs (7.1% vs. 1.4%). This number is higher compared to the median ADR 
prevalence of 5.3% (interquartile range 2.7-9%) at hospital admission in a review 
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assessing the prevalence of ADR-associated hospitalizations [134]. Potential drug-
cost savings as a result of mere dose adjustment in patients with liver cirrhosis 
was minor, but considerable when taking into account hospitalizations due to 
preventable ADRs caused by IDDs. In the out-patient setting, IDDs may result in 
increased morbidity and additional costs. Besides the costs, IDDs may lead to an 
additional burden to the individual patient due to further morbidity and sequelae.  
 
Our results with a high prevalence of ADRs, pDDIs, and IDDs in cirrhotic patients 
demonstrate that pharmacotherapy is problematic in patients with liver cirrhosis. A 
CDS-tool giving dosage recommendations for patients with liver disease may help 
to improve drug safety in patients with liver cirrhosis. On the one hand, it would 
help prescribing physicians to choose an adequate dose. On the other hand, a 
reduction of IDDs would naturally lead to less ADRs, less ADR-associated 
morbidity in the out-patient setting, and less ADR-associated hospitalizations. 
Thus, a CDS-tool has the potential to reduce healthcare costs and patient 
morbidity.  
 
A limiting factor in the second and third studies is the retrospective nature of the 
chart review, not allowing for communication with the involved patients and 
healthcare professionals for further information. Our recorded data are based on 
the medical records, which might not always be complete. Another limitation is the 
limited population size, which resulted in relatively small numbers of ADRs, DDIs, 
and sometimes statistically non-significant results.  
The reason why we chose a cross-sectional study design is because it is a good 
design to determine prevalences. Additionally, cross-sectional studies are usually 
not associated with ethical difficulties, since exposure to a risk factor or treatment 
are not chosen deliberately [135].  
 
We are convinced that our studies provide important information on the principles 
of dosage adjustment in patients with liver disease as well as improve the 
awareness of problematic drugs and relevant safety data in patients with liver 
cirrhosis. We published the first study with a systematic investigation of dosage 
adjustment in patients with liver cirrhosis. Furthermore, we are going to contribute 
to the first CDS-software for patients with liver disease.  
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4.2 Conclusion 
Since data on drug-related problems or systematic investigations of dosage 
adjustment in patients with liver cirrhosis are lacking in the literature, our studies 
provide important information for a better understanding of the characteristics of 
patients with liver cirrhosis and for the improvement of drug safety in this patient 
population.  
 
We can conclude, that 
• Specific dosage recommendations for patients with liver disease are 
frequently not provided by the product information. 
• Elaboration of pharmacokinetic parameters of drugs allows for drug 
categorization and is the basis for dose recommendations. 
• About two thirds of the drugs prescribed to cirrhotic patients are primarily 
eliminated by the liver.  
• Drug-related problems are prevalent in patients with liver cirrhosis at 
hospital admission. Twenty-eight % and 21.5% of the patients in our study 
were affected by ADRs and pDDIs, respectively.  
• Twenty % of drugs prescribed to cirrhotic patients are incorrectly dosed or 
prescribed. 
• ADRs are more frequent with IDDs than with CDDs. 
• Most ADRs are considered dose-dependent and could be prevented, e.g. 
by dose adjustment to liver function. 
• Especially NSAIDs and psycholeptics were a frequent cause of preventable 
ADRs.  
• Patients with IDDs are more frequently admitted to hospital due to an ADR 
than patients with CDDs/NADs. 
• Potential cost savings due to mere dose adjustment in patients with liver 
cirrhosis is minor, but significant when taking into account additional 
hospitalizations due to preventable ADRs caused by IDDs.  
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These findings suggest that a CDS-tool providing dose recommendations for 
patients with liver disease is strongly needed to improve drug safety and to reduce 
healthcare costs in patients with liver disease. Our database, allowing for specific 
dose recommendations for patients with liver disease for many drugs, is the 
cornerstone for a CDS-software.  
 
 
4.3 Outlook 
In collaboration with Documed AG, our database is about to be implemented into a 
CDS-software. The marketing of the first version of this software is planned for 
autumn of 2012. This software will show an information box about the 
pharmacokinetics of a drug and is additionally will focus mainly on dosage 
recommendations given by the Swiss product information on the one hand and on 
our recommendations derived from pharmacokinetic and pharmacodynamic data 
on the other hand. Additionally, the plasma-concentration-time curves are going to 
be shown. The first version of the software only allows for the integration of single 
agent drugs and is will contain approximately 600 of 1000 systemically available 
drugs on the Swiss market. 
Based on this project, additional work can be done for further versions of the 
software:  
• Further development of the database 
o Elaboration of the remaining systemically available drugs on the 
Swiss market (approximately 400) 
o Additional considerations for the inclusion of combination products  
• Validation of the database 
o Ask opinion of physicians using the CDS by questionnaire, regarding 
for example the clinical relevance and helpfulness of the CDS  
o Prospective follow-up study, where patients with liver cirrhosis could 
either be treated by physicians using the CDS or they could be 
treated as usual.  
 Study in in-patients with liver cirrhosis, since the CDS-tool 
may probably not be available in the out-patient setting in the 
near future 
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 Prospective consideration and recognition of ADRs, e.g. by 
clinical pharmacists 
 Analysis of the impact the CDS-tool has on different 
parameters such as the occurrence of ADRs or healthcare 
costs 
 Validate usefulness of the recommendations in the database 
by investigation of the prevalence of IDDs in the cases and 
controls 
 
  
 
 
  
 
 
 
 
 
 
 
 
5 References 
 
- 80 - 
 
5 References 
1. Luxon, BA. Anatomy and Physiology of the Liver and Biliary Tree. In: Bacon 
B, Di Bisceglie, AM, editor. Liver Disease: Diagnosis and Management. 
Philadelphia: Churchill Livingstone; 2000. p. 3-15. 
2. Thews, G., Mutschler, E., Vaupel. P. Anatomie, Physiologie, 
Pathophysiologie des Menschen. 5th ed. Stuttgart: Wissenschaftliche 
Verlagsgesellschaft mbH Stuttgart; 1999. p.363-406. 
3. Sanyal, AJ. Gastroesophageal Varices: Pathophysiology and Prevention of 
Bleeding. In: Bacon B, Di Bisceglie, AM, editor. Liver Disease: Diagnosis 
and Management. Philadelphia: Churchill Livingstone; 2000. p. 229-37. 
4. Verbeeck, R. K. Pharmacokinetics and dosage adjustment in patients with 
hepatic dysfunction. Eur J Clin Pharmcol. 2008 Dec;64(12):1147-61. 
5. Eichelbaum, M., Schwab, M. Wirkungen des Organismus auf Pharmaka: 
allgemeine Pharmakokinetik. In: Forth W, Henschler, D., Rummel, W., 
editor. Allgemeine und spezielle Pharmakologie und Toxikologie. 10th ed. 
München: Elsevier, Urban & Fischer; 2009. p. 36ff. 
6. Jancova, P., Anzenbacher, P., Anzenbacherova, E. Phase II drug 
metabolizing enzymes. Biomed Pap Med Fac Univ Palacky Olomouc Czech 
Repub. 2010 Jun;154(2):103-16. 
7. Wittwer, E., Kern, S. E. Role of morphine's metabolites in analgesia: 
concepts and controversies. AAPS J. 2006;8(2):E348-52. 
8. Burke, A, Smyth, E, FitzGerald GA. Analgesic-antipyretic and 
antiinflammatory agents; pharmacotherapy of gout. In: Brunton L, editor. 
Goodman & Gilman's the pharmacological basis of therapeutics. Eleventh 
ed. New York: McGraw Hill; 2006. p. 693. 
9. Shayiq, R. M., Roberts, D. W., Rothstein, K., Snawder, J. E., Benson, W., et 
al. Repeat exposure to incremental doses of acetaminophen provides 
protection against acetaminophen-induced lethality in mice: an explanation 
for high acetaminophen dosage in humans without hepatic injury. 
Hepatology. 1999 Feb;29(2):451-63. 
10. Krahenbuhl, S., Brauchli, Y., Kummer, O., Bodmer, M., Trendelenburg, M., 
et al. Acute liver failure in two patients with regular alcohol consumption 
ingesting paracetamol at therapeutic dosage. Digestion. 2007;75(4):232-7. 
5 References 
 
- 81 - 
 
11. Leon, D. A., McCambridge, J. Liver cirrhosis mortality rates in Britain from 
1950 to 2002: an analysis of routine data. Lancet. 2006 Jan 
7;367(9504):52-6. 
12. Schuppan, D., Afdhal, N. H. Liver cirrhosis. Lancet. 2008 Mar 
8;371(9615):838-51. 
13. Leuschner, U. Leberzirrhose und Komplikationen. In: Caspary W, 
Leuschner, U, Zeuzem, S, editor. Therapie von Leber- und 
Gallenkrankheiten. Berlin Heidelberg: Springer-Verlag; 1997. p. 217-22. 
14. Verbeeck, R. K., Horsmans, Y. Effect of hepatic insufficiency on 
pharmacokinetics and drug dosing. Pharm World Sci. 1998 Oct;20(5):183-
92. 
15. Poynard, T., McHutchison, J., Manns, M., Trepo, C., Lindsay, K., et al. 
Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in 
patients with chronic hepatitis C. Gastroenterology. 2002 May;122(5):1303-
13. 
16. Dienstag, J. L., Goldin, R. D., Heathcote, E. J., Hann, H. W., Woessner, M., 
et al. Histological outcome during long-term lamivudine therapy. 
Gastroenterology. 2003 Jan;124(1):105-17. 
17. Gines, P, Arroyo, V, Rodes, J. Complications of Cirrhosis: Ascites, 
Hyponatremia, Hepatorenal Syndrome, and Spontaneous Bacterial 
Peritonitis. In: Bacon B, Di Bisceglie, AM, editor. Liver Disease: Diagnosis 
and Management. Philadelphia: Churchill Livingstone; 2000. p. 238-50. 
18. Mullen, KD, Sarbah, SA, Kyprianou, A. Portosystemic Encephalopathy. In: 
Bacon B, Di Bisceglie, AM, editor. Liver Disease: Diagnosis and 
Management. Philadelphia: Churchill Livingstone; 2000. p. 251-60. 
19. Rosen, HR, Keeffe, EB. Evaluation of Abnormal Liver Enzymes, Use of 
Liver Tests, and Serology of Viral Hepatitis. In: Bacon B, Di Bisceglie, AM, 
editor. Liver Disease: Diagnosis and Management. Philadelphia: Churchill 
Livingstone; 2000. p. 24-35. 
20. Kamath, P. S., Wiesner, R. H., Malinchoc, M., Kremers, W., Therneau, T. 
M., et al. A model to predict survival in patients with end-stage liver disease. 
Hepatology. 2001 Feb;33(2):464-70. 
21. Malinchoc, M., Kamath, P. S., Gordon, F. D., Peine, C. J., Rank, J., et al. A 
model to predict poor survival in patients undergoing transjugular 
intrahepatic portosystemic shunts. Hepatology. 2000 Apr;31(4):864-71. 
5 References 
 
- 82 - 
 
22. Pugh, R. N., Murray-Lyon, I. M., Dawson, J. L., Pietroni, M. C., Williams, R. 
Transection of the oesophagus for bleeding oesophageal varices. Br J 
Surg. 1973 Aug;60(8):646-9. 
23. Cholongitas, E., Marelli, L., Kerry, A., Senzolo, M., Goodier, D. W., et al. 
Different methods of creatinine measurement significantly affect MELD 
scores. Liver Transpl. 2007 Apr;13(4):523-9. 
24. Cholongitas, E., Marelli, L., Shusang, V., Senzolo, M., Rolles, K., et al. A 
systematic review of the performance of the model for end-stage liver 
disease (MELD) in the setting of liver transplantation. Liver Transpl. 2006 
Jul;12(7):1049-61. 
25. Pique, J. M. Portal Hypertensive gastropathy. Baillieres Clin Gastroenterol. 
1997 Jun;11(2):257-70. 
26. Morgan, D. J., McLean, A. J. Clinical pharmacokinetic and 
pharmacodynamic considerations in patients with liver disease. An update. 
Clin Pharmacokinet. 1995  Nov;29(5):370-91. 
27. Delco, F., Tchambaz, L., Schlienger, R., Drewe, J., Krahenbuhl, S. Dose 
adjustment in patients with liver disease. Drug Saf. 2005;28(6):529-45. 
28. Eichelbaum, M, Schwab, M. Arzneistoffkonzentration im Organismus in 
Abhängigkeit von der Zeit: Pharmakokinetik im engeren Sinn. In: Forth W, 
Henschler, D., Rummel, W., editor. Allgemeine und spezielle 
Pharmakologie und Toxikologie. München: Elsevier, Urban & Fischer; 2009. 
p. 65-79. 
29. Adedoyin, A., Arns, P. A., Richards, W. O., Wilkinson, G. R., Branch, R. A. 
Selective effect of liver disease on the activities of specific metabolizing 
enzymes: investigation of cytochromes P450 2C19 and 2D6. Clin 
Pharmacol Ther. 1998 Jul;64(1):8-17. 
30. George, J., Murray, M., Byth, K., Farrell, G. C. Differential alterations of 
cytochrome P450 proteins in livers from patients with severe chronic liver 
disease. Hepatology. 1995 Jan;21(1):120-8. 
31. Frye, R. F., Zgheib, N. K., Matzke, G. R., Chaves-Gnecco, D., Rabinovitz, 
M., et al. Liver disease selectively modulates cytochrome P450--mediated 
metabolism. Clin Pharmacol Ther. 2006 Sep;80(3):235-45. 
32. Tschida, S. J., Vance-Bryan, K., Zaske, D. E. Anti-infective agents and 
hepatic disease. Med Clin North Am. 1995 Jul;79(4):895-917. 
5 References 
 
- 83 - 
 
33. Ramond, M. J., Comoy, E., Lebrec, D. Alterations in isoprenaline sensitivity 
in patients with cirrhosis: evidence of abnormality of the sympathetic 
nervous activity. Br J Clin Pharmacol. 1986 Feb;21(2):191-6. 
34. Schwartz, S., Brater, D. C., Pound, D., Green, P. K., Kramer, W. G., et al. 
Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide in 
patients with cirrhosis. Clin Pharmacol Ther. 1993 Jul;54(1):90-7. 
35. Gentilini, P., La Villa, G., Marra, F., Carloni, V., Melani, L., et al. 
Pharmacokinetics and pharmacodynamics of torasemide and furosemide in 
patients with  diuretic resistant ascites. J Hepatol. 1996 Oct;25(4):481-90. 
36. Keller, E., Hoppe-Seyler, G., Mumm, R., Schollmeyer, P. Influence of 
hepatic cirrhosis and end-stage renal disease on pharmacokinetics and 
pharmacodynamics of furosemide. Eur J Clin Pharmacol. 1981;20(1):27-33. 
37. Villeneuve, J. P., Verbeeck, R. K., Wilkinson, G. R., Branch, R. A. 
Furosemide kinetics and dynamics in patients with cirrhosis. Clin Pharmacol 
Ther. 1986 Jul;40(1):14-20. 
38. Marcantonio, L. A., Auld, W. H., Murdoch, W. R., Purohit, R., Skellern, G. 
G., et al. The pharmacokinetics and pharmacodynamics of the diuretic 
bumetanide in hepatic and renal disease. Br J Clin Pharmacol. 1983 
Feb;15(2):245-52. 
39. Dao, M. T., Villeneuve, J. P. Kinetics and dynamics of triamterene at 
steady-state in patients with cirrhosis. Clin Invest Med. 1988 Feb;11(1):6-9. 
40. Villeneuve, J. P., Rocheleau, F., Raymond, G. Triamterene kinetics and 
dynamics in cirrhosis. Clin Pharmacol Ther. 1984 Jun;35(6):831-7. 
41. Ahboucha, S., Pomier-Layrargues, G., Butterworth, R. F. Increased brain 
concentrations of endogenous (non-benzodiazepine) GABA-A receptor 
ligands in human hepatic encephalopathy. Metab Brain Dis. 2004 Dec;19(3-
4):241-51. 
42. Breyer, M. D., Breyer, R. M. Prostaglandin receptors: their role in regulating 
renal function. Curr Opin Nephrol Hypertens. 2000 Jan;9(1):23-9. 
43. Gines, P., Arrovo, V., Rodes, J. Pharmacotherapy of ascites associated 
with cirrhosis. Drugs. 1992 Mar;43(3):316-32. 
44. Pentikainen, P. J., Neuvonen, P. J., Tarpila, S., Syvalahti, E. Effect of 
cirrhosis of the liver on the pharmacokinetics of chlormethiazole. Br Med J. 
1978 Sep 23;2(6141):861-3. 
5 References 
 
- 84 - 
 
45. Barre, J. [Pharmacokinetic properties of cefixime]. Presse Med. 1989 Oct 
11;18(32):1578-82. 
46. Singlas, E., Lebrec, D., Gaudin, C., Montay, G., Roche, G., et al. [Effect of 
hepatic failure upon the pharmacokinetics of cefixime]. Presse Med. 1989 
Oct 11;18(32):1587-8. 
47. Hoyumpa, A. M., Trevino-Alanis, H., Grimes, I., Humphries, T. J. 
Rabeprazole: pharmacokinetics in patients with stable, compensated 
cirrhosis. Clin Ther. 1999 Apr;21(4):691-701. 
48. Peukert, W.E. (editori). Theophrast Paracelsus: Werke. Band 2. Darmstadt: 
Wissenschaftliche Buchgesellschaft; 1965. p. 510. 
49. van den Bemt, P. M., Egberts, T. C., de Jong-van den Berg, L. T., 
Brouwers, J. R. Drug-related problems in hospitalised patients. Drug Saf. 
2000 Apr;22(4):321-33. 
50. Leape, L. L. Preventing adverse drug events. Am J Health Syst Pharm. 
1995 Feb 15;52(4):379-82. 
51. WHO. The Importance of Pharmacovigilance (Glossary, p. 40). 2002 [cited 
2011 October 19th]; Available from: 
http://apps.who.int/medicinedocs/pdf/s4893e/s4893e.pdf  
52. Ferner, R. E., Aronson, J. K. Clarification of terminology in medication 
errors: definitions and classification. Drug Saf. 2006;29(11):1011-22. 
53. Ellenhorn, M. J., Sternad, F. A. Problems of drug interactions. J Am Pharm 
Assoc. 1966 Feb;6(2):62-5 passim. 
54. Osterberg, L., Blaschke, T. Adherence to medication. N Engl J Med. 2005 
Aug 4;353(5):487-97. 
55. Meyboom, R. H., Lindquist, M., Egberts, A. C. An ABC of drug-related 
problems. Drug Saf. 2000 Jun;22(6):415-23. 
56. Krahenbuhl-Melcher, A., Schlienger, R., Lampert, M., Haschke, M., Drewe, 
J., et al. Drug-related problems in hospitals: a review of the recent literature. 
Drug Saf. 2007;30(5):379-407. 
57. Rodriguez-Monguio, R., Otero, M. J., Rovira, J. Assessing the economic 
impact of adverse drug effects. Pharmacoeconomics. 2003;21(9):623-50. 
58. Classen, D. C., Pestotnik, S. L., Evans, R. S., Lloyd, J. F., Burke, J. P. 
Adverse drug events in hospitalized patients. Excess length of stay, extra 
costs, and attributable mortality. JAMA. 1997 Jan 22-29;277(4):301-6. 
5 References 
 
- 85 - 
 
59. Bates, D. W., Cullen, D. J., Laird, N., Petersen, L. A., Small, S. D., et al. 
Incidence of adverse drug events and potential adverse drug events. 
Implications for prevention. ADE Prevention Study Group. JAMA. 1995 Jul 
5;274(1):29-34. 
60. Classen, D. C., Pestotnik, S. L., Evans, R. S., Burke, J. P. Computerized 
surveillance of adverse drug events in hospital patients. JAMA. 1991 Nov 
27;266(20):2847-51. 
61. Queneau, P., Bannwarth, B., Carpentier, F., Guliana, J. M., Bouget, J., et al. 
Emergency department visits caused by adverse drug events: results of a 
French survey. Drug Saf. 2007;30(1):81-8. 
62. Wooten, J. M. Adverse drug reactions: part II. South Med J. 2010 
Nov;103(11):1138-45; quiz 46-7. 
63. Wooten, J. M. Adverse drug reactions: Part I. South Med J. 2010 
Oct;103(10):1025-8; quiz 9. 
64. Franz, CC, Hildbrand, C, Born, C, Egger, S, Rätz Bravo, AE, Krähenbühl, S. 
Dose Adjustment in Patients with Liver Cirrhosis: Impact on Drug Safety 
and Healthcare Costs. 2012 (submitted to J Hep) 
65. Physicians' Desk Reference (electronic version), Thomson Reuters 
(Healthcare) Inc.: Greenwood Village, Colorado, USA; [cited 01/01/2010-
05/31/2012]; Available from: http://www.thomsonhc.com. 
66. Ingelman-Sundberg, M. Pharmacogenomic biomarkers for prediction of 
severe adverse drug reactions. N Engl J Med. 2008 Feb 7;358(6):637-9. 
67. Eichelbaum, M., Ingelman-Sundberg, M., Evans, W. E. Pharmacogenomics 
and individualized drug therapy. Annu Rev Med. 2006;57:119-37. 
68. Franz, C. C., Egger, S., Born, C., Ratz Bravo, A. E., Krahenbuhl, S. 
Potential drug-drug interactions and adverse drug reactions in patients with 
liver cirrhosis. Eur J Clin Pharmacol. 2012 Feb;68(2):179-88. 
69. Chan, M., Nicklason, F., Vial, J. H. Adverse drug events as a cause of 
hospital admission in the elderly. Intern Med J. 2001 May-Jun;31(4):199-
205. 
70. Baxter, K, editor. Stockley's Drug Interactions. 9th ed. London: 
Pharmaceutical Press; 2010. 
71. Micromedex® 1.0 (Healthcare Series), (electronic version). Thomson 
Reuters (Healthcare) Inc.: Greenwood Village, Colorado, USA; [cited 
01/01/2010-09/30/2011]; Available from: http://www.thomsonhc.com. 
5 References 
 
- 86 - 
 
72. Nebeker, J. R., Barach, P., Samore, M. H. Clarifying adverse drug events: a 
clinician's guide to terminology, documentation, and reporting. Ann Intern 
Med. 2004 May 18;140(10):795-801. 
73. Bond, C. A., Raehl, C. L., Franke, T. Medication errors in United States 
hospitals. Pharmacotherapy. 2001 Sep;21(9):1023-36. 
74. Cheng, C. M. Hospital systems for the detection and prevention of adverse 
drug events. Clin Pharmacol Ther. 2011 Jun;89(6):779-81. 
75. Raschetti, R., Morgutti, M., Menniti-Ippolito, F., Belisari, A., Rossignoli, A., 
et al. Suspected adverse drug events requiring emergency department 
visits or hospital admissions. Eur J Clin Pharmacol. 1999 Feb;54(12):959-
63. 
76. Aronson, J. K., Ferner, R. E. Preventability of drug-related harms - part II: 
proposed criteria, based on frameworks that classify adverse drug 
reactions. Drug Saf. 2010 Nov 1;33(11):995-1002. 
77. Bönisch, H., Schlicker, E., Göthert, M., Maier, W. Psychopharmaka - 
Pharmakotherapie psychischer Erkrankungen. In: Forth W, Henschler, D., 
Rummel, W., editor. Allgemeine und spezielle Pharmakologie und 
Toxikologie. München: Elsevier, Urban & Fischer; 2009. p. 308-41. 
78. Forni, A., Chu, H. T., Fanikos, J. Technology utilization to prevent 
medication errors. Curr Drug Saf. 2010 Jan;5(1):13-8. 
79. Corrigan, O. P. A risky business: the detection of adverse drug reactions in 
clinical trials and post-marketing exercises. Soc Sci Med. 2002 
Aug;55(3):497-507. 
80. Egger SS, Schlienger RG, Krähenbühl S, Stoller R, Fattinger K. [Adverse 
drug reactions]. In: Schweizerische Gesellschaft für Klinische 
Pharmakologie und Toxikologie, editor. Grundlagen der 
Arzneimitteltherapie. 16th ed. Basel: Documed AG; 2005. p. 54-63. 
81. Jefferys, D. B., Leakey, D., Lewis, J. A., Payne, S., Rawlins, M. D. New 
active substances authorized in the United Kingdom between 1972 and 
1994. Br J Clin Pharmacol. 1998 Feb;45(2):151-6. 
82. Hazell, L., Shakir, S. A. Under-reporting of adverse drug reactions : a 
systematic review. Drug Saf. 2006;29(5):385-96. 
83. Westphal, J. F., Brogard, J. M. Drug administration in chronic liver disease. 
Drug Saf. 1997 Jul;17(1):47-73. 
5 References 
 
- 87 - 
 
84. McLean, A. J., Morgan, D. J. Clinical pharmacokinetics in patients with liver 
disease. Clin Pharmacokinet. 1991 Jul;21(1):42-69. 
85. Williams, R. L., Mamelok, R. D. Hepatic disease and drug 
pharmacokinetics. Clin Pharmacokinet. 1980 Nov-Dec;5(6):528-47. 
86. Rodighiero, V. Effects of liver disease on pharmacokinetics. An update. Clin 
Pharmacokinet. 1999 Nov;37(5):399-431. 
87. Arzneimittel-Kompendium der Schweiz (online). Basel: Documed AG; 
Updated periodically [cited 01/01/2010-05/31/2012]; Available from: 
http://www.kompendium.ch. 
88. Micromedex® 2.0 (Healthcare Series), (electronic version). Thomson 
Reuters (Healthcare) Inc.: Greenwood Village, Colorado, USA; [cited 
01/10/2011-05/31/2012]; Available from: http://www.thomsonhc.com. 
89. Speight TM, Holford NHG, editor. Avery's drug treatment. 4th ed. Auckland: 
Adis International, 1997. 
90. Dollery, C, editor. Therapeutic drugs. 2nd ed. Edinburgh: Churchill 
Livingstone, 1999. 
91. Thummel KE, Shen DD, Isoherranen N, et al. Design and optimization of 
dosage regimens: pharmacokinetic data. In: Brunton L, editor. Goodman & 
Gilman's: the pharmacological basis of therapeutics. 11th ed. New York: Mc 
Graw-Hill, 2006. 
92. Zimmerman, HJ. Hepatotoxicity: the adverse effects of drugs and other 
chemicals on the liver. 2nd ed. Philadelphia (PA): Lippincott Williams & 
Wilkins, 1999. 
93. Bircher J, Sommer W. Klinisch-pharmakologische Datensammlung. 2nd ed. 
Stuttgart: Wissenschaftliche Verlagsgesellschaft mbH, 1999. 
94. Tchambaz, L., Schlatter, C., Jakob, M., Krahenbuhl, A., Wolf, P., et al. Dose 
adaptation of antineoplastic drugs in patients with liver disease. Drug Saf. 
2006;29(6):509-22. 
95. Schlatter, C., Egger, S. S., Tchambaz, L., Krahenbuhl, S. Pharmacokinetic 
changes of psychotropic drugs in patients with liver disease: implications for 
dose adaptation. Drug Saf. 2009;32(7):561-78. 
96. Periti, P., Mazzei, T., Mini, E., Novelli, A. Pharmacokinetic drug interactions 
of macrolides. Clin Pharmacokinet. 1992 Aug;23(2):106-31. 
97. Brook, I. Pharmacodynamics and pharmacokinetics of spiramycin and their 
clinical significance. Clin Pharmacokinet. 1998 Apr;34(4):303-10. 
5 References 
 
- 88 - 
 
98. Periti, P., Mazzei, T., Mini, E., Novelli, A. Clinical pharmacokinetic 
properties of the macrolide antibiotics. Effects of age and various 
pathophysiological states (Part I). Clin Pharmacokinet. 1989 Apr;16(4):193-
214. 
99. Frydman, A. M., Le Roux, Y., Desnottes, J. F., Kaplan, P., Djebbar, F., et al. 
Pharmacokinetics of spiramycin in man. J Antimicrob Chemother. 1988 
Jul;22 Suppl B:93-103. 
100. Descotes, J., Vial, T., Delattre, D., Evreux, J. C. Spiramycin: safety in man. 
J Antimicrob Chemother. 1988 Jul;22 Suppl B:207-10. 
101. Mazzei, T., Surrenti, C., Novelli, A., Crispo, A., Fallani, S., et al. 
Pharmacokinetics of azithromycin in patients with impaired hepatic function. 
J Antimicrob Chemother. 1993 Jun;31 Suppl E:57-63. 
102. Singlas, E. [Clinical pharmacokinetics of azithromycin]. Pathol Biol (Paris). 
1995 Jun;43(6):505-11. 
103. Abel, S., van der Ryst, E., Rosario, M. C., Ridgway, C. E., Medhurst, C. G., 
et al. Assessment of the pharmacokinetics, safety and tolerability of 
maraviroc, a novel CCR5 antagonist, in healthy volunteers. Br J Clin 
Pharmacol. 2008 Apr;65 Suppl 1:5-18. 
104. Davey, P. G. Pharmacokinetics in liver disease. J Antimicrob Chemother. 
1988 Jan;21(1):1-5. 
105. Kolve, H., Silling, G., Ritter, J., Groll, A. H. [Antimicrobial agents in pediatric 
cancer patients with hepatic or renal impairment]. Klin Padiatr. 2005 
Nov;217 Suppl 1:S150-64. 
106. Zuckerman, M. J., Menzies, I. S., Ho, H., Gregory, G. G., Casner, N. A., et 
al. Assessment of intestinal permeability and absorption in cirrhotic patients 
with ascites using combined sugar probes. Dig Dis Sci. 2004 Apr;49(4):621-
6. 
107. Blaschke, T. F., Rubin, P. C. Hepatic first-pass metabolism in liver disease. 
Clin Pharmacokinet. 1979 Nov-Dec;4(6):423-32. 
108. Vyas, K., Gala, B., Sawant, P., Das, H. S., Kulhalli, P. M., et al. Assessment 
of portal hemodynamics by ultrasound color Doppler and laser Doppler 
velocimetry in liver cirrhosis. Indian J Gastroenterol. 2002 Sep-
Oct;21(5):176-8. 
109. Tegeder, I., Lotsch, J., Geisslinger, G. Pharmacokinetics of opioids in liver 
disease. Clin Pharmacokinet. 1999 Jul;37(1):17-40. 
5 References 
 
- 89 - 
 
110. MacGilchrist, A. J., Birnie, G. G., Cook, A., Scobie, G., Murray, T., et al. 
Pharmacokinetics and pharmacodynamics of intravenous midazolam in 
patients with severe alcoholic cirrhosis. Gut. 1986 Feb;27(2):190-5. 
111. Cockcroft, D. W., Gault, M. H. Prediction of creatinine clearance from serum 
creatinine. Nephron. 1976;16(1):31-41. 
112. Child CG, Turcotte JG. Surgery and portal hypertension. In: Child C, editor. 
The liver and portal hypertension. Philadelphia (PA): Saunders; 1964. p. 50-
64. 
113. Egger, S. S., Meier, S., Leu, C., Christen, S., Gratwohl, A., et al. Drug 
interactions and adverse events associated with antimycotic drugs used for 
invasive aspergillosis in hematopoietic SCT. Bone Marrow Transplant. 2010 
Jul;45(7):1197-203. 
114. Lucena, M. I., Andrade, R. J., Tognoni, G., Hidalgo, R., De La Cuesta, F. S. 
Multicenter hospital study on prescribing patterns for prophylaxis and 
treatment of complications of cirrhosis. Eur J Clin Pharmacol. 2002 
Sep;58(6):435-40. 
115. Lucena, M. I., Andrade, R. J., Tognoni, G., Hidalgo, R., Sanchez de la 
Cuesta, F. Drug use for non-hepatic associated conditions in patients with 
liver cirrhosis. Eur J Clin Pharmacol. 2003 May;59(1):71-6. 
116. Lazarou, J., Pomeranz, B. H., Corey, P. N. Incidence of adverse drug 
reactions in hospitalized patients: a meta-analysis of prospective studies. 
JAMA. 1998 Apr 15;279(15):1200-5. 
117. van der Hooft, C. S., Dieleman, J. P., Siemes, C., Aarnoudse, A. J., 
Verhamme, K. M., et al. Adverse drug reaction-related hospitalisations: a 
population-based cohort study. Pharmacoepidemiol Drug Saf. 2008 
Apr;17(4):365-71. 
118. Pirmohamed, M., James, S., Meakin, S., Green, C., Scott, A. K., et al. 
Adverse drug reactions as cause of admission to hospital: prospective 
analysis of 18 820 patients. BMJ. 2004 Jul 3;329(7456):15-9. 
119. Fattinger, K., Roos, M., Vergeres, P., Holenstein, C., Kind, B., et al. 
Epidemiology of drug exposure and adverse drug reactions in two swiss 
departments of internal medicine. Br J Clin Pharmacol. 2000 Feb;49(2):158-
67. 
5 References 
 
- 90 - 
 
120. Herr, R. D., Caravati, E. M., Tyler, L. S., Iorg, E., Linscott, M. S. Prospective 
evaluation of adverse drug interactions in the emergency department. Ann 
Emerg Med. 1992 Nov;21(11):1331-6. 
121. Ratz Bravo, A. E., Tchambaz, L., Krahenbuhl-Melcher, A., Hess, L., 
Schlienger, R. G., et al. Prevalence of potentially severe drug-drug 
interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA 
reductase inhibitor therapy. Drug Saf. 2005;28(3):263-75. 
122. Corsonello, A., Pedone, C., Corica, F., Mussi, C., Carbonin, P., et al. 
Concealed renal insufficiency and adverse drug reactions in elderly 
hospitalized patients. Arch Intern Med. 2005 Apr 11;165(7):790-5. 
123. Papadakis, M. A., Arieff, A. I. Unpredictability of clinical evaluation of renal 
function in cirrhosis. Prospective study. Am J Med. 1987 May;82(5):945-52. 
124. Angeli, P., Gatta, A., Caregaro, L., Menon, F., Sacerdoti, D., et al. Tubular 
site of renal sodium retention in ascitic liver cirrhosis evaluated by lithium 
clearance. Eur J Clin Invest. 1990 Feb;20(1):111-7. 
125. Amir, O., Hassan, Y., Sarriff, A., Awaisu, A., Abd Aziz, N., et al. Incidence of 
risk factors for developing hyperkalemia when using ACE inhibitors in 
cardiovascular diseases. Pharm World Sci. 2009 Jun;31(3):387-93. 
126. Sacerdoti, D., Bolognesi, M., Merkel, C., Angeli, P., Gatta, A. Renal 
vasoconstriction in cirrhosis evaluated by duplex Doppler ultrasonography. 
Hepatology. 1993 Feb;17(2):219-24. 
127. Wensing, G., Lotterer, E., Link, I., Hahn, E. G., Fleig, W. E. Urinary sodium 
balance in patients with cirrhosis: relationship to quantitative parameters of 
liver function. Hepatology. 1997 Nov;26(5):1149-55. 
128. De Ledinghen, V., Heresbach, D., Fourdan, O., Bernard, P., Liebaert-
Bories, M. P., et al. Anti-inflammatory drugs and variceal bleeding: a case-
control study. Gut. 1999 Feb;44(2):270-3. 
129. Le Couteur, D. G., Fraser, R., Hilmer, S., Rivory, L. P., McLean, A. J. The 
hepatic sinusoid in aging and cirrhosis: effects on hepatic substrate 
disposition and drug clearance. Clin Pharmacokinet. 2005;44(2):187-200. 
130. Miyajima, H., Nomura, M., Muguruma, N., Okahisa, T., Shibata, H., et al. 
Relationship among gastric motility, autonomic activity, and portal 
hemodynamics in patients with liver cirrhosis. J Gastroenterol Hepatol. 2001 
Jun;16(6):647-59. 
5 References 
 
- 91 - 
 
131. Mathews, R. E., Jr., McGuire, B. M., Estrada, C. A. Outpatient management 
of cirrhosis: a narrative review. South Med J. 2006 Jun;99(6):600-6. 
132. Changani, K. K., Jalan, R., Cox, I. J., Ala-Korpela, M., Bhakoo, K., et al. 
Evidence for altered hepatic gluconeogenesis in patients with cirrhosis 
using in vivo 31-phosphorus magnetic resonance spectroscopy. Gut. 2001 
Oct;49(4):557-64. 
133. Hassan, Y., Al-Ramahi, R. J., Aziz, N. A., Ghazali, R. Impact of a renal drug 
dosing service on dose adjustment in hospitalized patients with chronic 
kidney disease. Ann Pharmacother. 2009 Oct;43(10):1598-605. 
134. Kongkaew, C., Noyce, P. R., Ashcroft, D. M. Hospital admissions 
associated with adverse drug reactions: a systematic review of prospective 
observational studies. Ann Pharmacother. 2008 Jul;42(7):1017-25. 
135. Mann, C. J. Observational research methods. Research design II: cohort, 
cross sectional, and case-control studies. Emerg Med J. 2003 Jan;20(1):54-
60. 
136. Saivin, S., Houin, G. Clinical pharmacokinetics of doxycycline and 
minocycline. Clin Pharmacokinet. 1988 Dec;15(6):355-66. 
137. Firouzmand, M., Zafrani, E. S., Dhumeaux, D., Mallat, A. [Microvacuolar 
steatosis following low doses of doxycycline]. Gastroenterol Clin Biol. 2002 
Dec;26(12):1176-7. 
138. Min, D. I., Burke, P. A., Lewis, W. D., Jenkins, R. L. Acute hepatic failure 
associated with oral minocycline: a case report. Pharmacotherapy. 
1992;12(1):68-71. 
139. Bernard, B., Yin, E. J., Simon, H. J. Clinical pharmacologic studies with 
minocycline. J Clin Pharmacol New Drugs. 1971 Sep-Oct;11(5):332-48. 
140. Bonilla, M. F., Avery, R. K., Rehm, S. J., Neuner, E. A., Isada, C. M., et al. 
Extreme alkaline phosphatase elevation associated with tigecycline. J 
Antimicrob Chemother. 2011 Apr;66(4):952-3. 
141. Korth-Bradley, J. M., Baird-Bellaire, S. J., Patat, A. A., Troy, S. M., Bohmer, 
G. M., et al. Pharmacokinetics and safety of a single intravenous dose of 
the antibiotic tigecycline in patients with cirrhosis. J Clin Pharmacol. 2011 
Jan;51(1):93-101. 
142. Grange, J. D., Gouyette, A., Gutmann, L., Amiot, X., Kitzis, M. D., et al. 
Pharmacokinetics of amoxycillin/clavulanic acid in serum and ascitic fluid in 
cirrhotic patients. J Antimicrob Chemother. 1989 Apr;23(4):605-11. 
5 References 
 
- 92 - 
 
143. Murphy, E. S., Mireles, M. Shock, liver necrosis, and death after penicillin 
injection. Arch Pathol. 1962 May;73:355-62. 
144. el Touny, M., el Guinaidy, M., Abdel Barry, M., Osman, L., Sabbour, M. S. 
Pharmacokinetics of aztreonam in patients with liver cirrhosis and ascites. J 
Antimicrob Chemother. 1992 Sep;30(3):387-95. 
145. Hary, L., Smail, A., Ducroix, J. P., Baillet, J., Andrejak, M. Pharmacokinetics 
and ascitic fluid penetration of piperacillin in cirrhosis. Fundam Clin 
Pharmacol. 1991;5(9):789-95. 
146. Ohashi, K., Tsunoo, M., Tsuneoka, K. Pharmacokinetics and protein binding 
of cefazolin and cephalothin in patients with cirrhosis. J Antimicrob 
Chemother. 1986 Mar;17(3):347-51. 
147. Okolicsanyi, L., Venuti, M., Orlando, R., Xerri, L., Pugina, M. 
Pharmacokinetic studies of cefuroxime in patients with liver cirrhosis. 
Arzneimittel-Forschung. 1982;32(7):777-82. 
148. Bilici, A., Karaduman, M., Cankir, Z. A rare case of hepatitis associated with 
cefprozil therapy. Scand J Infect Dis. 2007;39(2):190-2. 
149. Shyu, W. C., Wilber, R. B., Pittman, K. A., Garg, D. C., Barbhaiya, R. H. 
Pharmacokinetics of cefprozil in healthy subjects and patients with hepatic 
impairment. J Clin Pharmacol. 1991 Apr;31(4):372-6. 
150. el Touny, M., el Guinaidy, M. A., Abd el Barry, M., Osman, L., Sabbour, M. 
S. Pharmacokinetics of ceftazidime in patients with liver cirrhosis and 
ascites. J Antimicrob Chemother. 1991 Jul;28(1):95-100. 
151. Oakes, M., MacDonald, H., Wilson, D. Abnormal laboratory test values 
during ceftriaxone therapy. Am J Med. 1984 Oct 19;77(4C):89-96. 
152. Balant, L., Dayer, P., Auckenthaler, R. Clinical pharmacokinetics of the third 
generation cephalosporins. Clin Pharmacokinet. 1985 Mar-Apr;10(2):101-
43. 
153. Stoeckel, K., Koup, J. R. Pharmacokinetics of ceftriaxone in patients with 
renal and liver insufficiency and correlations with a physiologic nonlinear 
protein binding model. Am J Med. 1984 Oct 19;77(4C):26-32. 
154. Stoeckel, K., Tuerk, H., Trueb, V., McNamara, P. J. Single-dose ceftriaxone 
kinetics in liver insufficiency. Clin Pharmacol Ther. 1984 Oct;36(4):500-9. 
155. Yuk, J. H., Nightingale, C. H., Quintiliani, R. Clinical pharmacokinetics of 
ceftriaxone. Clin Pharmacokinet. 1989 Oct;17(4):223-35. 
5 References 
 
- 93 - 
 
156. Hary, L., Andrejak, M., Leleu, S., Orfila, J., Capron, J. P. The 
pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with 
ascites. Eur J Clin Pharmacol. 1989;36(6):613-6. 
157. Joos, B., Luethy, R., Muehlen, E., Siegenthaler, W. Variability of ceftriaxone 
pharmacokinetics in hospitalized patients with severe infections. Am J Med. 
1984 Oct 19;77(4C):59-62. 
158. Taburet, A. M., Attali, P., Bourget, P., Etienne, J. P., Singlas, E. 
Pharmacokinetics of ornidazole in patients with acute viral hepatitis, 
alcoholic cirrhosis, and extrahepatic cholestasis. Clin Pharmacol Ther. 1989 
Apr;45(4):373-9. 
159. Barr, W. H., Lin, C. C., Radwanski, E., Lim, J., Symchowicz, S., et al. The 
pharmacokinetics of ceftibuten in humans. Diagn Microbiol Infect Dis. 1991 
Jan-Feb;14(1):93-100. 
160. Swabb, E. A., Singhvi, S. M., Leitz, M. A., Frantz, M., Sugerman, A. 
Metabolism and pharmacokinetics of aztreonam in healthy subjects. 
Antimicrob Agents Chemother. 1983 Sep;24(3):394-400. 
161. MacLeod, C. M., Bartley, E. A., Payne, J. A., Hudes, E., Vernam, K., et al. 
Effects of cirrhosis on kinetics of aztreonam. Antimicrob Agents Chemother. 
1984 Oct;26(4):493-7. 
162. Mouton, J. W., Touzw, D. J., Horrevorts, A. M., Vinks, A. A. Comparative 
pharmacokinetics of the carbapenems: clinical implications. Clin 
Pharmacokinet. 2000 Sep;39(3):185-201. 
163. Thyrum, P. T., Yeh, C., Birmingham, B., Lasseter, K. Pharmacokinetics of 
meropenem in patients with liver disease. Clin Infect Dis. 1997 Feb;24 
Suppl 2:S184-90. 
164. Redman, R., File, T. M., Jr. Safety of intravenous infusion of doripenem. 
Clin Infect Dis. 2009 Aug 15;49 Suppl 1:S28-35. 
165. Berg, P. A., Daniel, P. T. Co-trimoxazole-induced hepatic injury--an analysis 
of cases with hypersensitivity-like reactions. Infection. 1987;15 Suppl 
5:S259-64. 
166. Rieder, V. J., Schwartz, D. E. [Comparison of pharmacokinetics of the 
combination trimethoprim and sulfamethoxazole in patients with liver 
diseases and healthy persons]. Arzneimittel-Forschung. 1975 
Apr;25(4):656-66. 
5 References 
 
- 94 - 
 
167. Angelucci, L., Baldieri, M., Barba, C., Lentini, S., Linari, G., et al. [Plasma 
levels of cotrimoxazole in patients with hepatic insufficiency]. Clin Ter. 1977 
Apr 30;81(2):111-22. 
168. Kroboth, P. D., Brown, A., Lyon, J. A., Kroboth, F. J., Juhl, R. P. 
Pharmacokinetics of single-dose erythromycin in normal and alcoholic liver 
disease subjects. Antimicrob Agents Chemother. 1982 Jan;21(1):135-40. 
169. Hall, K. W., Nightingale, C. H., Gibaldi, M., Nelson, E., Bates, T. R., et al. 
Pharmacokinetics of erythromycin in normal and alcoholic liver disease 
subjects. J Clin Pharmacol. 1982 Jul;22(7):321-5. 
170. Barre, J., Mallat, A., Rosenbaum, J., Deforges, L., Houin, G., et al. 
Pharmacokinetics of erythromycin in patients with severe cirrhosis. 
Respective influence of decreased serum binding and impaired liver 
metabolic capacity. Br J Clin Pharmacol. 1987 Jun;23(6):753-7. 
171. Azuma, T., Ito, S., Suto, H., Ito, Y., Miyaji, H., et al. Pharmacokinetics of 
clarithromycin in Helicobacter pylori eradication therapy in patients with liver 
cirrhosis. Aliment Pharmacol Ther. 2000 Apr;14 Suppl 1:216-22. 
172. Chu, S. Y., Granneman, G. R., Pichotta, P. J., Decourt, J. P., Girault, J., et 
al. Effect of moderate or severe hepatic impairment on clarithromycin 
pharmacokinetics. J Clin Pharmacol. 1993 May;33(5):480-5. 
173. Hardy, D. J., Guay, D. R., Jones, R. N. Clarithromycin, a unique macrolide. 
A pharmacokinetic, microbiological, and clinical overview. Diagn Microbiol 
Infect Dis. 1992 Jan;15(1):39-53. 
174. Rodvold, K. A. Clinical pharmacokinetics of clarithromycin. Clin 
Pharmacokinet. 1999 Nov;37(5):385-98. 
175. Wynalda, M. A., Hutzler, J. M., Koets, M. D., Podoll, T., Wienkers, L. C. In 
vitro metabolism of clindamycin in human liver and intestinal microsomes. 
Drug Metab Dispos. 2003 Jul;31(7):878-87. 
176. Elmore, M., Rissing, J. P., Rink, L., Brooks, G. F. Clindamycin-associated 
hepatotoxicity. Am J Med. 1974 Oct;57(4):627-30. 
177. Avant, G. R., Schenker, S., Alford, R. H. The effect of cirrhosis on the 
disposition and elimination of clindamycin. Am J Dig Dis. 1975 
Mar;20(3):223-30. 
178. Brandl, R., Arkenau, C., Simon, C., Malerczyk, V., Eidelloth, G. [The 
pharmacokinetics of clindamycin in abnormal liver and renal function]. Dtsch 
Med Wochenschr. 1972 Jul 14;97(28):1057-9. 
5 References 
 
- 95 - 
 
179. Hinthorn, D. R., Baker, L. H., Romig, D. A., Hassanein, K., Liu, C. Use of 
clindamycin in patients with liver disease. Antimicrob Agents Chemother. 
1976 Mar;9(3):498-501. 
180. Williams, D. N., Crossley, K., Hoffman, C., Sabath, L. D. Parenteral 
clindamycin phosphate: pharmacology with normal and abnormal liver 
function and effect on nasal staphylococci. Antimicrob Agents Chemother. 
1975 Feb;7(2):153-8. 
181. Eng, R. H., Gorski, S., Person, A., Mangura, C., Chmel, H. Clindamycin 
elimination in patients with liver disease. J Antimicrob Chemother. 1981 
Oct;8(4):277-81. 
182. Sampliner, R., Perrier, D., Powell, R., Finley, P. Influence of ascites on 
tobramycin pharmacokinetics. J Clin Pharmacol. 1984 Jan;24(1):43-6. 
183. Rosdahl, N., Andersen, J. B. Aspects of the pharmacology of gentamicin 
during the neonatal period. Acta Pathol Microbiol Scand B Microbiol 
Immunol. 1973:Suppl 241:119-. 
184. Lietman, P. S. Liver disease, aminoglycoside antibiotics and renal 
dysfunction. Hepatology. 1988 Jul-Aug;8(4):966-8. 
185. Orlando, R., Sawadogo, A., Miglioli, P. A., Cappellazzo, M. G., Palatini, P. 
Oral disposition kinetics of ofloxacin in patients with compensated liver 
cirrhosis. Chemotherapy. 1992;38(1):1-6. 
186. Silvain, C., Bouquet, S., Breux, J. P., Becq-Giraudon, B., Beauchant, M. 
Oral pharmacokinetics and ascitic fluid penetration of ofloxacin in cirrhosis. 
Eur J Clin Pharmacol. 1989;37(3):261-5. 
187. Sambatakou, H., Giamarellos-Bourboulis, E. J., Galanakis, N., Giamarellou, 
H. Pharmacokinetics of fluoroquinolones in uncompensated cirrhosis: the 
significance of penetration in the ascitic fluid. Int J Antimicrob Agents. 2001 
Nov;18(5):441-4. 
188. Dixit, R. K., Satapathy, S. K., Kumar, R., Dhiman, R. K., Garg, S. K., et al. 
Pharmacokinetics of ciprofloxacin in patients with liver cirrhosis. Indian J 
Gastroenterol. 2002 Mar-Apr;21(2):62-3. 
189. Ruhnke, M., Trautmann, M., Borner, K., Hopfenmuller, W. 
Pharmacokinetics of ciprofloxacin in liver cirrhosis. Chemotherapy. 
1990;36(6):385-91. 
5 References 
 
- 96 - 
 
190. Esposito, S., Miniero, M., Barba, D., Sagnelli, E. Pharmacokinetics of 
ciprofloxacin in impaired liver function. Int J Clin Pharmacol Res. 
1989;9(1):37-41. 
191. Frost, R. W., Lettieri, J. T., Krol, G., Shamblen, E. C., Lasseter, K. C. The 
effect of cirrhosis on the steady-state pharmacokinetics of oral ciprofloxacin. 
Clin Pharmacol Ther. 1989 Jun;45(6):608-16. 
192. Wise, R. Norfloxacin--a review of pharmacology and tissue penetration. J 
Antimicrob Chemother. 1984 May;13 Suppl B:59-64. 
193. Eandi, M., Viano, I., Di Nola, F., Leone, L., Genazzani, E. Pharmacokinetics 
of norfloxacin in healthy volunteers and patients with renal and hepatic 
damage. Eur J Clin Microbiol. 1983 Jun;2(3):253-9. 
194. Holmes, B., Brogden, R. N., Richards, D. M. Norfloxacin. A review of its 
antibacterial activity, pharmacokinetic properties and therapeutic use. 
Drugs. 1985 Dec;30(6):482-513. 
195. Ghassemi, S., Garcia-Tsao, G. Prevention and treatment of infections in 
patients with cirrhosis. Best Pract Res Clin Gastroenterol. 2007;21(1):77-93. 
196. Nightingale, C. H. Moxifloxacin, a new antibiotic designed to treat 
community-acquired respiratory tract infections: a review of microbiologic 
and pharmacokinetic-pharmacodynamic characteristics. Pharmacotherapy. 
2000 Mar;20(3):245-56. 
197. Soto, S., Lopez-Roses, L., Avila, S., Lancho, A., Gonzalez, A., et al. 
Moxifloxacin-induced acute liver injury. Am J Gastroenterol. 2002 
Jul;97(7):1853-4. 
198. Ball, P. New antibiotics for community-acquired lower respiratory tract 
infections: improved activity at a cost? Int J Antimicrob Agents. 2000 
Nov;16(3):263-72. 
199. Moise, P. A., Birmingham, M. C., Schentag, J. J. Pharmacokinetics and 
metabolism of moxifloxacin. Drugs Today (Barc). 2000 Apr;36(4):229-44. 
200. Balfour, J. A., Lamb, H. M. Moxifloxacin: a review of its clinical potential in 
the management of community-acquired respiratory tract infections. Drugs. 
2000 Jan;59(1):115-39. 
201. Barth, J., Jager, D., Mundkowski, R., Drewelow, B., Welte, T., et al. Single- 
and multiple-dose pharmacokinetics of intravenous moxifloxacin in patients 
with severe hepatic impairment. J Antimicrob Chemother. 2008 
Sep;62(3):575-8. 
5 References 
 
- 97 - 
 
202. Harada, H., Miyagawa, S., Kawasaki, S., Hayashi, K., Kitamura, H., et al. 
Study of the pharmacokinetics of vancomycin in patients with impaired liver 
function. J Infect Chemother. 1999 Jun;5(2):104-7. 
203. Wenk M, Follath F. Konzentrationsmessung von Arzneistoffen (Therapeutic 
Drug Monitoring). In: Schweizerische Gesellschaft für Klinische 
Pharmakologie und Toxikologie, editor. Grundlagen der 
Arzneimitteltherapie. 16th ed. Basel: Documed AG; 2005. p. 19ff. 
204. Kutty, K. P., Nath, I. V., Kothandaraman, K. R., Barrowman, J. A., Perkins, 
P. G., et al. Fusidic acid-induced hyperbilirubinemia. Dig Dis Sci. 1987 
Aug;32(8):933-8. 
205. Humble, M. W., Eykyn, S., Phillips, I. Staphylococcal bacteraemia, fusidic 
acid, and jaundice. Br Med J. 1980 Jun 21;280(6230):1495-8. 
206. Peter, J. D., Jehl, F., Pottecher, T., Dupeyron, J. P., Monteil, H. 
Pharmacokinetics of intravenous fusidic acid in patients with cholestasis. 
Antimicrob Agents Chemother. 1993 Mar;37(3):501-6. 
207. Daneshmend, T. K., Homeida, M., Kaye, C. M., Elamin, A. A., Roberts, C. J. 
Disposition of oral metronidazole in hepatic cirrhosis and in hepatosplenic 
schistosomiasis. Gut. 1982 Oct;23(10):807-13. 
208. Farrell, G., Baird-Lambert, J., Cvejic, M., Buchanan, N. Disposition and 
metabolism of metronidazole in patients with liver failure. Hepatology. 1984 
Jul-Aug;4(4):722-6. 
209. Farrell, G., Buchanan, N., Baird-Lambert, J. Impaired elimination of 
metronidazole in decompensated chronic liver disease. Br Med J (Clin Res 
Ed). 1984 Mar 31;288(6422):1009. 
210. Ljungberg, B., Nilsson-Ehle, I., Ursing, B. Metronidazole: pharmacokinetic 
observations in severely ill patients. J Antimicrob Chemother. 1984 
Sep;14(3):275-83. 
211. Lau, A. H., Evans, R., Chang, C. W., Seligsohn, R. Pharmacokinetics of 
metronidazole in patients with alcoholic liver disease. Antimicrob Agents 
Chemother. 1987 Nov;31(11):1662-4. 
212. Plaisance, K. I., Quintiliani, R., Nightingale, C. H. The pharmacokinetics of 
metronidazole and its metabolites in critically ill patients. J Antimicrob 
Chemother. 1988 Feb;21(2):195-200. 
5 References 
 
- 98 - 
 
213. Muscara, M. N., Pedrazzoli, J., Jr., Miranda, E. L., Ferraz, J. G., Hofstatter, 
E., et al. Plasma hydroxy-metronidazole/metronidazole ratio in patients with 
liver disease and in healthy volunteers. Br J Clin Pharmacol. 1995 
Nov;40(5):477-80. 
214. Lamp, K. C., Freeman, C. D., Klutman, N. E., Lacy, M. K. Pharmacokinetics 
and pharmacodynamics of the nitroimidazole antimicrobials. Clin 
Pharmacokinet. 1999 May;36(5):353-73. 
215. Roe, F. J. Safety of nitroimidazoles. Scand J Infect Dis Suppl. 1985;46:72-
81. 
216. Ersoz, G., Karasu, Z., Akarca, U. S., Gunsar, F., Yuce, G., et al. 
Nitroimidazole-induced chronic hepatitis. Eur J Gastroenterol Hepatol. 2001 
Aug;13(8):963-6. 
217. Kosar, Y., Sasmaz, N., Oguz, P., Kacar, S., Erden, E., et al. Ornidazole-
induced autoimmune hepatitis. Eur J Gastroenterol Hepatol. 2001 
Jun;13(6):737-9. 
218. Tabak, F., Ozaras, R., Erzin, Y., Celik, A. F., Ozbay, G., et al. Ornidazole-
induced liver damage: report of three cases and review of the literature. 
Liver Int. 2003 Oct;23(5):351-4. 
219. Taburet, A. M., Delion, F., Attali, P., Thebault, J. J., Singlas, E. 
Pharmacokinetics of ornidazole in patients with severe liver cirrhosis. Clin 
Pharmacol Ther. 1986 Sep;40(3):359-64. 
220. Durupt, S., Josserand, R. N., Sibille, M., Durieu, I. Acute, recurrent 
fosfomycin-induced liver toxicity in an adult patient with cystic fibrosis. 
Scand J Infect Dis. 2001;33(5):391-2. 
221. Paladino, J. A. Linezolid: an oxazolidinone antimicrobial agent. Am J Health 
Syst Pharm. 2002 Dec 15;59(24):2413-25. 
222. Cholongitas, E., Georgousaki, C., Spyrou, S., Dasenaki, M. Linezolid-
induced severe hyperbilirubinemia in a patient with decompensated 
cirrhosis. J Infect. 2010 Feb;60(2):182-3. 
223. De Bus, L., Depuydt, P., Libbrecht, L., Vandekerckhove, L., Nollet, J., et al. 
Severe drug-induced liver injury associated with prolonged use of linezolid. 
J Med Toxicol. 2010 Sep;6(3):322-6. 
224. Stalker, D. J., Jungbluth, G. L. Clinical pharmacokinetics of linezolid, a 
novel oxazolidinone antibacterial. Clin Pharmacokinet. 2003;42(13):1129-
40. 
5 References 
 
- 99 - 
 
225. Di Paolo, A., Malacarne, P., Guidotti, E., Danesi, R., Del Tacca, M. 
Pharmacological issues of linezolid: an updated critical review. Clin 
Pharmacokinet. 2010 Jul;49(7):439-47. 
226. Dvorchik, B. Moderate liver impairment has no influence on daptomycin 
pharmacokinetics. J Clin Pharmacol. 2004 Jul;44(7):715-22. 
 
  
 
 
   
 
 
 
 
 
 
 
   
  
6 Appendix  
Tab. 11 Draft of the database summarizing pharmacokinetic data, adverse drug reactions, pharmacokinetic studies, and recommendations in liver disease for anti-
infectives for systemic use. All the antibacterials, exclusively the high hepatic extraction drugs (see section 3.1.4 Tab. 4), are listed according to the therapeutic 
groups. The whole database for all anti-infective drugs studied is available on the attached CD. 
Drug (route of 
application)  
Metabolism Kinetic 
parameters 
Hepatic ADRs Potentially dose-dependent ADRs Studies, product information, and dose recommendations 
Antibacterials for systemic use 
Tetracyclines 
Doxycycline 
(oral, 
parenteral) 
No significant 
metabolism. 
Enterohepatic cycling. 
A part is inactivated by 
chelation (Ca2+, 
Mg2+) in the intestine 
[87, 90, 136]. 
Q0: 0.70 
T1/2: 23h 
Vd: 0.75L/kg 
PB: 85% 
Foral: 95% 
CLsys: 2.2L/h 
E: 0.03 
BE: n.k. 
CAT: 3 
Rare: hepatitis, 
cholestatic liver 
injury [87, 92]. 
Case report: 
microvesicular 
steatosis [137].  
gastrointestinal disturbances, 
esophageal ulcerations, intestinal 
overgrowth by non-susceptible 
organisms, discoloration of teeth, 
decreased plasma prothrombin 
activity, benign intracranial 
hypertension, rise in BUN [87, 90] 
Studies: No clinical studies available in patients with liver 
disease.  
Product information: Caution in patients with severe liver 
dysfunction. No pharmacokinetic data in patients with liver 
disease [87].  
Recommendation: According to pharmacokinetic data, start 
with normal initial doses. Reduce maintenance dose by up 
to 50%. Adjust maintenance dose according to clinical effect 
and dose-dependent ADRs. 
Lymecycline 
(oral) 
Prodrug of tetracycline. 
The data reported refer 
to tetracycline. About 
5% of tetracycline is 
metabolized by C-4 
epimerization [90]. 
Enterohepatic 
circulation. 
Q0: 0.40 
T1/2: 10h 
Vd: 1.5L/kg 
PB: 60% 
Foral: n.k. 
CLsys: 7L/h 
E: 0.05 
BE: minor 
CAT: 4 
Rare: liver 
function 
disturbances, 
jaundice, 
steatosis of the 
liver [71, 87]. 
gastrointestinal disturbances, 
esophageal ulcerations, discoloration 
of teeth, intestinal overgrowth by non-
susceptible organisms, decreased 
plasma prothrombin activity, 
neuromuscular blockade, increase in 
BUN, benign intracranial 
hypertension, dizziness, convulsions 
[71, 87, 90] 
Studies: No clinical studies available in patients with liver 
disease.  
Product information: Caution in patients with liver disease 
[87].  
Recommendation: According to pharmacokinetic data, no 
dose adjustment seems necessary in patients with liver 
disease. Choose normal initial dose and adjust maintenance 
dose by means of creatinine clearance. Due to the risk for 
hepatic adverse effects, better alternatives may be chosen.   
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Tab. 11 (continued) 
Drug (route of 
application)  
Metabolism Kinetic 
parameters 
Hepatic ADRs Potentially dose-dependent 
ADRs 
Studies, product information, and dose recommendations 
Minocycline 
(oral) 
20% excreted 
unchanged by 
the feces. 
Metabolism to 
a significant 
degree to 9-
hydroxyminocy
cline and 
demethylated 
derivatives (all 
inactive) [87, 
136]. 
Q0: 0.85 
T1/2: 15h 
Vd: 1.4L/kg 
PB: 68% 
Foral: 95% 
CLsys: 5L/h 
E: 0.08 
BE: major 
CAT: 3 
Rare: liver enzyme 
elevation, hepatic 
failure, autoimmune 
hepatitis, 
hypersensitivity 
reaction (with 
hepatitis), 
hyperbilirubinemia, 
macrovesicular 
steatosis [87, 92, 
138]. 
gastrointestinal 
disturbances, esophageal 
ulcerations, vestibular 
disorders (dizziness, vertigo, 
ataxia, tinnitus), intestinal 
overgrowth by non-
susceptible organisms, 
decreased plasma 
prothrombin activity, benign 
intracranial hypertension, 
discoloration of teeth, rise in 
BUN [65, 87, 90] 
Studies: Serum t1/2 independent of hepatic dysfunction [139]. 
Product information: Contraindicated in patients with severe liver disease. 
Minocycline is excreted significantly by biliary tract. In the case of cholestatic 
liver disease, accumulation may occur. Caution in patients with liver 
dysfunction or if combined with other hepatotoxic drugs [87].  
Recommendation: According to pharmacokinetic data, start with normal 
initial dose and reduce maintenance dose by up to 50%. Adjust 
maintenance dose according to clinical effect and dose-dependent ADRs. 
Monitor liver function for adverse hepatic reactions. Caution in patients with 
cholestasis due to significant BE.   
Tigecycline 
(parenteral) 
Minor 
metabolism by 
glucuronidation
, N-acetylation 
[65, 87]. 
Q0: 0.78 
T1/2: 42h 
Vd: 8L/kg 
PB: 80% 
Foral: n.k. 
CLsys: 24L/h 
E: 0.35 
BE: major 
CAT: 2 
Frequent: elevated 
AST, ALT, AP, 
elevated bilirubin. 
Occasionally: liver 
injury (mainly 
cholestatic), 
jaundice. Post-
marketing: liver 
insufficiency [71, 
87, 140]. 
gastrointestinal 
disturbances, intestinal 
overgrowth by non-
susceptible organisms, 
decreased plasma 
prothrombin activity, 
pseudotumor cerebri, 
discoloration of teeth, rise in 
BUN, QT prolongation, 
pancreatitis [65, 87, 90] 
Studies: In patients with liver cirrhosis Child Pugh A, B, and C compared to 
healthy subjects (CL = 29.8L/h), mean tigecycline CL was 31.2L/h, 22.1L/h, 
and 13.5L/h, respectively [141]. 
Product information: Pharmacokinetics unchanged in patients with mild liver 
disease. In patients with moderate or severe liver disease, CLsys prolonged 
by 25% and 55% and t1/2 by 23% and 43%, respectively. No dosage 
adjustment necessary in patients with mild and moderate liver disease. 
Reduction of maintenance dose to 25mg/12h recommended in patients with 
severe liver disease [87].  
Recommendation: According to pharmacokinetic data and product 
information, use normal doses in patients with mild and moderate liver 
disease. In patients with severe liver disease, reduce maintenance dose by 
50%. Adjust maintenance dose by means of clinical effect and dose-
dependent ADRs. Caution in patients with cholestasis due to significant BE.   
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Tab. 11 (continued)  
Drug (route of 
application)  
Metabolism Kinetic 
parameters 
Hepatic ADRs Potentially dose-
dependent ADRs 
Studies, product information, and dose recommendations 
Beta-lactam antibacterials, penicillins 
Penicillins with extended spectrum 
Amoxicillin 
(oral, 
parenteral) 
10-25% is 
metabolized in the 
liver by hydrolysis 
of the β-lactam ring 
to penicilloic acid, 
which is excreted in 
the urine. 
Enterohepatic 
circulation occurs 
[87, 90]. 
Q0: 0.15 
T1/2: 1.5h 
Vd: 0.3L/kg 
PB: 18% 
Foral: 89% 
CLsys: 15L/h 
E: 0.04 
BE: minor 
CAT: 4 
Rare: transient 
elevations of liver 
enzymes, 
hyperbilirubinemi
a, cholestatic 
liver injury, acute 
hepatic 
dysfunction, 
hepatitis [87, 92]. 
gastrointestinal 
disturbances, intestinal 
overgrowth by non-
susceptible organisms, 
crystalluria, neurotoxicity 
(agitation, anxiety, 
confusion, convulsions) 
[65, 87] 
Studies: A single dose study of combined amoxicillin/clavulanic acid 
(1000/200mg) in cirrhotic patients showed an increased t1/2 of amoxicillin 
(274 min in ascitic vs. 53 min in non-ascitic subjects) probably due to 
increased Vd in patients with ascites. However, no dose recommendations 
were made. Monitoring of patients might be advisable [142]. 
Product information: Monitor liver function during long-term treatment [87].  
Recommendation: According to pharmacokinetic data, choose normal initial 
dose and adjust maintenance dose and/or dosage interval according to 
creatinine clearance. In patients with ascites: adjust initial dose according to 
body weight and adjust maintenance dose according to creatinine clearane. 
Beta-lactamase sensitive penicillins 
Benzyl-
penicillin 
(parenteral) 
Mainly renal 
elimination, but 
also partially 
metabolized to 
inactive 
benzylpenicilloic 
acid by hydrolysis 
of the lactam ring 
[90]. 
Q0: 0.3 
T1/2: 0.8h 
Vd: 0.4L/kg 
PB: 55% 
Foral: n.k. 
CLsys: 30L/h 
E: 0.17 
BE: minor 
CAT: 4 
Rare: cholestasis 
and/or hepatitis, 
elevated AST, 
often in 
combination with 
idiosyncratic 
reactions [71, 87, 
143]. 
gastrointestinal 
disturbances, intestinal 
overgrowth by non-
susceptible organisms, 
neurotoxicity (agitation, 
anxiety, confusion, visual 
disturbances, 
convulsions), 
hematological 
disturbances (e.g. 
neutropenia) [87, 90, 93] 
Studies: After 1g aztreonam i.v. (single dose), t1/2 was 1.82 h in healthy 
volunteers, 6.6 h in cirrhotic patients with ascites, and 8.87 h in patients with 
cirrhosis, ascites and renal failure [144]. 
Product information: No recommendation provided.  
Recommendation: According to pharmacokinetic data, choose normal initial 
dose and adjust maintenance dose and/or dosage interval by means of 
creatinine clearance. In patients with ascites: adjust initial dose according to 
body weight and adjust maintenance dose according to creatinine clearane. 
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Tab. 11 (continued) 
Drug (route of 
application)  
Metabolism Kinetic 
parameters 
Hepatic ADRs Potentially dose-
dependent ADRs 
Studies, product information, and dose recommendations 
Phenoxy-
methyl-
penicillin 
(oral) 
Metabolism to 
phenoxymethylpeni
cilloic acid and 
small amounts of 6-
amino penicilloic 
acid; enterohepatic 
cycling [87, 90]. 
Q0: 0.6 
T1/2: 0.5h 
Vd: 0.5L/kg 
PB: 80% 
Foral: 50% 
CLsys: 29L/h 
E: 0.32 
BE: minor 
CAT: 2 
Rare: transient 
increase of liver 
enzymes, 
hepatotoxic 
reactions [87]. 
gastrointestinal 
disturbances, intestinal 
overgrowth by non-
susceptible organisms, 
neurotoxicity (agitation, 
anxiety, confusion, visual 
disturbances, 
convulsions), 
encephalopathy [87, 90] 
Studies: No clinical studies available in patients with liver disease. 
Product information: Generally no dose reduction is necessary in patients 
with mild to moderate liver insufficiency because of its low toxicity. Caution 
in patients with severe liver disease. T1/2 may be prolonged in patients with 
severe liver disease and concomitant renal impairment [87].  
Recommendation: According to pharmacokinetic data and product 
information, no dose modification seems necessary in patients with liver 
disease if renal function is normal. Adjust maintenance dose by means of 
clinical effect and dose-dependent ADRs. In patients with ascites: adjust 
initial dose according to body weight and choose maintenance dose in the 
lower range of normal.   
Beta-lactamase resistant penicillins 
Flucloxacillin 
(oral, 
parenteral) 
Mainly renal 
elimination. 
Metabolism to 
active 5-
hydroxymethylfloxa
cillin and inactive 
penicilloic acid [87].  
Q0: 0.3 
T1/2: 1h 
Vd: 0.15L/kg 
PB: 95% 
Foral: 55% 
CLsys: 5L/h 
E: 0.03 
BE: minor 
CAT: 4 
Rare: transient 
increase of liver 
enzymes, 
hepatitis, 
cholestatic liver 
injury (onset may 
be delayed, 
protracted liver 
dysfunction has 
been observed 
following 
withdrawal of 
therapy) [71, 87]. 
gastrointestinal 
disturbances, intestinal 
overgrowth by non-
susceptible organisms, 
neurotoxicity (convulsions) 
[87] 
Studies: No clinical studies available in patients with liver disease. 
Product information: Contraindicated in patients with anamnestic jaundice or 
liver dysfunction associated with flucloxacillin. The active metabolite 
contributes up to 10% to the total activity. Due to its possible hepatotoxicity, 
flucloxacillin should be used with caution in patients with hepatic 
insufficiency [87]. 
Recommendation: According to pharmacokinetic data, choose normal initial 
dose and adjust maintenance dose and/or dosage interval by means of 
creatinine clearance. Monitoring of liver function is recommended. In 
patients with ascites: Adjust initial dose according to body weight and adjust 
maintenance dose according to creatinine clearance. Use with caution in 
patients with hypoalbuminemia due to decreased PB. 
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Tab. 11 (continued)  
Drug (route of 
application)  
Metabolism Kinetic 
parameters 
Hepatic ADRs Potentially dose-
dependent ADRs 
Studies, product information, and dose recommendations 
Combinations of penicillins, incl. beta-lactamase inhibitors 
Amoxicillin / 
Clavulanic 
acid (oral, 
parenteral) 
Amoxicillin: 10-25% is 
metabolized in the liver 
by hydrolysis of the β-
lactam ring to penicilloic 
acid, which is excreted 
in the urine. 
Enterohepatic 
circulation occurs [87, 
90]. Clavulanic acid: 35-
60% metabolized to 
inactive metabolites 
[87]. 
Q0: 0.15/0.55 
T1/2: 1.5/1h 
Vd: 0.3/0.23L/kg 
PB: 18/25% 
Foral: 89/70% 
CLsys: 15/13L/h 
E: 0.04/0.13 
BE: minor/minor 
CAT: 4/3 
Rare: transient 
elevations of liver 
enzymes, 
hyperbilirubinemi
a, cholestatic 
liver injury 
(believed to be 
principally related 
to clavulanic acid 
moiety), acute 
hepatic 
dysfunction, 
hepatitis [87, 92]. 
gastrointestinal 
disturbances, intestinal 
overgrowth by non-
susceptible organisms, 
crystalluria, 
neurotoxicity (agitation, 
anxiety, confusion, 
convulsions) [65, 87] 
Studies: A single dose study of combined amoxicillin/clavulanic acid 
(1000/200mg) in cirrhotic patients showed an increased t1/2 of 
amoxicillin (274 min in ascitic vs. 53 min in non-ascitic subjects) and 
clavulanic acid (200 min in ascitic vs. 54 min in non-ascitic subjects) 
probably due to increased Vd in patients with ascites. However, no 
dose recommendations were made [142]. 
Product information: Contraindicated in patients with anamnestic 
jaundice or liver dysfunction associated with the combination of 
amoxicillin/clavulanic acid. Caution in patients with liver disease. 
Monitor liver function during long-term treatment [87].  
Recommendation: According to pharmacokinetic data, choose 
normal initial dose and adjust maintenance dose according to 
creatinine clearance. In patients with ascites: adjust initial dose 
according to body weight and adjust maintenance dose according to 
creatinine clearance.  
Piperacillin / 
Tazobactam 
(parenteral) 
Piperacillin: Mainly renal 
elimination. 10-20% are 
excreted unchanged 
into the bile. Some 
metabolism to 
desethylpiperacillin 
(inactive). Tazobactam: 
Mainly renal elimination. 
Some metabolism to an 
inactive metabolite [71, 
87]. 
Q0: 0.3/0.2 
T1/2: 1/0.7h 
Vd: 0.2/0.2L/kg 
PB: 19/23% 
Foral: n.k. 
CLsys: 10/22L/h 
E: 0.06/0.08 
BE: minor/minor 
CAT: 4/4 
Occasionally: 
elevated AST, 
ALT. Rare: 
elevated bilirubin, 
GGT, AP, 
hepatitis, 
cholestatic liver 
disease [71, 87]. 
gastrointestinal 
disturbances, intestinal 
overgrowth by non-
susceptible organisms, 
neurotoxicity (agitation, 
headache, hallucination, 
confusion, convulsion), 
hematological 
disturbances (e.g. 
leukopenia, 
thrombocytopenia) [65, 
87, 90] 
Studies: Piperacillin: Plasma t1/2 of piperacillin was prolonged in 
cirrhotic patients compared to controls and even longer in those with 
ascites (1.95h vs. 0.91h; p<0.01) [145]. All patients had normal 
creatinine values. Total body CL was reduced in cirrhotics (not 
statistically significant). Mean Vd was similar in both groups. 
Tazobactam: No clinical studies available in patients with liver 
disease. 
Product information: The excretion of piperacillin/tazobactam is 
decreased in patients with liver dysfunction, but no dose reduction is 
necessary [87]. 
Recommendation: According to pharmacokinetic data, choose 
normal initial dose and adjust dose according to creatinine clearance. 
In patients with ascites: adjust initial dose according to body weight 
and adjust maintenance dose according to creatinine clearance. 
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Tab. 11 (continued) 
Drug (route of 
application)  
Metabolism Kinetic 
parameters 
Hepatic ADRs Potentially dose-
dependent ADRs 
Studies, product information, and dose recommendations 
Other beta-lactam antibacterials 
First-generation cephalosporins 
Cefazolin 
(parenteral) 
80-100% is excreted 
unchanged in the 
urine [87]. 
Q0: 0.06 
T1/2: 2h 
Vd: 0.13L/kg 
PB: 80% 
Foral: n.k. 
CLsys: 3L/h 
E: 0.01 
BE: minor 
CAT: 4 
Occasionally: 
elevation of liver 
enzymes and 
bilirubin. Rare: 
hepatitis, 
cholestatic 
jaundice [71, 
87]. 
gastrointestinal 
disturbances, 
intestinal overgrowth 
by non-susceptible 
organisms, 
neurotoxicity 
(agitation, confusion, 
seizures), 
encephalopathy [90, 
93]  
Studies: Elimination t1/2 of cefazolin was significantly shorter (1.82h vs. 2.57h) 
and plasma PB of cefazolin was significantly reduced by 18.4% in cirrhosis 
compared to healthy volunteers. No dose reduction is necessary in severe 
hepatic impairment [146]. In patients with obstructive biliary disease, 
cefazoline bile levels are considerably lower than serum levels (<1.0 µg/mL) 
[71]. 
Product information: No dose recommendations provided. Cefazoline can 
cause coagulation disorders, monitor quick values in patients with an elevated 
risk for bleedings (e.g. liver disease) [87].  
Recommendation: According to pharmacokinetic data, choose normal initial 
dose and adjust maintenance dose and/or dosage interval by means of 
creatinine clearance. In patients with ascites: adjust initial dose according to 
body weight and adjust maintenance dose according to creatinine clearance. 
Second-generation cephalosporins 
Cefuroxime 
(oral, 
parenteral) 
After p.o. application, 
cefuroxime axetil 
(prodrug) is 
hydrolyzed in the 
intestine to 
cefuroxime. 
Cefuroxime is mainly 
renally eliminated [71, 
87, 90]. The 
pharmacokinetic data 
refer to cefuroxime. 
Q0: 0.1 
T1/2: 1.5h 
Vd: 0.2L/kg 
PB: 33% 
Foral: 50% 
CLsys: 25L/h 
E: 0.05 
BE: minor 
CAT: 4 
Frequent: 
increase in ALT, 
AST. 
Occasionally: 
increase in AP 
and bilirubin. 
Rare: hepatitis, 
cholestatic 
jaundice 
[71, 87]. 
gastrointestinal 
disturbances, 
intestinal overgrowth 
by non-susceptible 
organisms, 
neurotoxicity 
(headache, dizziness, 
seizures) [65, 87, 90, 
93] 
Studies: Pharmacokinetics were not affected in cirrhotic patients without 
ascites compared to healthy volunteers [147]. 
Product information: Monitor hemogram, liver and renal function during long-
term treatment [87]. 
Recommendation: According to pharmacokinetic data, choose normal initial 
dose and adjust maintenance dose and/or dosage interval by means of 
creatinine clearance. In patients with ascites: adjust initial dose according to 
body weight and adjust maintenance dose according to creatinine clearance. 
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Tab. 11 (continued) 
Drug (route of 
application)  
Metabolism Kinetic 
parameters 
Hepatic ADRs Potentially dose-
dependent ADRs 
Studies, product information, and dose recommendations 
Cefamandole 
(parenteral) 
No 
metabolism 
occurs. 
Mainly renal 
elimination 
[87, 90]. 
Q0: 0.04 
T1/2: 0.9h 
Vd: 0.24L/kg 
PB: 70% 
Foral: n.k. 
CLsys: 10L/h 
E: 0.01 
BE: minor 
CAT: 4 
Unknown 
frequency: liver 
enzyme elevations 
(ALT, AST, AP), 
increase in bilirubin, 
hepatitis, cholestatic 
jaundice [71, 87]. 
gastrointestinal 
disturbances, intestinal 
overgrowth by non-
susceptible organisms, 
neurotoxicity (agitation, 
confusion, seizures), 
encephalopathy [87, 
90, 93]  
Studies: No clinical studies available in patients with liver disease. 
Product information: In case of treatment with cefamandole 50mg/kg over a few 
days, liver and renal function should be monitored, as well as hemogram [87].  
Recommendation: According to pharmacokinetic data, choose normal initial 
dose and adjust maintenance dose and/or dosage interval by means of 
creatinine clearance. In patients with ascites: adjust initial dose according to 
body weight and adjust maintenance dose according to creatinine clearance. 
Cefaclor (oral) Mainly renal 
elimination. 
Up to 15% 
are 
metabolized 
or otherwise 
degraded 
[87, 90]. 
Q0: 0.25 
T1/2: 0.75h 
Vd: 0.35L/kg 
PB: 25% 
Foral: 95% 
CLsys: 30L/h 
E: 0.14 
BE: minor 
CAT: 4 
Occasionally: liver 
enzyme elevations 
(AST, ALT, AP). 
Rare: hepatitis, 
cholestatic liver 
injury with jaundice 
[71, 87]. 
gastrointestinal 
disturbances, intestinal 
overgrowth by non-
susceptible organisms, 
neurotoxicity (agitation, 
confusion, seizures) 
[87, 90, 93] 
Studies: No clinical studies available in patients with liver disease.  
Product information: Monitor hemogram, liver and renal function during long-
term treatment [87]. 
Recommendation: According to pharmacokinetic data, choose normal initial 
dose and adjust maintenance dose by means of creatinine clearance. In patients 
with ascites: adjust initial dose according to body weight and adjust maintenance 
dose according to creatinine clearance. 
Cefprozil 
(oral) 
Mainly renal 
elimination 
[71, 87, 90]. 
Q0: 0.35 
T1/2: 1.3h 
Vd: 0.23L/kg 
PB: 36% 
Foral: 90% 
CLsys: 12.6L/h 
E: 0.08 
BE: minor 
CAT: 4 
Frequent: increased 
ALT, AST. 
Occasionally: 
increase of AP. 
Rare: increase of 
bilirubin, cholestatic 
jaundice [71, 87]. 
Case report: 
hepatitis [148]. 
gastrointestinal 
disturbances, intestinal 
overgrowth by non-
susceptible organisms, 
neurotoxicity 
(headache, dizziness, 
confusion) [87, 90] 
Studies: Beside a moderate prolongation of elimination t1/2 of cefprozil (27-37%), 
no statistically significant difference was observed between subjects with hepatic 
impairment and healthy volunteers [149]. 
Product information: The pharmacokinetics are not significantly affected in the 
presence of hepatic impairment. No dosage adjustment is required in patients 
with hepatic dysfunction [87]. 
Recommendation: According to pharmacokinetic data, choose normal initial 
dose and adjust maintenance dose by means of creatinine clearance. In patients 
with ascites: adjust initial dose according to body weight and adjust maintenance 
dose according to creatinine clearance. 
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Tab. 11 (continued) 
Drug (route of 
application)  
Metabolism Kinetic 
parameters 
Hepatic ADRs Potentially dose-
dependent ADRs 
Studies, product information, and dose recommendations 
Third-generation cephalosporins 
Ceftazidime 
(parenteral) 
Mainly 
renal 
elimination 
[87, 90]. 
Q0: 0.1 
T1/2: 1.8h 
Vd: 0.23L/kg 
PB: 10% 
Foral: n.k. 
CLsys: 6.9L/h 
E: 0.01 
BE: minor 
CAT: 4 
Frequent: liver 
enzyme elevations 
(ALT, AST, GGT, 
AP). Rare: increase 
of bilirubin, 
jaundice.[65, 71, 
87]. 
gastrointestinal 
disturbances, intestinal 
overgrowth by non-
susceptible organisms, 
neurotoxicity 
(headache, dizziness, 
paresthesia, seizures, 
myoclonia), 
encephalopathy [65, 
87, 90] 
Studies: In a single dose study of 1g i.v. in patients with cirrhosis and ascites, t1/2 
was significantly prolonged probably due to slow return from the ascitic 
compartment. Nevertheless, the overall CL did not differ significantly [150]. Hepatic 
dysfunction had no effect on the pharmacokinetics of ceftazidime in individuals 
administered 2 g i.v. every 8 hours for 5 days [65]. 
Product information: Dose adjustment is not necessary in patients with hepatic 
dysfunction, provided renal function is not impaired [65]. 
Recommendation: According to pharmacokinetic data, choose normal initial dose 
and adjust maintenance dose and/or dosage interval by means of creatinine 
clearance. In patients with ascites: adjust initial dose according to body weight and 
adjust maintenance dose according to creatinine clearance. 
Ceftriaxone 
(parenteral) 
40-50% are 
excreted 
unchanged 
in the bile, 
where it is 
metabo-
lized by the 
intestinal 
flora into 
inactive 
metabolites 
[87, 90]. 
Q0: 0.5 
T1/2: 8h 
Vd: 0.14L/kg 
PB: 90% 
Foral: n.k. 
CLsys: 1L/h 
E: 0.01 
BE: minor 
CAT: 3 
Non-linear 
pharmaco-
kinetics 
Frequent: liver 
enzyme elevations 
(AST, ALT, AP), 
precipitation of 
calcium salts in the 
gallbladder 
(children), 
reversible 
cholelithiasis 
(children), 
increased bilirubin. 
Rare: jaundice, 
reversible biliary 
pseudolithiasis, 
gallbladder sludge 
[65, 87, 90, 151]. 
gastrointestinal 
disturbances, intestinal 
overgrowth by non-
susceptible organisms, 
neurotoxicity 
(headache, dizziness, 
seizures), biliary 
pseudolithiasis, 
nephrolithiasis [65, 87, 
90]  
Studies: In patients with chronic liver damage (alcoholic fatty liver, cirrhosis with and 
without ascites), pharmacokinetics were similar to healthy subjects after 1g 
ceftriaxone (single dose). Vd was significantly increased in cirrhotics with ascites, 
but t1/2 was not different, probably because of lower PB [152-155]. Similar results 
were seen in another study [156]. One study showed increase in fu up to 320% in 
patients with cirrhosis and ascites compared to healthy controls [154]. Due to the 
wide therapeutic range, no dose adjustment is necessary in chronic liver disease 
[154], but indicated in patients with concomitant renal and hepatic impairment [153, 
157]. 
Product information: In patients with impaired hepatic function, pharmacokinetics of 
ceftriaxone are minimally altered. Renal route of elimination may increase. Thus, no 
dose adjustment is necessary provided that renal function is normal [87].  
Recommendation: According to pharmacokinetic data and clinical studies, dosage 
adjustment is only needed in patients with concomitant liver and renal impairment. 
In patients with ascites: adjust initial dose according to body weight and choose 
maintenance dose in the lower range of normal. 
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Tab. 11 (continued) 
Drug (route of 
application)  
Metabolism Kinetic 
parameters 
Hepatic ADRs Potentially dose-
dependent ADRs 
Studies, product information, and dose recommendations 
Cefixime 
(oral) 
No metabolic 
pathways have yet 
been identified 
[87, 90]. 
Q0: 0.5 
T1/2: 3.5h 
Vd: 0.24L/kg 
PB: 65% 
Foral: 45% 
CLsys: 5.5L/h 
E: 0.05 
BE: minor 
CAT: 3 
Rare: mild and 
transient 
elevations in 
liver enzymes, 
hepatitis, 
cholestatic 
jaundice [87, 
92]. 
gastrointestinal 
disturbances, 
intestinal overgrowth 
by non-susceptible 
organisms, 
neurotoxicity 
(headache, dizziness, 
agitation) [87, 90, 93]  
Studies: In a single dose study with 200mg in patients with moderate to severe 
cirrhosis, t1/2 was significantly increased (6.4h) due to an increased Vd. Renal CL 
(+43%) was also increased significantly (possibly because of reduced extra-
renal CL), AUC and Cmax remained unchanged. Despite a twofold increase in 
t1/2, modification of kinetics was judged as modest. No dose adjustment was 
considered necessary in patients with moderate to severe cirrhosis [45, 158]. 
Product information: Citation of the same results as reported in clinical studies 
[87].  
Recommendation: According to pharmacokinetic data and clinical studies, start 
with normal initial dose. Reduce maintenance dose by up to 50%. Adjust 
maintenance dose according to clinical effect and dose-dependent ADRs. In 
patients with ascites: adjust initial dose according to body weight and choose 
maintenance dose in the lower range of normal. 
Cefpodoxime 
(oral) 
Cefpodoxime 
proxetil is a 
prodrug and 
hydrolyzed 
presystemically in 
the small intestine 
to the active 
cefpodoxime. 
Cefpodoxime is 
mainly renally 
eliminated [71, 87, 
90]. The kinetic 
data refer to 
cefpodoxime. 
Q0: 0.2 
T1/2: 2.4h 
Vd: 0.45L/kg 
PB: 25% 
Foral: 50% 
CLsys: 14.4L/h 
E: 0.05 
BE: minor 
CAT: 4 
Occasionally: 
moderate and 
transient 
increase in AST, 
ALT, AP. Rare: 
elevated 
bilirubin [87]. 
gastrointestinal 
disturbances, 
intestinal overgrowth 
by non-susceptible 
organisms, 
neurotoxicity 
(headache, dizziness, 
tinnitus, paresthesia), 
asthenia [87, 90, 93] 
Studies: Pharmacokinetics in cirrhotic patients are only minimally altered [87]. 
No effect of ascites on the pharmacokinetics of the drug [90]. 
Product information: Dosage adjustment is not necessary in cirrhotic patients 
[87]. 
Recommendation: According to pharmacokinetic data, choose normal initial 
dose and adjust maintenance dose and/or dosage interval by means of 
creatinine clearance. In patients with ascites: adjust initial dose according to 
body weight and adjust maintenance dose according to creatinine clearance. 
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Tab. 11 (continued) 
Drug (route of 
application)  
Metabolism Kinetic 
parameters 
Hepatic ADRs Potentially dose-
dependent ADRs 
Studies, product information, and dose recommendations 
Ceftibuten 
(oral) 
Mainly renal 
elimination [71, 
87, 159]. The 
trans isomer is 
also active. 
Q0: 0.25 
T1/2: 2.5h 
Vd: 0.21L/kg 
PB: 65% 
Foral: 90% 
CLsys: 4.6L/h 
E: 0.03 
BE: minor 
CAT: 4 
Occasionally: 
elevated liver 
enzymes and 
bilirubin. Case 
reports: 
jaundice [71, 
87]. 
gastrointestinal 
disturbances, intestinal 
overgrowth by non-
susceptible organisms, 
neurotoxicity (dizziness, 
paresthesia, seizure) 
[87, 93] 
Studies: The pharmacokinetics do not change significantly in patients with chronic 
active hepatitis, liver cirrhosis, alcoholic hepatopathy, or other necrotic liver 
diseases [87].  
Product information: No recommendation provided.  
Recommendation: According to pharmacokinetic data, choose normal initial dose 
and adjust maintenance dose or dosage interval by means of creatinine 
clearance. In patients with ascites: adjust initial dose according to body weight and 
adjust maintenance dose according to creatinine clearance. 
Fourth-generation cephalosporins 
Cefepime 
(parenteral) 
Mainly renal 
elimination. 7% 
is metabolized 
to methyl-
pyrrolidine oxide 
(tertiary amine) 
[71, 87].  
Q0: 0.2 
T1/2: 2h 
Vd: 0.26L/kg 
PB: 16% 
Foral: n.k. 
CLsys: 7.2L/h 
E: 0.03 
BE: minor 
CAT: 4 
Frequent: 
increases in 
liver enzymes 
and bilirubin 
[71, 87]. 
gastrointestinal 
disturbances, intestinal 
overgrowth by non-
susceptible organisms, 
neurotoxicity (blurred 
vision, tinnitus, 
paresthesia, seizures), 
encephalopathy [65, 
87] 
Studies: Pharmacokinetics of cefepime were unaltered in patients with impaired 
hepatic function who received a single 1 g dose (n=11) [87].  
Product information: No dosage adjustments are necessary for patients with 
hepatic dysfunction in case of normal renal function [87]. 
Recommendation: According to pharmacokinetic data, choose normal initial dose 
and adjust maintenance dose and/or dosage interval by means of creatinine 
clearance. In patients with ascites: adjust initial dose according to body weight and 
adjust maintenance dose according to creatinine clearance. 
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Tab. 11 (continued) 
Drug (route of 
application)  
Metabolism Kinetic 
parameters 
Hepatic ADRs Potentially dose-
dependent ADRs 
Studies, product information, and dose recommendations 
Monobactams 
Aztreonam 
(parenteral) 
About 20% are 
metabolized in 
the liver by 
hydrolytic 
opening of the 
β-lactam ring 
[87, 90, 160].  
Q0: 0.2 
T1/2: 1.7h 
Vd: 0.18L/kg 
PB: 56% 
Foral: n.k. 
CLsys: 5.5L/h 
E: 0.02 
BE: minor 
CAT: 4 
Frequent: 
elevations of 
liver enzymes 
and bilirubin. 
Rare: 
hepatitis, 
jaundice [71, 
87]. 
gastrointestinal 
disturbances, intestinal 
overgrowth by non-
susceptible organisms, 
neurotoxicity 
(headache, dizziness, 
paresthesia, seizures) 
[87, 90, 93] 
Studies: After 1g aztreonam i.v. (single dose), t1/2 was 1.82 h in healthy 
volunteers, 6.6 h in cirrhotic patients with ascites, and 8.87 h in patients with 
cirrhosis, ascites and renal failure [144]. T1/2 was significantly longer (+68%) and 
serum CL decreased (-27%) in alcoholic cirrhotics compared to normal subjects 
[161]. Patients with primary biliary cirrhosis had only a longer t1/2 (+16%). 
Product information: Dose reduction of 20-25% recommended during long-term 
therapy in patients with alcoholic cirrhosis. For patients with stable biliary tract 
cirrhosis or other chronic liver disease, dose adjustment is not necessary, 
provided that renal function is normal [87]. In patients with hepatic impairment 
monitoring of liver function is recommended [87, 90] 
Recommendation: According to pharmacokinetic data and clinical studies, choose 
normal initial dose and adjust maintenance dose by means of creatinine 
clearance. For patients with alcoholic cirrhosis, see Swiss product information. In 
patients with ascites: adjust initial dose according to body weight and adjust 
maintenance dose according to creatinine clearance. 
Carbapenems 
Meropenem 
(parenteral) 
25% are 
metabolized by 
dehydro-
peptidase-I to an 
inactive 
derivative [71, 
87, 162].  
Q0: 0.3 
T1/2: 1h 
Vd: 0.3L/kg 
PB: 2% 
Foral: n.k. 
CLsys: 16.8L/h 
E: 0.09 
BE: minor 
CAT: 4 
Frequent: liver 
enzyme 
elevations 
(ALT, AST, 
AP, GGT). 
Occasionally: 
increased 
bilirubin. Rare: 
cholestatic 
jaundice [71, 
87]. 
gastrointestinal 
disturbances, intestinal 
overgrowth by non-
susceptible organisms, 
neurotoxicity 
(headache, 
paresthesia, seizures) 
[65, 87, 90] 
Studies: No difference in pharmacokinetics were found between subjects with 
stable alcoholic cirrhosis and eight matched controls with normal liver function 
[163].  
Product information: A pharmacokinetic study in patients with hepatic impairment 
has shown no effects of liver disease on the pharmacokinetics of meropenem. No 
dosage adjustment is needed in patients with liver impairment. Monitor liver 
function regularly in patients with liver disease [87].  
Recommendation: According to pharmacokinetic data and clinical studies, choose 
normal initial dose and adjust maintenance dose and/or dosage interval by means 
of creatinine clearance. In patients with ascites: adjust initial dose according to 
body weight and adjust maintenance dose according to creatinine clearance. 
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Tab. 11 (continued) 
Drug (route of 
application)  
Metabolism Kinetic 
parameters 
Hepatic ADRs Potentially dose-
dependent ADRs 
Studies, product information, and dose recommendations 
Ertapenem 
(parenteral) 
Hydrolysis by the 
renal 
dehydropeptidase 
enzyme [71, 87]. 
About 10% of a dose 
excreted into the 
feces.  
Q0: 0.6 
T1/2: 4h 
Vd: 0.12L/kg 
PB: 90% 
Foral: n.k. 
CLsys: 1.8L/h 
E: 0.02 
BE: minor 
CAT: 3 
Frequent: elevated 
ALT, AST, AP. 
Occasionally: 
elevated bilirubin. 
Rare: cholecystitis, 
jaundice, elevated 
urobilinogen [71, 
87]. 
gastrointestinal 
disturbances, intestinal 
overgrowth by non-
susceptible organisms, 
confusion, 
hallucination, dizziness, 
tremor, seizure [71, 87] 
Studies: No clinical studies available in patients with liver disease. 
Product information: No studies available. However, because 
metabolism in the liver seems negligible, no major change in 
pharmacokinetics is expected in patients with liver disease. No dose 
adjustment required in patients with impaired liver function [87].   
Recommendation: According to pharmacokinetic data, start with 
normal initial dose and reduce maintenance dose by up to 50%. 
Adjust maintenance dose according to clinical effect and dose-
dependent ADRs. In patients with ascites: adjust initial dose 
according to body weight and choose maintenance dose in the lower 
range of normal. 
Doripenem 
(parenteral) 
Dehydropeptidase I 
[71, 87].  
Q0: 0.3 
T1/2: 1h 
Vd: 0.24L/kg 
PB: 8.1% 
Foral: n.k. 
CLsys: 15.9L/h 
E: 0.09 
BE: minor 
CAT: 4 
Frequent: elevated 
liver enzymes [71, 
87]. 
gastrointestinal 
disturbances, intestinal 
overgrowth by non-
susceptible organisms, 
neurotoxicity 
(headache seizures), 
rash [87, 164] 
Studies: No clinical studies available in patients with liver disease.  
Product information: No studies available. Since there is no evidence 
for hepatic metabolism of doripenem, liver insufficiency is not 
expected to influence the drugs pharmacokinetics. No dosage 
adjustment is necessary [87].  
Recommendation: According to pharmacokinetic data and clinical 
results, monitor creatinine clearance and adjust dose accordingly. In 
patients with ascites: adjust initial dose according to body weight and 
adjust maintenance dose according to creatinine clearance. 
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Tab. 11 (continued) 
Drug (route of 
application)  
Metabolism Kinetic 
parameters 
Hepatic ADRs Potentially dose-
dependent ADRs 
Studies, product information, and dose recommendations 
Imipenem / 
Cilastatin 
(parenteral) 
Imipenem: Imipenem would 
be extensively metabolized 
in the kidney by the 
dehydropeptidase-1 if 
administered without 
cilastatin, a 
dehydropeptidase-1-inhibitor. 
Cilastatin: 10% metabolized 
to active N-acetyl metabolite 
[71, 87].  
Q0: 0.3/0.3 
T1/2: 1/0.9h 
Vd: 0.2/0.2L/kg 
PB: 20/15% 
Foral: n.k. 
CLsys: 12/12L/h 
E: 0.07/0.07 
BE: minor 
CAT: 4/4 
Frequent: 
elevated ALT, 
AST, AP. 
Occasionally: 
elevated 
bilirubin. Rare: 
jaundice, 
hepatitis, liver 
failure [71, 87]. 
gastrointestinal 
disturbances, intestinal 
overgrowth by non-
susceptible organisms, 
neurotoxicity (dizziness, 
paresthesia, 
hallucinations, confusion, 
seizures), 
encephalopathy [65, 87, 
90] 
Studies: No clinical studies available in patients with liver disease.  
Product information: Monitoring of hematopoietic, renal and 
hepatic function recommended during long-term treatment. No 
dose recommendations provided [87].  
Recommendation: According to pharmacokinetic data, monitor 
creatinine clearance and adjust dose accordingly. In patients with 
ascites: adjust initial dose according to body weight and adjust 
maintenance dose according to creatinine clearance. 
Sulfonamides and trimethoprim 
Combinations of sulfonamides and trimethoprim, incl. derivatives 
Sulfamethoxa
zole / 
Trimethoprim 
(oral, 
parenteral) 
Sulfamethoxazole: N-
acetylation (N-
acetylsulfamethoxazole) and 
glucuronidation. 
Trimethoprim: Metabolism to 
1- and 3- oxides, 3’- and 4’-
hydroxyderivatives (active) 
[87, 90].  
Q0: 0.8/0.45 
T1/2: 11/10h 
Vd: 0.2/1.3L/kg 
PB: 66/46% 
Foral: 90/90% 
CLsys: 1.2/6L/h 
E: 0.02/0.05 
BE: minor/minor 
CAT: 3/4 
Rare: liver 
necrosis, 
elevated liver 
enzymes, 
hepatitis, 
hyperbilirubine
mia, 
cholestasis, 
jaundice, 
vanishing bile 
duct syndrome 
[87, 165]. 
gastrointestinal 
disturbances, intestinal 
overgrowth by non-
susceptible organisms, 
neurotoxicity (headache, 
dizziness, ataxia, 
convulsions, vertigo, 
tinnitus, hallucinations), 
crystalluria, 
hypoglycemia, 
hypokalemia, folate 
deficiency, hematological 
disturbances (leukopenia, 
agranulocytosis, 
thrombocytopenia) [65, 
87, 90] 
Studies: In patients with alcoholic liver cirrhosis (incl. Child C) no 
significant difference in pharmacokinetics was observed after a 
single dose of 800mg sulfamethoxazole (SMX)/160mg 
trimethoprim (TMP) compared to healthy subjects. Sporadic 
increases of t1/2 of TMP up to 2-fold have been observed in 
cirrhotics, but also in healthy subjects. No dose adjustment was 
considered necessary [166]. After multiple doses (800mg 
SMX/160mg TMP every 12 hours for 7 days) differences in 
kinetics disappeared after the third day of administration, 
suggesting that no dose adjustment is required [167]. 
Product information: Contraindicated in patients with marked 
parenchymal liver injury. Risk for severe adverse effects may be 
increased in patients with liver disease. Caution with high doses in 
patients with severe hepatic insufficiency, even though kinetics 
are not considerably altered [87].  
Recommendation: According to pharmacokinetic data and clinical 
studies, no dose adjustment seems necessary in patients with 
liver cirrhosis. Caution in patients with severe liver disease. 
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Tab. 11 (continued) 
Drug (route of 
application)  
Metabolism Kinetic 
parameters 
Hepatic ADRs Potentially dose-dependent 
ADRs 
Studies, product information, and dose recommendations 
Macrolides, lincosamides and streptogramins 
Macrolides 
Erythromycin 
(oral, 
parenteral) 
Inactivation by 
N-demethylation 
by CYP 3A to 
des-N-methyl-
erythromycin. 
Enterohepatic 
cycling [87, 90].  
Q0: 0.9 
T1/2: 1.5h 
Vd: 1.1L/kg 
PB: 60% 
Foral: 40% 
CLsys: 26L/h 
E: 0.41 
BE: major 
CAT: 2 
Rare: 
cholestatic 
hepatitis, 
jaundice (10-
14 days after 
the start of 
treatment), 
associated 
with raised 
AST/ALT 
levels and 
eosinophilia 
[87, 90]. 
gastrointestinal disturbances, 
increased gut motility, 
intestinal overgrowth by non-
susceptible organisms, 
ototoxicity, convulsions, 
paresthesia, ataxia, 
psychosis, cholestatic 
jaundice, arrhythmia (QT-
prolongation, torsades de 
pointes), aggravation of 
myasthenia gravis [65, 87, 
90, 93] 
Studies: AUC and Cmax were higher (no significance) and t1/2 significantly 
longer (3.2h vs. 2h) in patients with alcoholic liver disease compared to normal 
subjects [168, 169]. Clinical significance unknown. In patients with alcoholic 
cirrhosis (Child B and C), fu (58.3% vs. 30.5%; due to decreased levels of 
alpha1-acid glycoprotein) and Vd (86L vs. 58L) were significantly increased, CL 
of unbound erythromycin was significantly reduced (42.2L/h vs. 113.2L/h) 
[170]. Because of a large therapeutic index of erythromycin, dosage 
adjustment probably not necessary. 
Product information: Contraindicated in patients with severe liver insufficiency. 
Use with caution in patients with impaired hepatic function. Maximal daily dose 
1g in patients with liver insufficiency. Monitoring for oto- and hepatotoxic 
adverse effects [87].   
Recommendation: According to product information, reduce maximal daily 
dose to 1g and adjust maintenance dose according to clinical effect and dose-
dependent ADRs. Caution in patients with cholestasis. 
Clarithromycin 
(oral, 
parenteral) 
N-
demethylation, 
hydroxylation to 
14-hydroxy-
clarithromycin 
(active; Q0 0.9, 
t1/2 5.5h). 
Substrate of 
CYP P450 3A4 
[87, 90].  
Q0: 0.65 
T1/2: 3.5h 
Vd: 3L/kg 
PB: 72% 
Foral: 55% 
CLsys: 37L/h 
E: 0.45 
BE: minor 
CAT: 2 
Non-linear 
elimination 
Frequent: 
elevated AST, 
ALT. Rare: 
hepatocellular 
and/or 
cholestatic 
hepatitis, with 
or without 
jaundice, liver 
failure [87, 90, 
92]. 
gastrointestinal disturbances, 
taste perversion, intestinal 
overgrowth by non-
susceptible organisms, 
ototoxicity, neurotoxicity 
(headache, dizziness, 
convulsions, hallucinations, 
paresthesia, ataxia), 
arrhythmias (QT-
prolongation, torsades de 
pointes), cholestatic hepatitis 
[65, 87, 90] 
Studies: No differences in pharmacokinetics of clarithromycin observed in 
cirrhotic patients (Child A, B and C) compared to healthy controls [171-173], 
but AUC of 14-(R)-hydroxyclarithromycin was significantly lower in patients 
with severe liver cirrhosis [171, 172]. Caution if the hydroxy-metabolite is 
necessary for antimicrobial activity (e.g. haemophilus influenzae) [172, 174]. 
Product information: No changes in kinetics observed in patients with mild liver 
disease. Concentration of the active metabolite was generally lower in these 
patients. Because of its high hepatic metabolism, monitoring of patients with 
severe liver disease is recommended [87]. No dosage adjustment necessary in 
the presence of hepatic impairment in case of normal renal function [65] 
Recommendation: According to clinical studies, normal initial dose can be 
used in patients with liver disease. Adjust maintenance dose by means of 
clinical effect and dose-dependent ADRs. 
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Tab. 11 (continued) 
Drug (route of 
application)  
Metabolism Kinetic 
parameters 
Hepatic ADRs Potentially dose-
dependent ADRs 
Studies, product information, and dose recommendations 
Spiramycin  CAT1, see Tab. 4, p. 35  
Azithromycin  CAT1, see Tab. 4, p. 35 
Lincosamides 
Clindamycin 
(oral, 
parenteral) 
N-demethylation, 
sulfoxidation (by CYP 
3A4), hydrolysis to 
some active 
metabolites [87, 90, 
175]. 
Q0: 0.9 
T1/2: 2.5h 
Vd: 0.85L/kg 
PB: 65% 
Foral: 90% 
CLsys: 12L/h 
E: 0.2 
BE: major 
CAT: 3 
Frequent: 40-50% of 
patients develop 
elevated liver enzymes 
which may return to 
normal despite 
continuation of the 
treatment. 
Occasionally: jaundice. 
Rare: hepatocellular 
toxicity, exacerbation of 
pre-existing liver 
disease [87, 92, 176]. 
gastrointestinal 
disturbances, intestinal 
overgrowth by non-
susceptible organisms, 
hypotension, cardiac 
arrest (after too rapid 
injection), liver enzyme 
elevations, jaundice 
[87, 90] 
Studies: Studies revealed 1.2-5 fold increase in t1/2 in patients with 
severe liver disease (hepatitis, cirrhosis, obstructive jaundice) [177, 
178], one study only in cirrhotics but not in those with hepatitis [179]. 
Concentration after 5h was 3 times higher in patients with moderate 
to severe hepatic dysfunction compared to normal controls [180]. 
Positive correlation between t1/2, serum concentration and AST [177, 
178, 180] or indirect bilirubin [181] found in some reports, but not in 
others [179, 181]. Monitoring of drug level and liver function 
recommended [179]. 
Product information: T1/2 is increased in patients with severe liver 
dysfunction, but dose adjustment not necessary in patients with mild 
and moderate liver disease. Use with caution and monitor clindamycin 
levels in case of high dose regimen [87]. 
Recommendation: According to pharmacokinetic data, start with 
normal initial dose and reduce maintenance dose by up to 50%. 
Adjust maintenance dose according to clinical effect and dose-
dependent ADRs. Monitoring of liver function recommended. Caution 
in patients with cholestasis. 
6
 App
e
ndix
 
-
 117
 
-
 
  
Tab. 11 (continued) 
Drug (route of 
application)  
Metabolism Kinetic 
parameters 
Hepatic ADRs Potentially dose-
dependent ADRs 
Studies, product information, and dose recommendations 
Aminoglycoside antibacterials 
Other aminoglycosides 
Tobramycin 
(inhalative, 
parenteral) 
Mainly renal 
elimination [87].  
Q0: 0.02 
T1/2: 2.5h 
Vd: 0.25L/kg 
PB: 10% 
Foral: n.k. 
CLsys: 5.6L/h 
E: 0.01 
BE: minor 
CAT: 4 
Occasionally: increased 
liver enzymes (ALT, 
AST, AP) and bilirubin 
[71, 87]. 
ototoxicity, vestibular 
toxicity, neurotoxicity 
(paresthesia, 
convulsions), lethargy, 
confusion, 
neuromuscular 
blockade (aggravation 
of myasthenia gravis, 
postoperative 
respiratory distress), 
nephrotoxicity [87, 90, 
93] 
Studies: While no significant effect was observed for CL and t1/2 in 
cirrhotics, Vd was significantly larger when ascites was present (0.32 
vs. 0.26 L/kg) [182].  
Product information: No studies in patients with liver disease. Since 
minor metabolism of tobramycin occurs, liver disease is not expected 
to have an impact on tobramycin exposure [87].  
Recommendation: Aminoglycosides are considered contraindicated in 
liver cirrhosis. If no other possibilities exist, use weight-adapted initial 
dose and adjust maintenance dose by therapeutic drug monitoring. 
Monitor renal function. 
Gentamicin 
(parenteral, 
sponge) 
Mainly renal 
elimination [71, 87].  
Q0: 0.1 
T1/2: 2h 
Vd: 0.25L/kg 
PB: 30% 
Foral: 0.2% 
CLsys: 4L/h 
E: 0.01 
BE: minor 
CAT: 4 
Occasionally: 
elevations of liver 
enzymes and bilirubin, 
transient hepatomegaly 
[87]. 
ototoxicity, vestibular 
toxicity, neurotoxicity 
(hallucinations, 
encephalopathy, 
convulsions), 
pseudotumor cerebri, 
visual disturbances, 
neuromuscular 
blockade (aggravation 
of myasthenia gravis, 
postoperative 
respiratory distress), 
nephrotoxicity [87, 90, 
93] 
Studies: The t1/2 and effect of jaundice on excretion was evaluated in 
neonates. The presence of icterus or hyperbilirubinemia did not delay 
excretion in any patient [183].  
Product information: No specification.   
Recommendation: Aminoglycosides are considered contraindicated in 
liver cirrhosis. If no other possibilities exist, use weight-adapted initial 
dose and adjust maintenance dose by therapeutic drug monitoring. 
Monitor renal function. 
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Tab. 11 (continued)  
Drug (route of 
application)  
Metabolism Kinetic 
parameters 
Hepatic ADRs Potentially dose-dependent 
ADRs 
Studies, product information, and dose recommendations 
Amikacin 
(parenteral) 
No metabolism. 
90-98% is 
excreted 
unchanged in 
the urine [71, 
87].  
Q0: 0.02 
T1/2: 2h 
Vd: 0.3L/kg 
PB: 4% 
Foral: n.k. 
CLsys: 6L/h 
E: 0.01 
BE: minor 
CAT: 4 
Rare: liver enzyme 
elevations (ALT, AST, 
AP), elevated 
bilirubin, 
hepatomegaly, 
hepatic necrosis [71, 
87]. 
ototoxicity, vestibular toxicity, 
neurotoxicity (convulsions, 
hallucination, 
encephalopathy), visual 
disturbances, neuromuscular 
blockade (aggravation of 
myasthenia gravis, 
postoperative respiratory 
distress), nephrotoxicity, 
hypomagnesaemia [87, 93] 
Studies: No clinical studies available in patients with liver disease.  
Product information: No specification.    
Recommendation: Aminoglycosides are considered contraindicated in 
liver cirrhosis. If no other possibilities exist, use weight-adapted initial 
dose and adjust maintenance dose by therapeutic drug monitoring. 
Monitor renal function. 
Quinolone antibacterials 
Fluoroquinolones 
Ofloxacin 
(oral, 
parenteral) 
Less than 10% 
is metabolized 
by 
glucuronidation, 
demethylation 
and N-oxidation 
to inactive 
metabolites [90].  
Q0: 0.1 
T1/2: 6h 
Vd: 1.6L/kg 
PB: 25% 
Foral: 95% 
CLsys: 16L/h 
E: 0.07 
BE: minor 
CAT: 4 
Rare: elevations of 
liver enzymes and 
bilirubin, cholestatic 
jaundice, hepatitis, 
severe liver injury [71, 
87]. 
gastrointestinal disturbances, 
intestinal overgrowth by non-
susceptible organisms, 
neurotoxicity (dizziness, 
confusion, insomnia, seizures, 
hearing disturbances, visual 
disturbances, paresthesias), 
depression, psychotic reaction, 
hallucination, tremor, tendinitis 
[87, 90, 93] 
Studies: T1/2 and Vd were significantly increased by 55% and 33%, 
respectively, in cirrhotic patients (Child A) compared to controls [185]. 
A reduction in renal CL was observed (32%; not significant), although 
renal function was apparently normal. T1/2 was also increased by 66% 
in another study, probably related to impairment of tubular secretion 
[186]. No dose adjustment seems necessary in patients with cirrhosis 
and ascites [187].  
Product information: A dose of 400 mg per day should not be 
exceeded in patients with severe liver function disorders such as 
cirrhosis with ascites. The excretion of ofloxacin in these patients may 
be reduced [87]. 
Recommendation: Based on pharmacokinetic data, use normal initial 
dose and adjust maintenance dose and/or dosage interval according 
to creatinine clearance. Maximum dose of 400 mg daily is 
recommended. 
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Tab. 11 (continued) 
Drug (route of 
application)  
Metabolism Kinetic 
parameters 
Hepatic ADRs Potentially dose-
dependent ADRs 
Studies, product information, and dose recommendations 
Ciprofloxacin 
(oral, 
parenteral) 
About 16% are 
eliminated unchanged by 
the feces, enterohepatic 
circulation has been 
suggested. Metabolism to 
active and inactive 
metabolites [65, 87, 90].  
Q0: 0.4 
T1/2: 4h 
Vd: 2.5L/kg 
PB: 25% 
Foral: 75% 
CLsys: 30L/h 
E: 0.22 
BE: minor 
CAT: 4 
Occasionally: 
elevated liver 
enzymes and 
bilirubin. Rare: 
hepatic necrosis, 
hepatitis, 
cholestatic 
jaundice [71, 87, 
90, 92]. 
gastrointestinal 
disturbances, intestinal 
overgrowth by non-
susceptible organisms, 
neurotoxicity 
(dizziness, tremor, 
confusion, 
hallucinations, 
seizures), depression, 
psychotic reaction, 
vision and hearing 
disturbances [65, 87, 
90] 
Studies: Various studies showed no difference in pharmacokinetics 
between patients with liver cirrhosis (Child A, B and C) and healthy 
controls [188, 189], except one study [190]. Patients with Child C had 
higher Cmax, t1/2 and AUC. In one study, significant smaller quantities of 
oxociprofloxacin were found, probably due to decreased hepatic 
metabolism [191]. Pharmacokinetics were impaired in cirrhotics with 
moderate renal insufficiency [189]. Administration at usual doses in 
cirrhotics with normal renal function seems safe [188, 189, 191]. 
Product information: In patients with liver disease, elimination of 
ciprofloxacin is only minimally altered. According to its metabolism, 
accumulation in patients with liver disease seems unlikely. Dose 
adjustment is not necessary, provided that renal function is normal [87].  
Recommendation: According to pharmacokinetic data and clinical 
studies, use normal initial dose and adjust maintenance dose according 
to creatinine clearance. Clinical monitoring recommended.  
Norfloxacin 
(oral) 
Metabolites derived from 
chemical substitutions on 
the piperazine ring and 
glucuronidation. Main 
metabolite oxo-
piperazine. Active 
metabolites with less 
antimicrobial potency 
than norfloxacin. A 
possible first pass effect 
and enterohepatic 
circulation is discussed 
[71, 87, 90, 192].  
Q0: 0.7 
T1/2: 3.5h 
Vd: 2.8L/kg 
PB: 12.5% 
Foral: 35% 
CLsys: n.k. 
E: n.k. 
BE: minor 
CAT: 5 
Frequent: 
elevated liver 
enzymes. Rare: 
hepatocellular 
injury, cholestatic 
jaundice, 
hepatitis, hepatic 
failure (including 
fatalities) [71, 87, 
90, 92]. 
gastrointestinal 
disturbances, intestinal 
overgrowth by non-
susceptible organisms, 
neurotoxicity 
(dizziness, confusion, 
insomnia, seizures, 
hearing disturbances, 
visual disturbances, 
paresthesias), 
depression, 
hallucination, psychotic 
reactions, crystalluria, 
tendinitis [65, 87, 90] 
Studies: A single dose study (400mg) has reported that serum t1/2 and 
AUC were only slightly and not significantly altered in patients with 
moderate hepatic dysfunction (patients recovering from acute HBV 
infection) [193]. It is uncertain whether or not the liver is a major site of 
excretion of norfloxacin [192, 194]. No dose adjustment is probably 
necessary for patients with mild to moderate hepatic insufficiency. In 
cirrhotics norfloxacin may be indicated as prophylaxis of spontaneous 
bacterial peritonitis at a dose of 400mg once or twice daily in cirrhotic 
patients with gastrointestinal bleeding [195].  
Product information: No information provided. 
Recommendation: No specific dosage recommendations can be made 
due to lack of pharmacokinetic data. However, dose of 400mg up to 
twice daily is used for prophylaxis of spontaneous bacterial peritonitis in 
cirrhotics [195]. 
6
 
A
p
p
e
n
d
i
x
 
-
 
1
2
0
 
-
 
  
Tab. 11 (continued) 
Drug (route of 
application)  
Metabolism Kinetic 
parameters 
Hepatic ADRs Potentially dose-dependent 
ADRs 
Studies, product information, and dose recommendations 
Levofloxacin 
(oral, 
parenteral) 
Only minor 
metabolism to 
desmethyl-
levofloxacin and 
levofloxacin N-
oxide. Less than 
4% is excreted 
into the feces 
[71, 87].  
Q0: 0.15 
T1/2: 7h 
Vd: 1.36L/kg 
PB: 35% 
Foral: 99% 
CLsys: 10.6L/h 
E: 0.05 
BE: minor 
CAT: 4 
Frequent: 
elevations of liver 
enzymes. 
Occasionally: 
elevations of serum 
bilirubin. Rare: 
hepatitis, liver 
failure, hepatic 
necrosis, jaundice 
[71, 87]. 
gastrointestinal disturbances, 
intestinal overgrowth by non-
susceptible organisms, 
neurotoxicity (dizziness, 
hearing disturbances, tremors, 
confusion, seizures, asthenia, 
visual disturbances), 
hallucination, depression, 
torsade de pointes, 
hypoglycemia, tendinitis [65, 
87] 
Studies: No clinical studies available in patients with liver disease.  
Product information: Due to the limited extent of levofloxacin 
metabolism, no dosage adjustment is necessary in patients with 
impaired liver function [87]. 
Recommendation: According to pharmacokinetic data, use normal 
initial dose and adjust maintenance dose and/or dosage interval 
according to creatinine clearance. 
Moxifloxacin 
(oral, 
parenteral) 
Liver 
metabolism 
does not involve 
CYP P450 
system but 
phase II 
metabolism 
(sulfation, 
glucuronidation) 
generating 
inactive 
metabolites [87, 
196].  
Q0: 0.8 
T1/2: 12h 
Vd: 2L/kg 
PB: 45% 
Foral: 90% 
CLsys: 12L/h 
E: 0.18 
BE: major 
CAT: 3 
Frequent: elevated 
ALT, AST. 
Occasionally: 
increase in other 
liver enzymes (≤3 
ULN). Rare: acute 
liver failure, 
cholestatic hepatitis, 
jaundice, hepatic 
necrosis [71, 87, 
197, 198]. 
gastrointestinal disturbances, 
intestinal overgrowth by non-
susceptible organisms, 
neurotoxicity (dizziness, 
asthenia, somnolence, 
confusion, insomnia, seizures, 
paresthesias, tremors), 
hallucination, depression, 
psychotic reaction, tendinitis, 
torsade de pointes, QT-
prolongation [65, 87] 
Studies: Pharmacokinetics were similar in cirrhotics and healthy 
subjects [199-201]. AUC of moxifloxacin was 23% lower in cirrhotics 
(Child A and B), AUC of the sulfo-metabolite was 4 times higher 
compared to healthy controls [199, 200]. No dose adjustment 
necessary [199-201].  
Product information: No significant difference of pharmacokinetics of 
moxifloxacin in cirrhotics compared to healthy controls. AUC of the 
sulfo-metabolite was up to 6-fold higher, AUC of the glucuronide 
metabolite was 1.5-fold higher in cirrhotics Child B compared to 
healthy subjects. No dose adjustment necessary in patients with mild 
liver disease. Contraindicated in patients with cirrhosis Child C or 
transaminase elevations >5 ULN [87]. 
Recommendation: According to pharmacokinetic data and clinical 
studies, start with normal initial dose and reduce maintenance dose 
by up to 50%. Adjust maintenance dose according to clinical effect 
and dose-dependent ADRs. Caution in patients with cholestasis. 
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Tab. 11 (continued) 
Drug (route of 
application)  
Metabolism Kinetic 
parameters 
Hepatic ADRs Potentially dose-
dependent ADRs 
Studies, product information, and dose recommendations 
Other antibacterials 
Glycopeptide antibacterials 
Vancomycin 
(oral, 
parenteral) 
Metabolism negligible 
[87, 90].  
Q0: 0.1 
T1/2: 5h 
Vd: 0.6L/kg 
PB: 50% 
Foral: 0% 
CLsys: 4L/h 
E: 0.01 
BE: minor 
CAT: 4 
 ototoxicity, 
nephrotoxicity, 
gastrointestinal 
disturbances, intestinal 
overgrowth by non-
susceptible organisms, 
neutropenia, 
agranulocytosis [87, 90, 
93] 
Studies: Mean t1/2 in patients with different liver diseases and normal 
renal function was 7.8h (no controls). Renal CL was enhanced due to 
a reduction in PB and nonrenal CL was reduced, resulting in liver 
disease having no effect on total CL [202]. 
Product information: No information provided. 
Recommendation: Parenteral administration: Based on 
pharmacokinetic data, adjust maintenance dose according to 
creatinine clearance. Monitoring of plasma concentration 
recommended (reference values: Cmin 5-10 mg/l, Cmax <40 mg/l [203]. 
In patients with ascites: adjust initial dose according to body weight 
and choose maintenance dose according to plasma concentration 
monitoring. Oral administration: Use normal dose since oral 
absorption is low. Monitor dose-dependent toxicity. Determine serum 
concentration in case of possible toxicity. 
Teicoplanin 
(oral, 
parenteral) 
No absorption takes 
place if given orally and 
thus serves as local 
therapy in the intestine. 
There is no evidence 
for extensive hepatic 
metabolism of the drug 
[71, 87].  
Q0: 0.3 
T1/2: 90h 
Vd: 1.1L/kg 
PB: 90% 
Foral: 0% 
CLsys: 0.95L/h 
E: 0.01 
BE: minor 
CAT: 4 
Occasionally: 
elevated liver 
enzymes. Rare: 
cholestatic 
hepatitis [87]. 
ototoxicity, 
nephrotoxicity, 
gastrointestinal 
disturbances, intestinal 
overgrowth by non-
susceptible organisms, 
neurotoxicity (headache, 
drowsiness, seizures, 
rigor), fever, 
thrombocytopenia [87, 
90] 
Studies: No clinical studies available in patients with liver disease.  
Product information: No information provided. Periodic hematological 
studies, renal, liver and auditory function tests are advised during 
prolonged treatment. Monitoring Cmin (reference value: 5-15mg/l) [87]. 
Recommendation: Based on pharmacokinetic data, use normal initial 
dose and adjust maintenance dose and/or dosage interval according 
to creatinine clearance. Monitoring of serum levels recommended. 
Use with caution in patients with hypoalbuminemia due to decreased 
PB. 
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Tab. 11 (continued) 
Drug (route of 
application)  
Metabolism Kinetic 
parameters 
Hepatic ADRs Potentially dose-
dependent ADRs 
Studies, product information, and dose recommendations 
Polymyxins 
Colistin 
(inhalative) 
Colistimethate 
sodium is a 
prodrug and 
hydrolyzed to the 
active principle 
colistin [71]. The 
pharmacokinetic 
data refer to 
colistin. 
Q0: 0.4 
T1/2: 3h 
Vd: 0.34L/kg 
PB: low 
Foral: low 
CLsys: n.k. 
E: n.k. 
BE: minor 
CAT: 4 
Can exacerbate 
porphyrias [87]. 
nephrotoxicity, 
neurotoxicity 
(paresthesia, 
muscle weakness), 
oral candidiasis, 
bronchospasm [87, 
90] 
Studies: No clinical studies available in patients with liver disease.  
Product information: No recommendations provided. 
Recommendation: According to pharmacokinetic data, no dosage 
adjustment seems necessary in patients with liver disease. Adjust 
maintenance dose to renal function. 
Steroid antibacterials 
Fusidic acid 
(oral) 
Metabolism in the 
liver to glucuronic 
acid conjugates, 
dicarboxylic acid 
metabolite, 
hydroxy 
metabolite [87, 
90]. Metabolites 
have weak or no 
bioactivity. 
Q0: 1 
T1/2: 11h 
Vd: 0.3L/kg 
PB: 98.5% 
Foral: 91% 
CLsys: 2L/h 
E: 0.04 
BE: major 
CAT: 3 
Rare: liver enzyme 
elevations, 
hyperbilirubinemia, 
reversible cholestatic 
jaundice, hepatorenal 
syndrome [87, 90, 92, 
204, 205]. Jaundice may 
be due to intrahepatic 
cholestasis because of 
competition with the 
excretory pathways of 
hepatic bile acids related 
to the steroid-like 
structure of the drug 
[206] 
gastrointestinal 
disturbances, 
hyperbilirubinemia, 
jaundice, liver 
enzyme elevations, 
hematological 
reactions 
(neutropenia, 
granulocytopenia, 
agranulocytosis), 
lethargy, 
drowsiness, fatigue 
[87, 90] 
Studies: In patients with hypoalbuminemia with no cholestasis, cholestasis 
or hyperbilirubinemia, CL was higher compared to values in normal 
subjects because of increased free fraction. In patients with bilirubinemia, 
this effect was offset by competition for the glucuronidation step by bilirubin 
[206]. 
Product information: No data in patients with liver disease. Caution in 
patients with liver disease and/or impaired bilirubin transport or metabolism 
[87]. Caution in patients with mild and moderate liver disease and bile duct 
obstruction. Fusidic acid should not be used in patients with severe hepatic 
failure. Monitoring of liver function recommended [90]. 
Recommendation: According to pharmacokinetic data, start with normal 
intial dose and reduce maintenance dose by up to 50%. Adjust dosage 
according to clinical effect and dose-dependent ADRs. Monitoring of liver 
function necessary. In patients with ascites: adjust initial dose according to 
body weight and choose maintenance dose in the lower range of normal. 
Caution in patients with cholestasis due to significant BE. Use with caution 
in patients with hypoalbuminemia due to decreased PB.   
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Tab. 11 (continued) 
Drug (route of 
application)  
Metabolism Kinetic 
parameters 
Hepatic ADRs Potentially dose-
dependent ADRs 
Studies, product information, and dose recommendations 
Imidazole derivatives 
Metronidazole 
(oral, 
parenteral) 
30-60% metabolized in 
the liver by side-chain-
oxidation (active 
hydroxy metabolite t1/2 
10h; acetic acid 
metabolite), 
glucuronide 
conjugation. 
Enterohepatic 
circulation [87, 90, 93].  
Q0: 0.85 
T1/2: 7h 
Vd: 0.74L/kg 
PB: 20% 
Foral: 90% 
CLsys: 5L/h 
E: 0.08 
BE: minor 
CAT: 3 
Rare: abnormal liver 
function tests, 
hepatocellular and 
cholestatic hepatic 
injury [87, 92]. 
gastrointestinal 
disturbances, metallic 
taste, intestinal 
overgrowth by non-
susceptible organisms, 
peripheral neuropathy, 
confusion, hallucination, 
seizures, 
encephalopathy, 
paresthesia, ataxia, 
visual disturbances, 
discoloration of urine, 
hematological reactions 
[87, 90] 
Studies: No significant alterations of kinetics in patients with 
decompensated liver cirrhosis or schistosomiasis in one study [207]. 
Decompensated liver disease: t1/2 152% higher, Vd and CL 21% and 
66% lower compared to healthy controls [208]; significant reduction in 
Cmax and AUC of hydroxy metabolite [209]. T1/2 prolonged 2-fold in 
patients with hepatic and partly renal insufficiency compared to 
controls [210]. Alcoholic liver disease: t1/2 18.3h, Vd 0.77L/kg, and 
CLsys 0.51mL/min per kg (equivalent to 2.1L/h) [211]. Elimination 
more affected in patients with obstructive liver disease than in 
patients with hepatocellular liver injury [212]. T1/2 increased with 
severity of liver disease [213]. Decompensated liver disease: 
recommended to administer 0.5g i.v. 2x instead of 3x a day; oral dose 
200mg 4x a day [209]. Alcoholic liver disease: recommended to 
reduce intravenous dosage from 500mg every 6h to every 12h [211]. 
Product information: Dosage reduction and monitoring of drug levels 
recommended in patients with severe liver disease. Caution in 
patients with hepatic encephalopathy [87]. 50% dose reduction in 
patients with liver insufficiency [90]. 
Recommendation: According to pharmacokinetic data and clinical 
studies, start with normal intial dose and reduce maintenance dose by 
up to 50%. Adjust maintenance dose by means of clinical effect and 
dose-dependent ADRs. 
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Tab. 11 (continued) 
Drug (route of 
application)  
Metabolism Kinetic 
parameters 
Hepatic ADRs Potentially dose-
dependent ADRs 
Studies, product information, and dose recommendations 
Ornidazole 
(oral, 
parenteral) 
Over 90% are 
metabolized in the 
liver by oxidative 
pathway and 
hydrolysis [87, 214]. 
The two major 
metabolites (t1/2 5-
6h) have almost the 
same activity as the 
parent compound.   
Q0: 0.95 
T1/2: 13h 
Vd: 0.9L/kg 
PB: 15% 
Foral: 90% 
CLsys: 3L/h 
E: 0.05 
BE: minor 
CAT: 3 
Case reports: 
hepatitis, 
autoimmune 
hepatitis, 
cholestatic 
jaundice [215-
218]. 
gastrointestinal 
disturbances, metallic 
taste, intestinal 
overgrowth by non-
susceptible organisms, 
central and peripheral 
neuropathy (confusion, 
dizziness, drowsiness, 
seizures, paresthesia, 
ataxia, tremor, rigidity), 
discoloration of urine, 
hematological reactions 
[71, 87] 
Studies: Single 500mg i.v. dose in patients with alcoholic liver cirrhosis: 
significant increase of t1/2 (22 vs. 14 h) and decrease of plasma CL (35 vs. 51 
mL/min) [219]. The interval between repeated doses could be doubled. 
Patients with hepatitis, noncholestatic cirrhosis and extrahepatic cirrhosis: 
CL decreased by 26-48% and t1/2 increased by 19-38% compared to healthy 
volunteers. No clear difference could be established between the different 
patient groups. Plasma concentration of active metabolites increased as a 
result of reduced elimination including decreased biliary excretion [158]. 
Product information: Compared to healthy subjects t1/2 is prolonged and CL 
decreased. Dosage interval should be doubled in patients with severe liver 
impairment. The ampullas contain alcohol, caution in patients with liver 
disease [87].  
Recommendation: According to pharmacokinetic and clinical data, start with 
normal initial dose. Adjust maintenance dose or dosage interval by means of 
clinical effect and dose-dependent ADRs. In patients with severe liver 
disease, double dosage interval. 
Other antibacterials 
Fosfomycin 
(oral) 
No metabolism. 
Enterohepatic 
circulation observed 
[87, 90].  
Q0: 0.1 
T1/2: 4h 
Vd: 2L/kg 
PB: 3% 
Foral: 50% 
CLsys: 11L/h 
E: 0.02 
BE: minor 
CAT: 4 
Case report: 
acute fatty liver 
(steatosis) [220]. 
gastrointestinal 
disturbances, dizziness, 
vertigo, asthenia [87, 90] 
Studies: No clinical studies available in patients with liver disease.  
Product information: No specification in the Swiss product information. 
Fosfomycin is not metabolized and dosing adjustments are not required in 
patients with hepatic insufficiency [71]. 
Recommendation: Based on the pharmacokinetic data, no dosage 
adjustment seems necessary in patients with liver insufficiency. Adjust 
maintenance dose according to creatinine clearance. 
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Tab. 11 (continued) 
Drug (route of 
application)  
Metabolism Kinetic 
parameters 
Hepatic ADRs Potentially dose-
dependent ADRs 
Studies, product information, and dose recommendations 
Linezolid 
(oral, 
parenteral) 
Metabolism to 
inactive ring-open 
metabolites 
probably by slow 
non-enzymatic 
morpholine-ring 
oxidation 
mediated by 
reactive oxygen 
species [87, 221]. 
About 9% of the 
dose are excreted 
as metabolites 
into the feces [87]. 
Q0: 0.65 
T1/2: 6h 
Vd: 0.64L/kg 
PB: 31% 
Foral: 100% 
CLsys: 8L/h 
E: 0.1 
BE: minor 
CAT: 3 
Frequent: 
abnormal liver 
function tests 
[87]. Case 
report: elevated 
bilirubin [222], 
severe 
cholestatic liver 
injury (with 
concomitant 
lactic acidosis) 
[223]. 
gastrointestinal 
disturbances, metallic 
taste, intestinal 
overgrowth by non-
susceptible organisms, 
neurotoxicity (dizziness, 
insomnia, vertigo, 
paresthesia, seizure, 
peripheral and optic 
neuropathy), 
hematological reactions 
[71, 87] 
Studies: In patients with mild to moderate liver disease by Child-Pugh scores, 
AUC and t1/2 both increased about 1.3-fold, while renal CL decreased by a 
factor of 1.3 compared to healthy volunteers. Urinary excretion of the two 
major metabolites was decreased [224]. Therapeutic drug monitoring is 
recommended for patients with severe liver disease [225]. 
Product information: No dosage adjustment is necessary in patients with 
cirrhosis Child-Pugh A and B. Linezolid pharmacokinetics in patients with 
severe hepatic failure have not been evaluated. Due to limited data available, 
linezolid should only be given to patients with liver disease if the benefit 
outweighs the risk [87].  
Recommendation: According to pharmacokinetic data and clinical study, start 
with normal initial dose. In patients with severe liver disease, maintenance 
dose should be reduced by up to 50%. Adjust maintenance dose according to 
clinical effect and dose-dependent ADRs. In patients with ascites: adjust initial 
dose according to body weight and choose maintenance dose in the lower 
range of normal. 
Daptomycin 
(parenteral) 
In vitro studies 
showed no 
metabolism of 
daptomycin by 
CYP P450 
enzymes [87].  
Q0: 0.5 
T1/2: 7.8h 
Vd: 0.1L/kg 
PB: 90% 
Foral: n.k. 
CLsys: 0.6L/h 
E: 0.01 
BE: minor 
CAT: 3 
Frequent: 
elevations of 
liver enzymes. 
Occasionally: 
jaundice [87]. 
gastrointestinal 
disturbances, intestinal 
overgrowth by non-
susceptible organisms, 
peripheral neuropathy, 
paresthesia, dizziness, 
insomnia, anxiety, 
elevations of creatine 
phosphokinase incl. 
myositis, muscle pain, 
muscle weakness and 
rhabdomyolysis, 
nephrotoxicity [71, 87] 
Studies: Pharmacokinetics of daptomycin (single i.v. dose 6mg/kg total body 
weight) in subjects with moderate hepatic liver disease (Child-Pugh B) were 
similar compared to healthy volunteers matched by weight, age, and sex [226]. 
Product information: No difference in pharmacokinetics in patients with liver 
insufficiency (Child B) compared to matched normal controls. No dose 
adjustment indicated in patients with moderate liver impairment. Caution in 
patients with liver cirrhosis Child C, because the safety has not been studied in 
this group of patients [87]. 
Recommendation: According to pharmacokinetic data, start with normal intial 
dose. Adjust maintenance dose according to clinical effect, dose-dependent 
ADRs, and/or serum levels. In patients with ascites: Adjust initial dose 
according to body weight and choose maintenance dose in the lower range of 
normal. Use with caution in patients with hypoalbuminemia due to decreased 
PB.  
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Tab. 11 (legend) 
ADRs = adverse drug reactions; ALT = alanine aminotransferase; AP = alkaline phosphatase; AST 
= aspartate aminotransferase; AUC = area under the concentration-time curve; BE = biliary 
elimination; BUN = blood urea nitrogen; CAT = drug category; CL = clearance; CLsys = systemic 
clearance; Cmax = maximal plasma concentration; Cmin = minimal plasma concentration; CYP = 
cytochrome P450 enzymes; E = hepatic extraction; Foral = systemic bioavailability after oral 
administration; GGT = gamma-glutamyltransferase; HBV = hepatitis B virus; HCV = hepatitis C 
virus; n.k. = not known; PB = protein binding; Q0 = extrarenal dose fraction; T1/2 = elimination half-
life; ULN = upper limit of normal; Vd = volume of distribution. 
 
 
 
Tab. 12 Demographic and clinical characteristics of 400 patients with liver cirrhosis. 
Characteristics Patients (n = 400) 
Age (years)a 60 (21-88) 
Male  274 (68.5%) 
Creatinine clearance (mL/min)a, b 82.8 (9-290) 
BMI (kg/m2)a, c 24.8 (13.5-47.2) 
Child Pugh classification 
Child Pugh A 
Child Pugh B 
Child Pugh C 
 
70 (17.5%) 
157 (39.3%) 
173 (43.2%) 
Causes of liver cirrhosis 
Alcohol 
Viral Hepatitis 
Both 
Other 
 
279 (69.8%) 
54 (13.5%) 
39 (9.7%) 
28 (7.0%) 
Length of hospital stay (days)a 13 (1-116) 
Patients died during hospitalization 67 (18.6%) 
BMI = body mass index; ADE = adverse drug event; DDI = drug-drug interaction 
a
 Data are presented as median (range) 
b
 n = 386 patients due to lack of data (body weight and/or serum creatinine) 
c
 n = 248 patients due to lack of data (body weight and/or height) 
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Tab. 13 Diagnoses in 400 patients with liver cirrhosis 
Diagnosis Patients  
(n = 400) 
Number of diagnoses, total 2415 
Diagnoses per patienta 6 (1-10) 
Number of not liver associated diagnoses, total 1467 
Not liver associated diagnosis per patienta 4 (0-8) 
Diseases of the digestive system, total diagnosesb 
Alcoholic liver disease (including cirrhosis) 
Non alcoholic fibrosis or cirrhosis of the liver 
Esophageal varices 
Gastrointestinal bleeding 
Gastritis and/or duodenitis 
Hepatic failure 
Spontaneous bacterial peritonitis 
687 
268 (67.0%) 
147 (36.8%) 
61 (15.3%) 
49 (12.3%) 
28 (7.0%) 
22 (5.5%) 
18 (4.5%) 
Diseases of the cardiovascular system, total diagnosesb 
Hypertension 
Ischemic heart diseases 
Atrial fibrillation 
Cerebrovascular diseases 
343 
80 (20.0%) 
46 (11.5%) 
17 (4.2%) 
16 (4.0%) 
Diseases of the blood and blood-forming organs, total diagnosesb 
Anemia 
Thrombocytopenia 
211 
139 (34.8%) 
40 (10.0%) 
Psychiatric disorders, total diagnosesb 
Mental and behavioral disorders due to use of alcohol 
Mental and behavioral disorders due to multiple drug use and/or use of 
other psychoactive substances 
Depression 
Mental and behavioral disorders due to use of tobacco 
182 
74 (18.5%) 
29 (7.3%) 
 
27 (6.8%) 
22 (5.5%) 
Endocrine, nutritional and metabolic diseases, total diagnosesb 
Diabetes mellitus 
Disorders of fluid and electrolyte balance 
170 
84 (21.0%) 
24 (6.0%) 
Diseases of the genitourinary system, total diagnosesb 
Renal failure 
Urinary tract infection 
126 
81 (20.3%) 
26 (6.5%) 
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Tab. 13 Diagnoses in 400 patients with liver cirrhosis (continued) 
Diagnosis Patients  
(n = 400) 
Infectious diseases, total diagnosesb 
Viral hepatitis 
Sepsis 
HIV 
124 
40 (10.0%) 
32 (8.0%) 
16 (4.0%) 
Neoplasms, total diagnosesb 
Liver and intrahepatic bile ducts 
Gastro-intestinal (other than liver) 
117 
45 (11.3%) 
16 (4.0%) 
Diseases of respiratory system, total diagnosesb 
COPD 
Pneumonia 
111 
43 (10.8%) 
18 (4.5%) 
Diseases of musculoskeletal system, total diagnosesb 58 
Diseases of the nervous system, total diagnosesb 
Epilepsy 
Alcoholic polyneuropathy 
54 
15 (3.8%) 
10 (2.5%) 
aData are presented as median (range). 
bOne individual patient may have >1 diagnosis of the corresponding group, % not calculated. 
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Fig. 11 Number of drugs at hospital admission, categorized according to their elimination pathway 
(category) and fraction of each category with incorrect dosing. Category 1 = high hepatic extraction 
drugs; category 2 = intermediate hepatic extraction drugs; category 3 = low hepatic extraction 
drugs; category 4 = renal elimination drugs; category 5 = drugs with unknown elimination pathway. 
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Fig. 12 Odds ratios (with 95% confidence intervals) for the development of ADRs associated with 
IDDs for the different drug classes (ATC-code). Odds ratios for not listed ATC-codes could not be 
calculated. A = alimentary tract and metabolism; ATC = anatomical therapeutic chemical 
classification system; B = blood and blood forming organs; C = cardiovascular system; CI max = 
upper value of 95% confidence interval; L = antineoplastic and immunomodulating agents; M = 
musculo-skeletal system; M01A = anti-inflammatory and antirheumatic products, non-steroids; N = 
nervous system; N05C = hypnotics and sedatives; N02B = other analgesics and antipyretics 
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Hometown Liesberg, BL 
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Education 
2009-2012 PhD thesis at the Division of Clinical Pharmacology &  
 Toxicology, University Hospital Basel, Switzerland  
 Title: ‘Drug-related Problems and Dosage Adjustment  
 in Patients with Liver Disease' 
  Supervised by Prof. Dr. Dr. Stephan Krähenbühl and Dr. 
 Alexandra Rätz Bravo. 
 
2003-2008 Study of Pharmacy with Swiss Federal Diploma at the  
 University of Basel, Switzerland 
 March to July 2007: Master thesis at the Division of
 Clinical Pharmacology & Toxicology, University Hospital  
 Basel, Switzerland 
 Title: 'Prevalence of Potential Adverse Drug Events as a 
 Reason for Hospital Admission“ 
 
2002-2003 Study of Translation at the Zürcher Hochschule Winterthur 
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1998-2002 Matura L (literary), Kantonsschule Olten, Switzerland 
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Work Experience 
2009-2012 Assistance in Regional Pharmacovigilance Center at the 
 Division of Clinical Pharmacology & Toxicology, University  
 Hospital Basel, Switzerland 
 Supervision of two master theses of pharmacy students 
 Titles: '[Relationship between dosage and adverse drug  
 events  as well as potential cost savings in patients with  
 liver  cirrhosis]'  written by Carole Hildbrand (2010) 
 '[Prevalence and possible causes of muscle disorders at
 the University Hospital Basel]' written by Anna Sabina 
  Zwahlen (2011) 
 Organisation and supervision of a workshop in  
 therapeutic drug monitoring for pharmacy students  
 
 Pharmacist at the DorfApotheke, Zuchwil, the 
HelvetiaplatzApotheke, Zürich, and the Hammer 
Apotheke, Olten, Switzerland 
 For one or two Saturdays per month and additional days if 
 required 
 
10/2008-12/2008 Pharmacist at the ZehntenhausApotheke, Zürich Affoltern, 
Switzerland, and other pharmacies of the Topwell-
Apotheken AG if required (full-time job) 
 
2007-2008 Assistant pharmacist at the Hammer Apotheke, Olten, 
 Switzerland 
 
2007  Assistance in Migros Gourmessa, Zürich Altstetten,  
 Switzerland 
 
2004-2007 Office assistance (pension fund) 
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Major Lectures 
2009-2012 • University of Basel, Switzerland: Seminars on Drug  
  Discovery and Development, Biostatistics I, Scientific 
   Writing, Research Seminar in Clinical Pharmacology & 
           Toxicology 
 • 'Pharmathemen' (organized by the Division of Clinical  
  Pharmacology & Toxicology, University Hospital Basel,  
  Switzerland) 
 • Various courses for pharmacists 
 • Various hospital-internal courses 
 
 
Attendance and Presentations at Congresses 
2012 • SGIM Jahresversammlung, Basel, Switzerland, Poster 
    and Poster Presentation  
  Title: ‘Importance of Dosage Adjustment in Patients  
  with Liver Cirrhosis: Influence on Safety and  
  Healthcare Costs’ 
2011 •  European Association of Hospital Pharmacists (EAHP),
  Vienna, Austria 
2010-2012 •  Annual Research Meeting, University of Basel, 
  Switzerland 
 Poster 1: ‘Prevalence of Drug-Drug Interactions and 
Adverse Drug Events in Patients with Liver Cirrhosis’ 
 Poster 2: ‘Necessity for Dosage Adjustment in Patients 
with Liver Disease – Development of a Drug Database’ 
 Poster 3: ‘Prevalence of and Possible Reasons for 
Myopathies at the University Hospital Basel’ 
 
7 Curriculum vitae 
- 137 - 
 
Language Skills 
German first language 
English advanced knowledge in reading, writing, and speaking 
Spanish advanced knowledge in reading, writing, and speaking 
French basic knowledge in reading, writing, and speaking 
Chinese basic knowledge in reading, writing, and speaking 
Portuguese basic knowledge in reading, writing, and speaking 
 
 
Computer skills 
Microsoft office Word, Excel, Powerpoint 
Pharmacy programs Propharma, Golden Gate 
Statistical programs Stata 10 
 
 
Interests 
Sports (biking, jogging, swimming, hiking, karate, pilates, yoga), nature, animals, 
travelling, reading, cooking, music 
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